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Introduction 
1. Introduction 
Articular cartilage damages affect a large number of the human population including 
both young and elderly patients, as well as domestic animals and livestock. Structure 
and disease thereof were described scientifically as early as in the 18th century by 
William Hunter (1742), indicating problems in cartilage regeneration that are still 
present today: “If we consult the standard Chirurgical Writers from Hippocrates down 
to the present Age, we shall find, that an ulcerated Cartilage is universally allowed to 
be a very troublesome Disease; that it admits of a Cure with more Difficulty than 
carious Bone; and that, when destroyed, it is not recovered”. 
The lack in cure or recovery is thus a major aspect in the treatment of cartilage 
damage, as articular cartilage usually does not achieve “restitutio ad integrum”, but 
instead often develops further deterioration during the course of the disease 
(Hunziker 2002). Cartilage regeneration is hampered by the specific tissue properties 
of articular cartilage. In adult humans, only about one percent of cartilage volume is 
made of cells, the other 99% being the avascular and aneural extracellular matrix 
(Buckwalter et al. 1997). In case of damage, this aggravates the healing process, 
which in vascularised tissues is usually dependent on processes involving blood 
supply. In these tissues, response to trauma, e.g. a cut, is almost always divided into 
three subsequent stages, i.e. necrosis, inflammation, and repair. Necrosis due to 
cellular damage and the resulting loss of blood supply in the affected tissue triggers 
inflammation. This in turn leads to increased blood flow, dilatation of vascular 
channels, increase of vessel wall permeability, as well as onset of further processes 
that finally fill up the extracellular spaces in the traumatised area, e.g. through the 
formation of fibrin clots. Finally, repair processes including recruiting of 
undifferentiated cells and new cell growth lead to repair or regeneration of the injury 
(Mankin 1982). In articular cartilage, on the other hand, these processes do not occur 
due to the avascular nature of the tissue. In case of injuries that do not affect the 
subchondral bone, necrosis happens in the cartilage tissue after injury, but no 
inflammation arises. Additionally, there are no processes supporting the formation of 
repair tissue or recruiting of undifferentiated cells to fill up the defect, leaving the 
repair to the small number of chondrocytes already present in the cartilage tissue 
(Mankin 1982). While chondrocytes proliferate and increase matrix synthesis near 
the injury as a response to tissue damage, this is not sufficient to fill up the defective 
area (Buckwalter 1998). In injuries involving the vascular subchondral plate though, 
cells, growth factors, and cytokines may migrate into the lesion and initiate processes 
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that lead to the formation of fibrocartilage to fill up the defect (Frenkel et al. 2004). 
Nevertheless, the newly built fibrocartilage is less resilient than the original articular 
cartilage (Coletti et al. 1972) and is thus prone to premature wear leading to further 
damage of the affected joint. 
Cartilage damage can occur due to multiple causes, including trauma e.g. from 
accidents, high impact sports (Buckwalter 2003), repetitive loading (Clements et al. 
2001), defective positions of joints, e.g. patellar malalignment (Vasiliadis et al. 2011), 
muscle weakness (Herzog et al. 2003; Herzog et al. 2007) and ligament injuries 
(Hunziker 2002), as well as sex and weight (Ding et al. 2006). Another factor for 
cartilage damage is age, where age-related modifications due to senescence of the 
muscosceletal system (Aigner et al. 2004; Loeser 2009) are playing an important 
role. Finally, disease affecting the underlying bone may lead to cartilage damage, as 
in case of Osteochondritis dissecans (OD). OD occurs in humans, but is also present 
in e.g. dogs (Newton et al. 1985), horses (Riley et al. 1998), and pigs (Busch et al. 
2011). 
Once damaged, cartilage is prone to further degeneration due to the poor healing 
capability and in addition, initial cartilage damage may also lead to the onset of 
secondary osteoarthritis (OA) (Buckwalter et al. 1996; Buckwalter et al. 1997; Ding et 
al. 2006), although the exact mechanisms thereof are not yet clear. However, 
besides these “mechanic” impacts, OA can also be caused without any preceding 
injury (primary OA), with risk factors including ethnicity, hormonal status, bone 
density, nutritional factors, and genetics (Felson et al. 2000). 
Several therapeutic strategies were developed for treating cartilage defects, which 
were initially based on surgery or arthroscopy alone, including cleaning of the 
affected joints, abrasion, debridement, Pridie drilling, or spongialisation, some of 
them trying to trigger the natural tissue healing response (Hunziker 2002). 
Transplantation techniques were developed in addition, e.g. by transplanting 
cartilage from lesser loaded areas into the defect (autologous osteochondral grafting, 
autologous osteochondral mosaicplasty) (Hangody et al. 1997; Hangody et al. 2008). 
However, lack of intact transplantable cartilage tissue and problems deriving from 
surgery are still a challenge in this kind of cartilage regeneration, as transplantation 
of cartilage or cartilage and bone plugs do not lead to complete recovery in the 
regions where the plugs are positioned. The transplanted cartilage does usually not 
integrate well into the adjacent intact cartilage, and spaces between the plugs do not 
get filled (Lane et al. 2001; Kock et al. 2004). Furthermore, necrosis may occur at the 
explantation sites (McGregor et al. 2011). 
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Another strategy that has thus emerged in cartilage regeneration in the last couple of 
years is the use of tissue engineering methods, trying to overcome some of the 
problems mentioned above. In tissue engineering, combined developments in 
biology, material science, engineering, manufacturing, and medicine are used in 
biologically based mechanisms (as opposed to mechanical devices) to achieve 
healing of damaged and diseased tissues (Hardingham et al. 2002). In case of 
cartilage, autologous chondrocyte transplantation (ACT) is used to amplify 
chondrocytes in vitro, easing the lack of chondrocytes/cartilage to fill up the defect 
(Brittberg et al. 1994). Chondrocytes are harvested from lesser loaded areas too, but 
in contrast to autologous chondral grafting, cells are amplified in in vitro cell culture 
first and subsequently implanted into the defective area. Second generation ACT 
includes cell-seeded bioabsorbable and biodegradable scaffolds (e.g. alginate beads, 
chitosan, or hybrids thereof) to provide the cells with growth conditions mimicking 
their natural localisation in the extracellular matrix of articular cartilage (Guo et al. 
1989; Iwasaki et al. 2004). Further enhancements are the use of cartilage-specific 
growth factors (single factors or combinations thereof) and/or specialised growth 
media, trying to achieve faster growth rates as well as improved regeneration and 
maintenance of the chondrogenic state of the cultured cells, which usually de-
differentiate when grown in culture (Harrison et al. 2000; Blunk et al. 2002; Malpeli et 
al. 2004), and the advent of stem-cell based procedures for cartilage formation 
(Sekiya et al. 2002). However, ACT still has room for improvement as there is a 
number of patients with complications arising from ACT (Harris et al. 2011). 
In regard to chondrocyte yield for ACT, besides factors such as IGF1 (Insulin-like 
growth factor 1 (somatomedin C)), IL4 (Interleukin 4), or PDGF (Platelet-derived 
growth factor), the use of embryonic proteins usually involved in developmental 
processes might be a promising strategy for increase of growth rates. This might be 
especially valid for proteins of the high mobility group (HMG) family, as variants 
thereof were shown to be involved in processes of chondrogenic differentiation (Kubo 
et al. 2006). 
HMG proteins are small (<30kDa) nuclear proteins that were first discovered in 
0.35M NaCl-extractable proteins from calf thymus chromatin (Goodwin et al. 1973). 
They were named according to their mobility in the electric field in acid 
polyacrylamide gel electrophoresis (PAGE), and could be separated from the Low 
Mobility Group proteins of the extracts due to their solubility in 2% trichloroacetic acid 
(Goodwin et al. 1973). HMGB1 and HMGB2 (formerly named HMG1 and HMG2) 
were the first proteins to be isolated and characterised from this fraction (Goodwin et 
al. 1973), which was followed by the isolation of HMGB3 (formerly HMG3) and 
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HMGN2 (formerly HMG17) (Goodwin et al. 1975), and HMGN1 (formerly HMG14) 
(Goodwin et al. 1977). Later, HMGA1a (formerly HMGI) and HMGA1b (formerly 
HMGY) proteins were discovered in HeLa-S3 cells (Lund et al. 1983), and were 
confirmed to be splicing variants of the HMGA1 (formerly HMGI(Y)) gene (Johnson et 
al. 1989). Furthermore, HMGA2 (formerly HMGIC) was detected in extracts from 
virus transformed cells (Giancotti et al. 1985; Goodwin et al. 1985; Giancotti et al. 
1987). 
HMG proteins can be divided into distinct protein families that are defined by the 
respective functional domains of the proteins. The functional motif also served as the 
basis for the new HMG nomenclature that was established when it became obvious 
that the initial protein names were causing confusion due to e.g. the similarity in their 
names (Bustin 2001), as for example in the case of HMG1 and HMGI. The root 
symbols chosen for the HMG protein families were thus HMGA for the AT-hook 
proteins (e.g. HMGA1, HMGA2), HMGB for proteins containing HMG-boxes (e.g. 
HMGB1, HMGB2, HMGB3), and HMGN for proteins with a nucleosome binding 
domain (e.g. HMGN1, HMGN2). 
HMGA proteins selectively bind to the minor groove of AT-rich deoxyribonucleic acid 
(DNA), but with no sequence specificity (Solomon et al. 1986). DNA binding is 
enabled by the so-called AT-hooks, which are highly conserved regions that are 
closely related to the consensus amino acid (aa) sequence of 
T-P-K-R-P-R-G-R-P-K-K found in all HMGA proteins (Reeves et al. 1990). Proteins of 
the HMGB family bind to DNA facilitated by their highly conserved HMG-boxes. DNA 
binding is sequence independent, but structure specific, e.g. when binding to four-
way junctions (Bianchi et al. 1992). HMGN proteins bind to the nucleosome core 
particle by use of their nucleosome binding domain, in particular to nucleosomal DNA 
and histone H2A (Abercrombie et al. 1978; Cook et al. 1989; Crippa et al. 1992). 
Concerning their function, although distinguished by their different functional 
domains, all HMG family proteins were named architectural transcription factors due 
to their involvement in transcription regulation by influencing DNA and protein 
structure and DNA-/protein interaction. For example, HMGA1 proteins were shown to 
play a key architectural role in the assembly and stability of transcription enhancer 
complexes in both the IFNB1 (interferon, beta 1, fibroblast) and SELE (selectin E) 
gene promoters (Whitley et al. 1994), while it was found out that HMGA2 enhances 
NF-kappaB (Nuclear factor NF-kappa-B p50/p65 heterodimer) mediated 
transcriptional activation through interacting with the PRDII (positive regulatory 
domain II) element of the IFNB1 enhancer (Mantovani et al. 1998). HMGB1 was 
shown to modulate DNA structure by bending, thus facilitating the formation of 
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higher-order DNA-protein structures (Grosschedl et al. 1994), and HMGN proteins 
were suggested to be architectural elements which assist in the assembly of an 
unfolded chromatin fibre thereby decreasing the repressive activity of histones and 
facilitating transcriptional processes (Bustin et al. 1995). 
Thus, while not being involved in direct transcription processes, by binding DNA and 
proteins and thus influencing their binding and structure, they are involved in the 
regulation of a large number of genes, for example those that are target genes of the 
NF-kappaB pathway (Henriksen et al. 2010), which correlates with the findings of 
Mantovani et al. (1998) mentioned above. 
Besides their initially known nuclear function in transcription regulation, further 
research on HMG proteins revealed additional extracellular functions in case of 
HMGB1. It was shown that HMGB1 promotes neurite outgrowth (Merenmies et al. 
1991), is a late mediator of endotoxin lethality in mice (Wang et al. 1999), and also 
plays a role in other inflammatory processes (Scaffidi et al. 2002). Later it was 
revealed that HMGB1 is involved in angiogenesis when it is released from necrotic 
cells e.g. in hypoxic regions of growing tumours (Schlueter et al. 2005). HMGA2 was 
recently shown to be highly expressed in human embryonic stem (hES) cells (Li et al. 
2006), acting as a regulator of human genes linked to mesenchymal cell 
differentiation, adipogenesis, and hES cell growth (Li et al. 2007), as well as 
regulating chromatin structure and maintenance of the undifferentiated cell state 
(Pfannkuche et al. 2009), thus having influence on the cells’ “stemness”. However, in 
mouse embryonic fibroblasts (MEF), it was shown that down-regulation of Hmga2, 
amongst other MEF-specific genes, increased the efficiency of induced pluripotent 
stem cell generation (Yang et al. 2011). 
As HMG proteins are involved in transcriptional regulation, with HMGA proteins being 
usually absent or only expressed at very low levels in non proliferating adult tissues 
(Rogalla et al. 1996), deregulation of HMG expression has widely been associated 
with the formation of both benign and malignant tumours (Hess 1998; Zhou et al. 
1998; Tallini et al. 1999; Wisniewski et al. 2000; Reeves et al. 2001; Evans et al. 
2004; Sgarra et al. 2004; Fusco et al. 2007; Young et al. 2007; Cleynen et al. 2008; 
Fedele et al. 2010; Tang et al. 2010). Intron 3 of the HMGA2 gene was shown to be 
the most frequent target of chromosomal aberrations in human tumours, leading to 
truncated HMGA2 or fusion proteins with other ectopic sequences (Kazmierczak et 
al. 1998). 
Concerning HMGA, especially mechanisms of HMGA2 gene regulation and de-
regulation were studied in detail, showing an involvement of the 3’ untranslated 
region (UTR) (Borrmann et al. 2001), which has been linked to interaction with micro-
- 8 - 
Introduction 
ribonucleic acids (miRNAs) of the let-7 family (Lee et al. 2007; Mayr et al. 2007). 
Binding of let-7 miRNAs to several regions of the 3’-UTR led to degradation of 
HMGA2 messenger ribonucleic acid (mRNA) and thus suppression of HMGA2 
protein levels (Lee et al. 2007). Loss of HMGA2 repression by let-7, e.g. through 
truncation of the 3’-UTR of HMGA2 or reduced let-7 miRNA levels can thus lead to 
HMGA2 re-expression due to reduced HMGA2 mRNA degradation and is associated 
with oncogenic transformation (Lee et al. 2007; Mayr et al. 2007). Involvement of 
miRNAs in HMGA1 regulation has been described also (Kaddar et al. 2009; Palmieri 
et al. 2011; Wei et al. 2011). The re-expression of HMGA2 and further let-7 regulated 
genes such as IGF2BP1 (insulin-like growth factor 2 mRNA binding protein 1), 
LIN28B (lin-28 homolog B (C. elegans)), as well as KRAS (v-Ki-ras2 Kirsten rat 
sarcoma viral oncogene homolog), NRAS (neuroblastoma RAS viral (v-ras) 
oncogene homolog), and MYC (v-myc myelocytomatosis viral oncogene homolog 
(avian)) was shown to lead to a process termed “reverse embryogenesis” (Johnson 
et al. 2005; Park et al. 2007; Peter 2009), meaning that their presence in adult cells 
promotes dedifferentiation and increase of “stemness”, which, if uncontrolled, might 
lead to the onset of tumour growth. 
However, controlled use of the stemness- and growth-inducing properties of HMGA 
proteins might also be used as a tool to regulate cell growth in situations where it is a 
wanted event such as in tissue engineering and -regeneration, i.e. in case of this 
thesis in the treatment of articular cartilage defects. Re-expression of HMGA proteins 
was shown to be involved in a large percentage of examined pulmonary chondroid 
hamartomas (Kazmierczak et al. 1995; Kazmierczak et al. 1996; Kazmierczak et al. 
1996; Wanschura et al. 1996; Kazmierczak et al. 1999; Rogalla et al. 2000; Tallini et 
al. 2000; Lemke et al. 2002). These benign tumours of the lung are characterised, 
amongst others, by their growth of chondroid, adipose and smooth muscle cells, and 
other cells of mesenchymal origin (Fletcher et al. 1995). Regulation and improvement 
of chondrocyte growth by HMGA proteins might thus be an important aspect 
overcoming some of the problems in cartilage tissue regeneration. On the one hand, 
increased cell proliferation might reduce the time needed for growing cells for 
autologous chondrocyte transplantation when cells are exposed to HMGA proteins or 
transfected with suitable vectors/agents inducing the expression of HMGAs. On the 
other hand, influence of HMGA proteins on chondrogenesis (Kubo et al. 2006) might 
prove beneficial for the cells’ differentiation stage, in the ideal case overcoming some 
of the problems of chondrocyte dedifferentiation in in-vitro cell culture (Harrison et al. 
2000; Veilleux et al. 2004; Chiang et al. 2010). 
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Concerning scaffolds, in addition to the already established biomaterials such as 
alginate or chitosan, non-biological matrices such as beta-tricalcium phosphate 
(?-TCP) might prove beneficial in cartilage regeneration, e.g. in case of defects 
involving both cartilage and the underlying bone like for example OD. Beta-TCP is an 
established material in bone repair and restoration, and usually gets degraded and 
replaced with newly-built tissue over time (Anker et al. 2005; Hirata et al. 2006). 
Preliminary studies with ?-TCP in combined bone and cartilage regeneration were 
successfully conducted in sheep and pigs (Guo et al. 2004; Gotterbarm et al. 2006; 
Jiang et al. 2007). No data was available for dogs, although some breeds are prone 
to develop OD leading to lameness. Seeding or connecting ?-TCP with chondrocytes 
thus might be a useful strategy in treating these kinds of defects, both for the benefit 
of the affected dog, as well as for humans using the dog as a model. 
Taken these aspects into consideration, application of HMGA proteins and 
derivatives thereof in cartilage tissue engineering seemed to be an auspicious 
therapeutic strategy. Therefore, the main focus of the work conducted during this 
thesis was set on this issue. HMGA proteins and peptides were examined in an in 
vitro animal model utilising porcine cartilage. In addition, a preliminary study 
concerning the applicability of ?-TCP structures for use in canine cartilage 
regeneration was investigated in an in vitro study, focusing on biocompatibility of 
these constructs with canine chondrocytes. 
Additional work included aspects of HMG and further genes in canine genetics and 
disease, as the dog has been established as a suitable model for various human 
diseases, promising benefit in treatment and cure for both dogs and their human 
owners (Ostrander et al. 1997; Kuska 1999; Ostrander et al. 2000; Ostrander et al. 
2000; Starkey et al. 2005; Shearin et al. 2010). 
 
Materials and Methods 
2. Materials and Methods 
2.1. Porcine cartilage 
Porcine cartilage was obtained from knee or elbow joints of freshly slaughtered pigs 
that were raised for meat production. The surrounding articular capsule was carefully 
removed and the cartilage cut from the subchondral bone in small chips by both a 
4mm biopsy punch and a scalpel. Cartilage was then washed in phosphate buffered 
saline (PBS) and transferred to a fresh petri dish containing the respective growth 
medium used in the adjacent procedures and experiments (see the particular 
Materials and Methods sections in the enclosed publications for details of medium 
used). 
2.2. Canine cartilage 
Canine cartilage was provided by the Small Animal Clinic, University of Veterinary 
Medicine Hannover, Foundation, Germany, and the Small Animal Clinic, Duisburg 
Asterlagen, Germany, from dog patients that underwent therapeutic surgery for either 
femoral head and neck excision or hip joint prosthesis implantation during therapy. 
Cartilage chips removed from the femoral head were immediately transferred into 
Hanks solution until further use. 
2.3. HMGA1a, HMGA1b, and HMGA2 expression vectors 
pET3a expression vectors (Merck Chemicals, Darmstadt, Germany) containing the 
complete coding sequences of the human HMGA1a, HMGA1b, and HMGA2 gene, 
respectively, were provided by the Centre for Human Genetics of the University of 
Bremen, Germany. For plasmid preparation, sequence verification, and long term 
storage, the expression vectors were transformed into the non-expression host 
Escherichia coli (E. coli) DH5? (Merck Chemicals) following the protocol of Inoue et 
al. (1990). Glycerol stocks were prepared by adding aliquots of 1ml bacterial culture 
to aliquots of 1ml 60% (v/v) glycerol in a sterile reaction tube for storage at -80°C. 
Plasmids were isolated using the QIAprep Spin Miniprep Kit (Qiagen, Hilden, 
Germany) according to the manufacturer’s instructions. Sequencing was done by 
Eurofins MWG GmbH (Ebersberg, Germany). 
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2.4. Recombinant protein expression 
The different HMGA proteins were recombinantly expressed in E. coli BL21(DE3) 
Rosetta pLysS (Merck Chemicals) following a protocol adapted from Schwanbeck 
(2000). Deviating from Schwanbeck’s protocol, the Rosetta pLysS strain was chosen 
and additional glucose was added to the growth medium leading to acceptable 
transformation efficiency through reduced background expression of the transgene, 
which proved impedimental to the previously used expression host 
E. coli BL21(DE3). Recombinant HMGA and other acid soluble proteins were 
recovered from the pelleted bacteria in a combined three cycle freeze and thaw 
acidic precipitation procedure in 5% (w/v) perchloric acid to remove non-acid soluble 
proteins with subsequent precipitation of HMGA by 6x vol. acidified -20°C acetone. 
The resulting pellet was freeze dried under vacuum and the proteins resolved in 
50mM ammonium hydrogen carbonate at 4°C. This crude acid soluble protein mix 
containing mostly HMGA was stored until further processing at -80°C. 
2.5. High-performance liquid chromatography 
Final purification of HMGA protein from the crude acid soluble protein mix was 
performed using a two-step high-performance liquid chromatography (HPLC) 
procedure. In the first step, acid soluble bacterial proteins as well as bacterial DNA, 
which were carried over from the acetone precipitation, were removed using a cation 
exchange column (TSKgel SP5 PW 20?m, Tosoh Bioscience GmbH, Stuttgart, 
Germany) and a gradient of 25mM H3BO3 pH 9.4 and 25mM H3BO3/1M NaCl pH 9.4 
at a flow rate of 1ml/min. Following this first purification step, a reverse phase HPLC 
purification (Grom-Sil 300 ODS-5 ST, Grom, Rottenburg-Hailfingen, Germany) with a 
gradient of 0.1% trifluoroacetic acid and 0.1% trifluoroacetic acid / 70% acetonitrile 
and a flow rate of 0.5ml/min of the fraction obtained from the cation exchanger was 
performed, enabling the removal of degraded or fragmentary HMGA, leading to a 
very pure fraction of intact protein. 
2.6. Sodium dodecyl sulphate polyacrylamide gel 
electrophoresis 
Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) was used 
for quality control of the purified HMGA protein fractions, in which an aliquot of the 
final HPLC-eluate was run on a discontinuous polyacrylamide gel (4% stacking gel, 
12% separating gel), followed by subsequent detection of protein bands by 
Coomassie staining. 
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2.7. Protein quantification 
For removal of eluent, gravimetric quantification, and long term storage of the 
complete protein batch, the fraction volume was first reduced using Amicon Ultra 
10000 MWCO (molecular weight cut off) centrifugation devices (Millipore, 
Schwalbach, Germany) and the proteins were subsequently lyophilised using a 
freeze dryer. Gravimetric quantification of the resulting HMGA protein pellets was 
performed on an analytical balance (Sartorius, Göttingen, Germany), and the pellets 
were frozen at -80°C for long term storage. For use in the particular experiments, 
aliquots of 10?g/?l protein in double distilled water (Invitrogen, Karlsruhe, Germany) 
were prepared and stored at -80°C. 
2.8. HMGA2 fragments 
The HMGA2 fragments (HMGA2-A: M-S-A-R-G-E-G-A-G-Q-P-S-T-S-A-Q-G-Q-P-A-
A-P-A-P-Q-K-R-G-R-G-R-P-R-K-Q-Q-Q-E-P-T-G-E-P-S-P-K-R-P-R-G-R-P-K-G-S-K-
N-K-S-P, 60 aa; HMGA2-B:, M-S-A-R-G-E-G-A-G-Q-P-S-T-S-A-Q-G-Q-P-A-A-P-A-P-
Q-K-R-G-R-G-R-P-R-K-Q-Q-Q-E-P-T-G-E-P-S-P-K-R-P-R-G-R-P-K-G-S-K-N-K-S-P-
S-K-A-A-Q-K-K-A-E-A-T-G-E-K-R-P-R-G-R-P, 80 aa) were provided by Aplagen 
GmbH, Baesweiler, Germany. They were synthesized by microwave assisted solid 
phase peptide synthesis and purified by liquid chromatography-mass spectrometry. 
The carboxyfluorescein labelled HMGA2-CC variant of the HMGA2-B peptide was 
synthesised and purified as described above, with additional coupling of 5/6-
carboxyfluorescein to the N-terminus at the final step of the solid phase synthesis. 
2.9. Primary cell culture 
The excised cartilage chips were further chopped and digested in 50% (v/v) 
collagenase NB8 (Serva Electrophoresis GmbH, Heidelberg, Germany) and tissue 
culture medium (for details of medium used, see the particular Materials & Methods 
sections in the enclosed publications) until the chondrocytes were released from the 
extracellular cartilage matrix. Following digestion, released cells were washed in 
tissue culture medium and transferred to a 25cm² tissue culture flask (Nunc, 
Wiesbaden, Germany) and grown at 37°C / 5% CO2 / 5ml tissue culture medium until 
75% confluency of the tissue culture flask. Cells were then detached with TrypLE 
(Invitrogen) and passaged once. Cells were again grown to 75% confluency of the 
flask and afterwards employed in the respective experiments. 
- 13 - 
Materials and Methods 
2.10. Cell proliferation assay 
Cell proliferation was measured using the Cell Proliferation ELISA, BrdU 
(colorimetric) kit (Roche Diagnostics, Mannheim, Germany) following the 
manufacturer’s instructions. Absorption reading was performed using the Anthos 
2001 microtitre plate reader (Anthos Mikrosysteme, Krefeld, Germany) or the BioTek 
Synergy HT microtitre plate reader (BioTek Instruments GmbH, Bad Friedrichshall, 
Germany). Data editing and visualisation was done with Excel 2003 software 
(Microsoft, Unterschleissheim, Germany). 
2.11. Cell penetration assay 
Uptake of the fluorescently labelled HMGA2-CC fragments was examined in a cell 
penetration assay with porcine chondrocytes in monolayer cell culture. Porcine 
chondrocytes were seeded onto glass plates in a 12-well microtitre cell culture plate 
(100,000 cells/well), and incubated with medium 199/10% foetal bovine serum (FBS) 
containing the fluorescently labelled HMGA2-CC peptide for 4h with peptide 
concentrations of 0?M (control), 10?M, and 50?M, respectively. Cells were washed 
to remove any residual peptides. To rule out any false positive signals caused by 
diffusion of peptides into permeable dead cells, vitality staining was performed prior 
to fluorescence microscopy. 
2.12. Beta-tricalcium phosphate cylinders (Cerasorb®) 
Cerasorb® cylinders were provided by Curasan AG, Kleinostheim, Germany. They 
consist of beta-tricalcium phosphate (?-TCP) with a phase purity of more than 99% 
and possess intrinsic interconnective porosity as caused by the material’s properties. 
Furthermore, so-called macropores (1mm diameter) are drilled throughout the 
cylinders, by which the complete inner and outer surfaces of the cylinder could be 
reached by medium flow-through and thus be colonised with cells. Also, the drill 
holes could be used to mount cartilage chips to the cylinders. 
2.13. Cerasorb® colonisation 
Colonisation of Cerasorb® cylinders with isolated canine chondrocytes was done in 
two steps. In the first step, the cylinders were stored in small volume containers (2 ml 
Gibco cryotube, Invitrogen) and inoculated with 1.2ml of tissue culture medium 
199/20% FBS containing 100,000 cells/ml each, so that the cells could settle on the 
cylinders and throughout the cylinders’ macropores. After the cells had attached (6h 
incubation), the cylinders were transferred to and fastened in a specially prepared 
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cell culture flask and covered with 15ml of medium 199/20% FBS. The cells were left 
to grow at 37°C 5% CO2 for one week, after which the cylinders were removed for 
analysis, i.e. vitality staining, visible light and fluorescence microscopy, and scanning 
electron microscopy. Medium was exchanged every three days. In addition, as no 
microscopic monitoring of the cells on the constructs was possible during the 
incubation period due to the specific experimental setup, control cells were seeded 
into 6-well multidish plates and grown under identical incubation conditions as the 
cells on the cylinders. These cells were microscopically checked during the 
incubation period and also subjected to the viability tests. 
Canine cartilage chips were cut to size so they would fit the drill holes and mounted 
to the cylinder using forceps. They were incubated under the same conditions as the 
isolated cells for one week, and examined accordingly. 
2.14. Vitality staining 
Viability of porcine chondrocytes following HMGA2-CC peptide application was 
determined by combined staining with propidium iodide (PI, detector stain, Sigma-
Aldrich Chemie GmbH, Munich, Germany) and 4?,6-Diamidin-2-phenylindol (DAPI, 
background stain, Roche Diagnostics, Mannheim, Germany), allowing the distinction 
of dead cells by the red PI stain in the nucleus. Medium (medium 199/10% FBS) was 
removed from the respective wells and replaced with medium 199/10% FBS 
containing 25?g/ml DAPI + 1?g/ml PI. After incubation for 5 minutes at room 
temperature, cells were washed with PBS to remove residual stains. In preparation 
for fluorescence microscopy, the glass plates were removed from the 12-well plate’s 
wells and embedded onto glass slides by rubber cement. 
Viability of canine chondrocytes on the Cerasorb® constructs as well as viability of 
the control cells grown in 6-well multidish plates was determined by trypan blue 
staining, followed by additional DAPI staining of the cells on the constructs, allowing 
the employment of fluorescence microscopy for determination of complete cell 
numbers and growth patterns. The control cells were not DAPI-stained, as these 
could easily be examined by phase contrast microscopy. The cylinders were 
removed from the cell culture flasks, washed in PBS, and incubated for 5 min in 0.2% 
trypan blue solution (Invitrogen). Afterwards, the constructs were washed with PBS to 
remove any residual trypan blue. The control cells were stained in the multidish plate 
following the same procedure. The washed cylinders were then incubated in 1?g/ml 
DAPI/methanol solution (Sigma-Aldrich Chemie GmbH) for 15 min and washed with 
methanol to remove any residual DAPI stain. 
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2.15. Visible light and fluorescence microscopy 
Microscopic evaluation was performed using an Axioskop 2 microscope (Carl-Zeiss-
AG, Oberkochen, Germany). An external light source was used for reflected visible 
light microscopy, while the built in UV-light source was used for fluorescence 
microscopy. Electronic documentation was done using Axiovision software releases 
4.5 and 4.8 (Carl-Zeiss-AG). 
2.16. Scanning electron microscopy 
Constructs were prepared for scanning electron microscopy (SEM) by fixation in 2% 
glutaraldehyde. SEM itself was conducted elsewhere on a LEO 1530 VP FE-SEM 
(Carl-Zeiss-AG). 
2.17. Statistical analysis 
Statistical analysis was performed with GraphPad Instat and GraphPad Prism 5 
software (GraphPad Software, La Jolla, USA) using the one way analysis of variance 
(ANOVA), with pairs of group means being compared by the Tukey test. A p value of 
<0.01 was deemed statistically significant. Before ANOVA, measured data were 
checked for identity of standard deviations by Bartlett’s test. In case of significant 
differences between the standard deviations of the different groups, logarithmic 
transformation (log10) of the raw data was performed, leading to identical standard 
deviations as is necessary for ANOVA. Gaussian distribution of sample data was 
checked for by the Kolmogorov-Smirnov test. 
2.18. In silico sequence analysis of the porcine HMGA genes 
During the work conducted for this thesis, the porcine genome had not been 
sequenced completely, and especially in regard to HMGA1 and HMGA2, information 
in the sequence databases was sparse. Thus, in silico sequence analysis of the 
porcine HMGA genes was conducted utilising known human sequence information, 
e.g. concerning exon / intron boundaries, and the porcine sequences that were 
available from the Entrez nucleotide and protein databases (National Center for 
Biotech Information (NCBI), National Library of Medicine, Bethesda, MD, United 
States of America) at that time. Sequence and structure of the porcine HMGA1 and 
HMGA2 mRNAs were determined using the Basic Local Alignment Search Tool 
(BLAST) (Altschul et al. 1990) provided by the NCBI. 
Results 
3. Results 
3.1. High mobility group proteins in cartilage regeneration 
In tissue engineering and regeneration of damaged articular cartilage, improved and 
controlled growth of chondrocytes is an important aspect. Usually in damaged areas, 
fibrocartilage formation occurs leading to less resilience of the affected joint and 
further damage due to premature abrasion of the recovered areas. Tissue 
engineering based therapies are hampered by the low number of viable cells 
available for growing new cartilage, as well as dedifferentiation of chondrocytes 
usually occurring when grown in culture. These strategies including the 
transplantation of autologous cells (autologous chondrocyte transplantation, ACT) 
amplified in cell culture or grown on matrices and in scaffolds thus still have room for 
improvement. 
Aberrations of HMGA genes were shown to be involved in the formation of 
pulmonary chondroid hamartomas (Kazmierczak et al. 1996; Kazmierczak et al. 
1999; von Ahsen et al. 2005), benign tumours of the lung that show, amongst others, 
focal differentiation into areas of articular cartilage (Koss 1990). Interestingly, 
overexpression of the HMGA2-LPP fusion gene was shown to promote expression of 
the chondrogenic COL11A2 (collagen, type XI, alpha 2) gene (Kubo et al. 2006). 
Therefore, the effect of recombinantly produced HMGA proteins on chondrocytes 
was evaluated in this study in regard to proliferation of the cells, a strategy that might 
improve tissue engineering techniques based on chondrocyte amplification. 
Due to the low availability of human articular cartilage specimens, porcine cartilage 
was chosen instead in these experiments. Protein sequence analysis showed 
complete agreement of the human and porcine HMGA1a and HMGA1b proteins, 
while the HMGA2 protein only showed one amino acid difference, but not in the 
functional motif of the AT-hooks. Thus, porcine cartilage was deemed sufficient for 
use in these trials. 
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Application of high-mobility-group-A proteins increases the proliferative 
activity of chondrocytes in vitro 
Richter et al., Tissue Engineering Part A, 2009 
The recombinant expression of the high mobility group proteins HMGA1a, HMGA1b, 
and HMGA2 was established in E. coli BL21(DE3) Rosetta pLysS (Merck 
Chemicals). While the procedure was described before (Schwanbeck 2000), it 
needed some adaptation to provide for successful transformation and growth 
efficiencies of the expression host as well as appropriate protein yield for the 
subsequent purification steps. The expression strain E. coli BL21(DE3) as used by 
Schwanbeck proved sensitive to transformation with the expression plasmids, and 
the small number of transformed clones showed impaired growth and protein 
production in culture. Therefore, a different strain E. coli BL21(DE3) Rosetta pLysS 
with reduced transgene background expression due to its additional pLysS plasmid, 
as well as growth medium supplemented with glucose for further reduction of 
background expression, was chosen for protein expression and led to sufficient 
amounts of crude recombinant protein. 
The basic HPLC purification procedure was also described before (Schwanbeck 
2000), and was successfully adapted to the HPLC equipment available. 
Application of these recombinant HMGA proteins to isolated porcine chondrocytes in 
cell culture showed some significant effects on proliferation of these cells in a dose 
dependent manner. Compared to the untreated control, at the lowest concentration of 
1?g/ml protein, a 1.5x increased growth could be detected for the HMGA1b protein, 
but not for HMGA1a and HMGA2 (there is a slight increase in measured cell 
proliferation, which however proved not statistically significant). However, at the 
increased amount of 10?g/ml, significant growth enhancing effects (about 1.5x) could 
be observed for all three proteins HMGA1a, HMGA1b, and HMGA2, when compared 
to the untreated control. Finally, at the highest administered dose of 100?g/ml, once 
again a significant increase in proliferation could be detected for all proteins 
HMGA1a, HMGA1b, and HMGA2 when compared to the untreated control, albeit 
with a protein specific effect of 1.7x in case of HMGA1a, and about 2x in case of 
HMGA1b and HMGA2. Concerning dosage, significant differences in proliferation 
could be seen between the application of 1?g/ml, 10?g/ml, and 100?g/ml in HMGA1a 
and HMGA2, but not HMGA1b. 
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Application of High-Mobility-Group-A Proteins Increases
the Proliferative Activity of Chondrocytes In Vitro
Andreas Richter, M.Sc.,1 Gregor Hauschild, D.V.M.,2 Hugo Murua Escobar, Ph.D.,1,3
Ingo Nolte, D.V.M.,3 and Jo¨rn Bullerdiek, Ph.D.1,3
The low capability of self-repair in hyaline cartilage tissue and chondrocytes de-differentiatingwhen grown in vitro
(e.g., for tissue engineering approaches) limits articular cartilage repair. It has been shown that the embryonic
architectural transcription factors of the high-mobility-group-A (HMGA) protein family affect the regulation of
cell differentiation by influencing the state of cell chromatin and are involved in hyaline cartilage development by
affecting the expression of chondrocyte-specific marker genes. Thus, the control of cartilage cell proliferation and
differentiation by HMGA proteins promises to be an important aspect in cartilage tissue repair. To elucidate the
effects on the proliferative activity of hyaline chondrocytes, HMGA proteins were recombinantly expressed,
highly purified, and applied to porcine hyaline cartilage cells growing in in vitro monolayer cell culture. Direct
application of HMGA1a, HMGA1b, and HMGA2 proteins onto porcine chondrocytes was shown to have a highly
significant influence on cell proliferation. Greater proliferation of chondrocytes was achieved than in the untreated
control group, indicating a promising approach to enhancing cartilage tissue repair.
Introduction
Articular cartilage defects affect a large number ofpatients from all age groups. Although normal wear
and tear affects a high percentage of the elderly, in younger
people, overstressing or injuring articular cartilage through,
for example, high-impact sports or defective positions of
joints may lead to damage and degradation.
In contrast to many other tissues, because of the absence of
a blood supply, damaged articular cartilage has only limited
capacity for self-repair, with joint surface defects above a
critical size healing poorly and eventually leading to osteo-
arthritis.1 Furthermore, the intrinsic repair mechanism of
articular cartilage usually leads to the formation of fibro-
cartilage, which is unable to sustain the pressures it is usually
exposed to in the joint, leading to new lesions that can affect
the underlying bone as well.2
Apart from applied surgical interventions such as lavage
and arthroscopy, shaving, debridement, laser abrasion and
chondroplasty, abrasion chondroplasty, and Pridie drilling,
tissue-engineering techniques are gaining a larger share in the
treatment of articular cartilage defects.3 Tissue engineering
uses biologically based mechanisms for repairing and healing
of damaged and diseased tissues, employing techniques from
various disciplines such as biology, material science, engi-
neering, manufacturing, and medicine.4 A tissue-engineering
approach that has gained attention in recent years in cartilage
regeneration is the transplantation of autologous chon-
drocytes (autologous chondrocyte transplantation, ACT) that
have been grown in vitro, with recent approaches including
the use of matrices or scaffolds for facilitating cell growth.
Nevertheless, the low quality of the engineered cartilage
hampers regeneration of the damaged regions because
chondrocytes usually dedifferentiate over time in vitro.5
Growth of cells in agarose gels,6 alginate beads,7 or collagen
matrices8 has a beneficial effect on the differentiation state of
cells, and the application of growth factors such as insulin-
like growth factor-I, interleukin-4, and transforming growth
factor-beta 1 has led to an increase in the rate of cartilage
tissue growth and extracellular matrix deposition.9
Another approach for directed cartilage cell growth and
differentiation is the specific use of embryonic proteins that
are involved in the control of cartilage formation in the de-
veloping organism (i.e., those of the high-mobility-group-A
(HMGA) family). HMGA proteins are chromatin-associated
nonhistone proteins strongly conserved in mammals that act
as architectural transcription factors, having no direct influ-
ence on transcription but acting indirectly by enabling the
interaction of various transcription factors (e.g., enhanceo-
some formation in interferone-beta).10 By acting as ‘‘master
switches’’ influencing the expression of more than 5000 genes,
HMGA proteins also influence the expression of genes
involved in chondrogenesis, such as COL11A2.11 Further-
more, it has been shown that HMGA2 is expressed at high
1Center for Human Genetics, University of Bremen, Bremen, Germany.
2Department of Orthopedics, University of Muenster, Muenster, Germany.
3Research Cluster of Excellence ‘‘REBIRTH,’’ University of Veterinary Medicine Hanover, Hanover, Germany.
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levels in human embryonic stem cells, regulating key devel-
opmental genes that are linked to mesenchymal cell differ-
entiation.12,13 The HMGA family genes being predominantly
expressed in embryonic tissue, no expression of HMGA2 had
been identified after birth or in fully differentiated adult tis-
sue14 until the recent advent of more-sensitive detection
methods such as quantitative real-time polymerase chain re-
action, which in some apparently normal adult tissues also
provided evidence for basal HMGA2 expression.15–17 Altera-
tions ofHMGA genes could be detected in a variety of tumors,
many of them showing areas with entopic or ectopic cartilage
growth. In soft tissue and skeletal chondromas, nonrandom
involvement of the region 12q13–15, which includes the
HMGA2 locus, has been shown with expression of truncated
(exons 1–3), fusion (e.g., HMGA2=LPP), or full-length tran-
scripts of HMGA2, respectively.18
In pulmonary chondroid hamartomas (PCHs), re-
expression of HMGA genes is a highly important aspect in
tumor formation. PCHs, which are the most common benign
tumors of the lung,19 consist of focal overgrowths of articular
cartilage, smooth muscle, mature adipocytes, and respiratory
tract epithelium.20 Chromosomal rearrangements of HMGA
genes or parts thereof (the DNA-binding AT-hooks), includ-
ing one of the most frequent fusion genes found in human
tumors, HMGA2-LPP, commonly cause re-expression of
HMGA proteins in PCHs.21 In a series of 191 PCHs, cytoge-
netic and fluorescence in situ hybridization analyses showed
6p21.3 (HMGA1) aberrations in 25% of cases and 12q14–15
(HMGA2) aberrations in 58.7% of cases.22
Because HMGA-family genes are frequently involved in
PCH formation and growth of articular cartilage is one pro-
minent feature of these tumors, the effect of HMGA proteins
on articular cartilage cell differentiation and growth is an
important aspect in the regeneration of articular cartilage. The
control of chondrocyte growth by HMGA proteins might
prove useful for the application of cell engineeringmethods in
articular cartilage repair, especially by facilitating and
speeding up the production of cells used for seeding struc-
tures and by keeping the cells in a differentiated state. Thus,
the aim of this study was the evaluation of the influence of
HMGA family proteins on chondrocyte growth by examin-
ing the proliferational effect of recombinantly produced
HMGA1a, HMGA1b, and HMGA2 proteins on porcine
chondrocytes grown in in vitro monolayer cell culture.
Materials and Methods
Expression and purification of recombinant
HMGA proteins
Recombinant HMGA proteins were produced using the
Novagen pET System (Merck Chemicals, Darmstadt, Ger-
many) following a protocol adapted from Schwanbeck et al.23
The complete coding sequences of the human HMGA1a,
HMGA1b, and HMGA2 were inserted into the pET3a vector.
Subsequently, transformation of the nonexpression host
Escherichia coli DH5a with these plasmids was performed for
verification using sequencing and long-term storage. Protein
expression was performed using freshly transformed E. coli
BL21(DE3) Rosetta pLysS (Merck Chemicals). A preparatory
culture was grown to an optical density (OD) of 0.6 in 10mL
Luria-Bertani (LB) broth supplied with 100mg=mL ampicillin,
34 mg=mL chloramphenicol, and 1% (w=v) glucose. After in-
oculation, 1 L of expression culture (LB broth supplemented
with 100mg=mL ampicillin, 34mg=mL chloramphenicol, and
0.5% (w=v) glucose) was grown to an OD of 0.6, followed by
induction of protein expression with 1mmol=L isopropyl-
beta-D-thiogalactopyranoside. Expression was performed for
120min at 378C, and the culture was thereafter stored on ice
and then pelleted using centrifugation.
HMGA and other acid-soluble proteins were recovered
from the bacteria by performing a combined three-cycle freeze
(208C) and thaw and acidic precipitation procedure with 3
(w=v) 5% perchloric acid, resulting in lysis of bacterial cells
and precipitation of bacterial debris and non-acid-soluble
proteins. After centrifugation, the HMGA-containing super-
natant was removed and acidified with 37% hydrochloric acid
(HCl) to a final concentration of 0.35m HCl. Precipitation of
HMGA proteins was performed by adding 6 volume of
208C acetone. Proteins were pelleted by centrifugation in
80-mL glass tubes, and the acetone supernatant was carefully
removed and the pellet frozen to 808C and dried under
vacuum. Pelleted proteins were resolved using 50mM am-
monium hydrogencarbonate at 48C. The crude acid-soluble
protein mix containing mostly HMGA was stored until fur-
ther processing at808C. Final purification ofHMGAproteins
was performed using a two-step high-performance liquid
chromatography procedure. In the first step, acid-soluble
bacterial proteins and bacterial DNA that were carried over
from acetone precipitation were removed using a cation ex-
change column (TSKgel SP5 PW 20mm, Tosoh Bioscience
GmbH, Stuttgart, Germany) and a gradient of 25mM boric
acid pH 9.4 and 25mM boric acid=1M sodium chloride, pH
9.4. Because of the lack of aromatic amino acids in HMGA
proteins, identification of the HMGA fraction was achieved
using a 215-nm absorption peak proximal to the absorption
maximum of the peptide bond at 205 nm. After this first pu-
rification step, reverse-phase high-performance liquid chro-
matography purification (Grom-Sil 300 ODS-5 ST, Grom,
Rottenburg-Hailfingen, Germany) with a gradient of 0.1%
trifluoroacetic acid and 0.1% trifluoroacetic acid=70% aceto-
nitrile of the fraction obtained was performed, enabling the
removal of degraded or fragmentaryHMGA, leading to a very
pure fraction of intact protein. Quality control was performed
using polyacrylamide gel electrophoresis (data not shown).
For removal of eluent, gravimetric quantitation, and long-term
storage, fraction volumewas first reduced usingAmicon Ultra
10000 MWCO centrifugation devices (Millipore, Schwalbach,
Germany) and then lyophilized using a freeze dryer.
Cell culture
Chondrocytes were obtained from the elbow joint of an
approximately 4-month-old pig for slaughter that was culled
for meat production at the local abattoir. This company op-
erates under the German animal protection law and is li-
censed formeat production by the Federal Office of Consumer
Protection and Food Safety, which indicates ethical treatment
of the animals slaughtered. Cartilage was carefully removed,
excluding the calcified inner cartilage layer, using a scalpel.
The cartilage pieces were further chopped and digested for at
least 6 h at 378C=5% carbon dioxide (CO2) in 50% v=v colla-
genase NB8 (Serva Electrophoresis GmbH, Heidelberg,
Germany) and tissue culture medium (medium 199 contain-
ing Earle’s salts and L-glutamine (Invitrogen, Karlsruhe,
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Germany), 200 IU penicillin, 200mg=mL streptomycin (Bio-
chrom, Berlin, Germany), and 10% pig serum (Invitrogen,
Karlsruhe, Germany)) until the chondrocytes were released
from the extracellular cartilage matrix. After digestion, re-
leased cells were washed, transferred to a 25-cm2 tissue cul-
ture flask (Nunc, Wiesbaden, Germany), and incubated at
378C=5% CO2=5mL tissue culture medium as described pre-
viously until three-quarters confluency of the tissue culture
flask was reached. This was followed by one further passage.
In vitro cell proliferation assay
Cells were harvested using TrypLE Express (Gibco, Karls-
ruhe, Germany), resuspended in fresh tissue culture medium
as described previously, and counted using a hemocytometer.
Concentration was adjusted to 75,000 cells=mL. HMGA pro-
teins HMGA1a, HMGA1b, and HMGA2 were adjusted
to concentrations of 1mg=mL, 10mg=mL, and 100 mg=mL,
respectively, in tissue culture medium. For each protein, as-
says with concentrations of 0mg=mL, 0,1 mg=mL, 1 mg=mL,
and 10 mg=mL were performed using a bromodeoxyuridine
(BrdU) cell proliferation enzyme-linked immunosorbent as-
say (ELISA) kit (Roche Diagnostics, Mannheim, Germany).
For each parameter, cells were seeded in eight wells of a 96-
well cell culture microtiter plate (Nunc, Wiesbaden, Ger-
many) with a concentration of 7500 cells per well (100mL of
cell solution). Cells were left at 378C=5% CO2 overnight, fol-
lowed by the addition of the corresponding amounts of pro-
tein. After an incubation period of 24 h at 378C=5% CO2, BrdU
was added followed by incubation at 378C=5% CO2 for an-
other 24 h. BrdU incorporation detection was performed ac-
cording to the manufacturer’s instructions using the Anthos
2001 microtiter plate reader (Anthos Mikrosysteme, Krefeld,
Germany). Data were normalized using the non-HMGA
control as the reference value.
Statistics
Statistical analysis was performed using GraphPad Instat
and GraphPad Prism 5 software (GraphPad Software,
La Jolla, Ca) using one-way analysis of variance ANOVA,
with pairs of group means being compared using the Tukey
test. The significance level was set at p< 0.01. Homogeneity of
variances was checked using Bartlett’s test, which showed
significant differences between the standard deviations of
the different groups. Therefore, logarithmic transformation
(log10) of raw data was performed as suggested by the soft-
ware, leading to identical standard deviations as assumed by
ANOVA. Gaussian distribution of sample data was demon-
strated using the Kolmogorov-Smirnov test with all popula-
tions passing the normality test.
Results
The proliferative response of porcine chondrocytes to hu-
man recombinantHMGAproteins in vitrowas examined in an
ELISA-based assay measuring the incorporation of BrdU into
the newly synthesized DNA of dividing cells. For compara-
bility, the absorbance values obtained from the microtiter
plate reader were normalized to the values of the non-HMGA
control, which was set to a value of 1 (Figure 1).
The one-way ANOVA resulted in a p-value< 0.001 indi-
cating extremely significant variation between the different
groups, leading to the conclusion that at least two groups
were significantly different. For determination of group dif-
ferences, pairs of group means were compared using the
Tukey test, as shown in Table 1.
Deducing from the statistical analysis, proliferative effects
of three human recombinant HMGA proteins, including the
splicing variants HMGA1a and HMGA1b and the closely re-
lated HMGA2, on porcine hyaline cartilage cells were com-
pared with those of the non-HMGA-treated control group.
Cell Proliferation Induced by HMGA Proteins
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FIG. 1. Cell proliferation of
porcine hyaline cartilage cells
induced by the addition of
high-mobility-group-A
(HMGA) proteins at different
concentrations. Values ob-
tained using the microtiter
plate reader were normalized
to the absorbance of the non-
high-mobility-group control,
which was set as 1. The error
bars indicate the standard
deviation. OD, optical density.
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Although at the lowest concentration of 1 mg=mL protein,
no differences from the control group were seen with
HMGA1a and HMGA2, significant greater cell proliferation
was visible for HMGA1b, leading to 1.5 times greater cell
proliferation than in the control group. At concentrations
of 10mg=mL of protein, a significant greater proliferative rate
is apparent for each protein, HMGA1a, HMGA1b, and
HMGA2, than for the non-HMGA-treated control group.
When adding 100mg=mL of protein, a significant difference in
proliferation from the control group can also be seen for all
proteins, with HMGA1b and HMGA2 nearly doubling the
proliferative rate of cells and HMGA1a leading to 1.7 times
greater cell proliferation.
As to the different concentrations, significant differences
between the application of 1m=mL and 100mg=mL were seen
for HMGA1a and HMGA2 but not for HMGA1b.
Discussion
Usually being expressed only in developing embryonic
tissue or at very low levels in adults,15–17 re-expression
of members of the HMGA protein family was found to be of
significant influence in a variety of benign tumors, some of
them displaying growth of differentiated chondrocytes at ec-
topic (pulmonary chondroid hamartomas) or entopic (chon-
dromas) sites.18,22 Furthermore, involvement of the complete
HMGA2 and the HMGA2=LPP fusion gene consisting of the
first three exons of HMGA2 (encoding the eponymous func-
tionalmotifs of theDNA-bindingAT-hooks) and exons 9–11 of
LPP in expression regulation of the chondrogenous COL11A2
has been demonstrated.11 Based on these findings, the pro-
liferative effect of recombinantly produced HMGA proteins
(human HMGA1a, HMGA1b, and HMGA2) on porcine
chondrocytes grown in-vitro in monolayer cell culture was
comparedwith an untreated control. BecauseHMGAproteins
are highly conserved between mammals, with the porcine
HMGA1a andHMGA1b showing only oneAA exchange from
threonine to alanine at the first AA position of the third AT
hook compared with their human counterparts (no sequence
data on porcine HMGA2 is available yet in the public data-
bases), the coding sequences of the human HMGA genes were
used for the expression vector. In this study, administration of
humanHMGA1a, HMGA1b, andHMGA2 proteins to porcine
chondrocytes showed a highly significant effect on cell pro-
liferation at levels of 10mg=mL or 100mg=mL of protein. In
addition, application of HMGA1b had a significant effect at
1mg=mL protein. Although HMGA proteins do not directly
regulate transcription, they indirectly influence gene expres-
sion by acting as architectural transcription factors (e.g., by
interacting with (AT-rich) DNA and several transcription
factors). For example, in the beta-interferon enhancer, the ac-
tivity of the transcription factor nuclear factor-kappaB is en-
hanced under the influence of HMGA2 bound to its AT-rich
target DNA sequence.24 In human embryonic stem cells,
HMGA2 plays an important role in chromatin structure,
which in turn is a key factor determining stem cell identity. By
influencing the state of embryonic stem cell chromatin,
HMGA2 might be an important factor in differentiation initi-
ation.14 Concerning PCHs, re-expression of HMGA proteins
might lead to differentiation of mesenchymal stem cells found
in the tumor toward the chondrocyte phenotype. Furthermore,
initial de-differentiation of fully differentiated chondrocytes
caused by HMGA proteins in conjunction with the chondro-
genic activity of HMGA might initiate growth of these cells
while keeping their chondrocyte phenotype. As to the mech-
anisms bywhich extracellularHMGAproteins can support the
growth of chondrocytes, two explanations can be advanced.
First, an uptake of the proteins may lead to higher intracellular
protein concentrations, the latter directly influencing the
chromatin structure of the target cells and enhancing their
proliferation. Second, extracellular functions of the proteins
that are unknown may account for the findings. HMGB1 is a
Table 1. Tukey Test Comparing the Effect of Different High-Mobility-Group-A (HMGA) Proteins
and Protein Concentrations on the Proliferation of Porcine Chondrocytes
Control
HMGA1a
1mg=ml
HMGA1a
10mg=ml
HMGA1a
100mg=ml
HMGA1b
1mg=ml
HMGA1b
10mg=ml
HMGA1b
100mg=ml
HMGA2
1mg=ml
HMGA2
10mg=ml
HMGA2
100mg=ml
Control
HMGA1a
1mg=ml
>0.01
HMGA1a
10mg=ml
<0.01 >0.01
HMGA1a
100mg=ml
<0.01 <0.01 >0.01
HMGA1b
1mg=ml
<0.01 >0.01 >0.01 >0.01
HMGA1b
10mg=ml
<0.01 >0.01 >0.01 >0.01 >0.01
HMGA1b
100mg=ml
<0.01 <0.01 >0.01 >0.01 >0.01 >0.01
HMGA2
1mg=ml
>0.01 >0.01 >0.01 <0.01 >0.01 >0.01 <0.01
HMGA2
10mg=ml
<0.01 >0.01 >0.01 >0.01 >0.01 >0.01 >0.01 >0.01
HMGA2
100mg=ml
<0.01 <0.01 >0.01 >0.01 >0.01 >0.01 >0.01 <0.01 >0.01
Grey cells indicate significant differences with a p-value< 0.01.
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protein of yet another subfamily of the high-mobility group
proteins. Initially, it has been described as a nuclear protein as
well, but it has been discovered that HMGB1 has extracellular
functions aswellwhen, for example, being released bynecrotic
cells or actively secreted by activatedmacrophages. Generally,
it cannot be ruled out that HMGA2 also has a yet-unknown
extracellular function. The application of HMGA proteins in
chondrocyte growth provides a promisingway to enhance the
methods of cartilage tissue repair.
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Results 
3.2.  Development of HMGA2 fragments for use in tissue 
engineering 
As was shown in the previous paper, the application of recombinant HMGA proteins 
could improve the growth of porcine chondrocytes in an in vitro proliferation assay 
(Richter et al. 2009). However, for application in a perspective therapeutic context, 
the use of recombinant agents from biological systems also has some 
disadvantages, such as potential unwanted modifications of the protein by the 
expression host or contaminations that still might remain in the final product in trace 
amounts albeit purification procedures. 
Thus, a variant of the active agent produced in a non-biological system might be of 
advantage diminishing any potential biological contamination provided that it shows 
comparable biological activity to the recombinantly produced protein. 
Due to their lack of secondary structure (Reeves et al. 2001), HMGA proteins can be 
synthesised synthetically e.g. by solid phase protein synthesis (SPPS). This method 
is constrained by the length of the synthesised fragment as the efficiency of every 
single coupling step adds up to the final yield of the product, leading to a maximum of 
70 amino acids that can be synthesised satisfactorily in SPPS. Longer fragments can 
be gained by chemically coupling two peptide strains. However, as it had been 
shown before that truncated HMGA2 remains active albeit the loss of the C-terminal 
part of the protein (Battista et al. 1999) as long as its functional motifs the AT-hooks 
are present (Geierstanger et al. 1994), two shorter variants of 60 aa and 80 aa, 
respectively, containing either two (HMGA2-A) or three (HMGA2-B) AT-hooks were 
synthesised, overcoming the limitations that would arise when trying to synthesise 
the complete HMGA2 protein (109 aa). 
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High-mobility group protein HMGA2-derived fragments stimulate the 
proliferation of chondrocytes and adipose tissue-derived stem cells 
Richter et al., European Cells and Materials, 2011 
Porcine chondrocytes were subjected to the same proliferation assay procedure as 
described before (Richter et al. 2009), where they were trialled for growth inducing 
effects of HMGA1a, HMGA1b, and HMGA2. For better comparability due to the 
differing sizes of the HMGA2 protein and the HMGA2 fragments, molarities instead of 
weight were used for determining the amount of active agent used in the 
experiments. In addition, only fragments of HMGA2 and the HMGA2 protein were 
used in this experimental setup. Supplementary to chondrocytes, canine adipose 
tissue derived stem cells (ADSCs) were trialled as well, as they can be differentiated 
into the chondrogenic lineage when exposed to specific factors (Zuk et al. 2001; Zuk 
et al. 2002). Supplementing the cell proliferation ELISA, fluorescence microscopy 
was performed for determination of the cellular uptake and localisation of a 
fluorescently labelled variant of one of the fragments as well for detection of cell 
viability allowing the exclusion of any false positive results in peptide take-up due to 
the permeability of dead cells. 
Fluorescence microscopy revealed an accumulation of the labelled HMGA2-CC 
variant in the nuclei of about 50% of the chondrocytes at both concentrations of 
10?M and 50?M peptide, while in ADSCs, a percentage of 24 could be detected at 
the concentration of 100?M. Nearly 100% of the cells showed green fluorescence in 
the cytoplasm, indicating accumulation of the peptide instead of nuclear transport. 
Only a minimum amount of cells showed red fluorescence indicating cell death. 
In chondrocytes, the cell proliferation ELISA revealed a significant doubling of 
proliferation caused by the 60 aa HMGA2-A peptide at both concentrations of 10?M 
and 50?M, as well as for the 109 aa recombinantly produced HMGA2 protein at 
10?M (there was no 50?M control for the HMGA2 protein), when compared to the 
untreated control. Between HMGA2-A and HMGA2, no significant difference could be 
detected in the proliferation inducing effect, indicating that the smaller 60 aa peptide 
is a suitable replacement for the complete HMGA2 protein. The HMGA2-B peptide on 
the other hand only showed a 1.5x increase at the lower concentration of 10?M, 
however, this was not statistically significant when compared to the untreated control. 
At 50?M, no significant difference could be seen when compared to the control. 
In canine ADSCs, there was a slightly different picture as the shorter HMGA2-A 
peptide could induce significant proliferation only at the higher concentration of 
- 26 - 
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50?M, while the longer HMGA2-B peptide induced significant proliferation at the 
lower concentration of 5?M. No positive control utilising recombinant HMGA2 was 
performed. 
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Abstract
In previous research, it was shown that recombinant 
HMGA2 protein enhances the proliferation of porcine 
chondrocytes grown in vitro, opening up promising 
applications of this embryonic architectural transcription 
factor for tissue engineering, such as in cartilage repair. 
In this paper, we describe the development and analyses 
of two synthetic fragments comprising the functional 
AT-hook motifs of the HMGA2 protein, as well as the 
nuclear transport domain. They can be synthesised up 
to large scales, while eliminating some of the problems 
of recombinant protein production, including unwanted 
modi? cation or contamination by the expression hosts, 
or of gene therapy approaches such as uncontrolled viral 
integration and transgene expression even after therapy. 
Application of one of these peptides onto porcine hyaline 
cartilage chondrocytes, grown in in vitro monolayer cell 
culture, showed a growth-promoting effect similar to 
that of the wild type HMGA2 protein. Furthermore, it 
also promoted cell growth of adult adipose tissue derived 
stem cells. Due to its proliferation inducing function and 
vast availability, this peptide is thus suitable for further 
application and investigation in various ? elds such as tissue 
engineering and stem cell research.
Keywords: High-mobility-group protein A2, cartilage, 
chondrocytes, adipose tissue derived stem cells, tissue 
regeneration.
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Introduction
Recombinant High-Mobility-Group A2 (HMGA2) 
proteins have been shown to signi? cantly increase the 
proliferative activity of chondrocytes in a dose-dependent 
manner in an in vitro system of porcine origin (Richter 
et al., 2009). Since articular cartilage defects are a major 
problem in patients from all ages, this opens up future 
possibilities to improve cell yield for in vitro propagation 
of these cells.
 However, in terms of a perspective therapeutic 
application of this protein and its authorisation, the 
recombinant HMGA2 protein production process has 
some disadvantages, including potential unwanted 
modi? cations of the protein by the expression hosts, 
microbial contamination including foreign DNA and 
proteins, as well as further contamination e.g. from the 
growth medium that all need to be taken care of. To 
avoid these issues, we developed two peptide fragments 
HMGA2-A (60mer) and HMGA2-B (80mer) that are 
synthesised by microwave assisted solid phase peptide 
synthesis thus eliminating any steps involving prokaryotic 
or eukaryotic protein expression systems and providing 
the ability of large scale synthesis of these biologically 
active substances for future ? elds of application in e.g. 
tissue engineering. This peptide approach also enables 
the direct application of the active agent only during the 
phase of treatment, as opposed to e.g. virus based delivery 
systems, where uncontrolled viral integration, genomic 
instability, and transgene expression even after therapy 
may occur, and also makes possible the direct delivery 
of the molecules into the cells due to the small molecule 
nature of the developed peptides. The two peptides or 
fragments thereof are expected to show comparable 
effects to the native protein by comprising the eponymous 
biologically active AT-hooks of HMGA2, which bind to 
the minor groove of AT-rich DNA and thereby in? uence 
DNA conformation and binding of various transcription 
factors, ? nally in? uencing the activity of a large number 
of genes (Reeves and Beckerbauer, 2001).
 As HMGA2 has virtually no secondary structure 
(Reeves and Beckerbauer, 2003), it allows for the use of 
synthesised peptides of parts thereof, i.e. in this case the 
DNA binding AT-hooks, without further modi? cation. 
In previous research, it had been shown that synthetic 
peptides comprising only the 3 AT-hooks still possess 
the DNA-binding capability of the native protein 
(Geierstanger et al., 1994); however, the focus was not set 
on any function besides DNA-binding. Later it was shown 
that truncated HMGA2 lacking the carboxy-terminus led 
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to increased growth of NIH3T3 cells as compared to wild 
type HMGA2 (Fedele et al., 1998) and remains functional 
in recombinant mice (Battista et al., 1999).
 While the function of the AT-hooks is thus well-known 
and described (Reeves and Nissen, 1990; Geierstanger et 
al., 1994; Chau et al., 1995; Goodwin, 1998; Reeves, 2000; 
Cattaruzzi et al., 2007; Cleynen and Van de Ven, 2008), the 
role of the acidic C-terminus is still not well understood, 
but it is assumed that it is responsible in parts, amongst 
others, for the protein binding capacity of HMGA2 (Noro 
et al., 2003), and sequence speci? city of DNA-binding 
(Yie et al., 1997).
 The aim of this study therefore was the evaluation of 
the two newly synthesised fragments of HMGA2 in respect 
to cell growth in the same in vitro cell culture system as 
described before (Richter et al., 2009), as well as to the cell 
penetration / DNA-binding capacity which was determined 
by ? uorescence microscopy of a labelled variant of the 
HMGA2-B peptide (HMGA2-CC). In addition to porcine 
chondrocytes, the peptides were also applied to canine adult 
adipose tissue derived stem cells (ADSCs), as these can 
be differentiated into chondrogenic cells in the presence 
of lineage-speci? c induction factors including insulin and 
TGF-?, leading to the formation of hyaline cartilage (Zuk 
et al., 2001; Huang et al., 2004).
Materials and Methods
HMGA2 fragment synthesis
Two fully synthetic HMGA2 fragments (60 AA and 80 
AA, Fig. 1) were synthesised at a scale of 0.25 mmol 
by microwave assisted solid phase peptide synthesis 
in an automated Liberty unit (CEM, Kamp-Lintfort, 
Germany). The growing peptide chain was assembled on 
PAL ChemMatrix resin (Matrix Innovation, Montreal, 
Canada). Deprotection was achieved by adding 10 mL 
Piperidine (5% in dimethylformamide / 0.1M HOBt 
(Biosolve BV, Valkenswaard, Netherlands)) and irridation 
with 65 W for 3 min. Coupling of the next amino acid 
was achieved using a ? vefold excess of reagents (amino 
acid, Pyclock (Livchem, Frankfurt/Main, Germany), 
Cl-HOBt (Biosolve, Valkenswaard, Netherlands), 
Diisopropylethylamine (Iris Biotech, Marktredwitz, 
Germany)) in 10 mL dimethylformamide and irradiation 
with 40 W for 5 min. All couplings were done by a double 
coupling procedure including capping with Z-2-Br-OSu 
(Iris Biotech, Marktredwitz, Germany). After washing 
with dichloromethane, the peptide was cleaved by adding 
40 mL cleavage cocktail (94% tri? uoroacetic acid, 1.0% 
triisopropylsilane (Sigma, Deisenhofen, Germany), 
2.5% H2O, 2.5% 3,6-Dioxa-1,8-octandithiol (Sigma, 
Fig. 1. Amino acid sequence and structure of the two HMGA2 peptides. DBD = DNA binding domain.
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Deisenhofen, Germany)) and reaction at room temperature 
for 3 h. The peptide was then precipitated in 160 mL cold 
ether, solved in acetonitrile/water and puri? ed by Liquid 
chromatography-mass spectrometry (LC-MS) using a 
Nebula (Gilson) puri? cation system (Column: C18 reprosil 
100 10 ?m 250 x 20mm; ? ow rate: 20 mL/min; eluent A: 
water and 0.1% TFA; eluent B: acetonitrile & 0.085% 
TFA). Analysis of the puri? ed peptides was performed 
by HPLC (Column: Phenomenex Gemini 5 ?m 110 A 
4.6 mm x 250 mm, eluent A: water & 0.1% TFA; eluent 
B: acetonitrile & 0.085% TFA; ? ow rate: 1 mL/min) and 
electrospray-ionisation mass spectrometry (ESI-MS) (Fig. 
2: HMGA2-A and Fig. 3: HMGA2-B).
Syn thesis of the carboxy? uorescein labelled 
HMGA2-B variant
The carboxy? uorescein labelled variant of the HMGA2-B 
peptide was synthesised as described above, with additional 
coupling of 5/6-carboxy? uorescein to the N-terminus at the 
? nal step of the solid phase synthesis. In this procedure, 
the label was coupled to the solid phase, i.e. all reactive 
groups excluding the N-terminus were still protected 
leading to selective N-terminal labelling of the peptide. For 
this cause, no further validation of the N-terminal coupling 
of the label was performed as it can be assumed from the 
procedure that the label can only bind to the N-terminus of 
the peptide. Coupling was performed by the use of N,N’-
Diisopropylcarbodiimid (Sigma) / HOBt and coupling for 
12 h at room temperature. The labelled fragment was then 
puri? ed as described above.
Expression and puri? cation of recombinant HMGA2 
protein
Recombinant HMGA2 produced using the Novagen 
pET System (Merck Chemicals, Darmstadt, Germany) 
following a protocol adapted from Schwanbeck (1995) 
served as a positive control. The complete coding 
sequences of HMGA2 was inserted into the pET3a vector. 
Subsequently, transformation of the non-expression host 
E. coli DH5? with these plasmids was performed for 
veri? cation by sequencing and long term storage. Protein 
expression was performed with freshly transformed E. 
coli BL21(DE3) Rosetta pLysS (Merck Chemicals). A 
preparatory culture was grown to an OD of 0.6 in 10 mL 
LB broth supplied with 100 ?g/mL ampicillin, 34 ?g/mL 
chloramphenicol and 1% (w/v) glucose. After inoculation, 
1L of expression culture (LB broth supplied with 100 ?g/
mL ampicillin, 34 ?g/mL chloramphenicol and 0.5% (w/v) 
glucose) was grown to an OD of 0.6, followed by induction 
of protein expression with 1 mmol/l IPTG. Expression was 
performed for 120 min at 37 °C, the culture was thereafter 
stored on ice and then pelleted by centrifugation.
 HMGA2 and other acid soluble proteins were recovered 
from the bacteria by performing a combined three cycle 
freeze (-20 °C) and thaw and acidic precipitation procedure 
with 3x (w/v) 5% perchloric acid, resulting in lysis of 
bacterial cells and precipitation of bacterial debris and 
non-acid soluble proteins. Following centrifugation, 
the HMGA2-containing supernatant was removed and 
acidi? ed with 37% HCl to a ? nal concentration of 0.35 M 
HCl. Precipitation of HMGA2 proteins was performed by 
Fig. 2. HPLC and ESI-MS analysis of the HMGA2-A synthesis product.
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adding 6x vol. of -20 °C acetone. Protein was pelleted by 
centrifugation in 80 mL glass tubes, the acetone supernatant 
carefully removed, the pellet frozen to -80 °C and dried 
under vacuum. Pelleted protein was resolved using 50 mM 
ammonium hydrogen carbonate at 4 °C. This crude acid 
soluble protein mix containing mostly HMGA2 was stored 
until further processing at -80 °C.
 Final puri? cation of HMGA2 protein was performed 
using a 2-step HPLC procedure. In the ? rst step, acid 
soluble bacterial proteins as well as bacterial DNA which 
were carried over from acetone precipitation were removed 
using a cation exchange column (TSKgel SP5 PW 20 
?m, Tosoh Bioscience GmbH, Stuttgart, Germany) and a 
gradient of 25 mM H3BO3 pH 9.4 and 25 mM H3BO3/1M 
NaCl pH 9.4. Due to the lack of aromatic amino acid in 
HMGA2 protein, identi? cation of the HMGA2 fraction 
was achieved using a 215 nm absorption peak proximal 
to the absorption maximum of the peptide bond at 205 
nm. Following this ? rst puri? cation step, a reverse phase 
HPLC purification (Grom-Sil 300 ODS-5 ST, Grom, 
Rottenburg-Hail? ngen, Germany) with a gradient of 0.1% 
TFA and 0.1% TFA/70% ACN of the fraction obtained was 
performed enabling the removal of degraded or fragmentary 
HMGA2, leading to a very pure fraction of intact protein. 
Quality control was performed by PAGE (data not shown). 
For removal of eluent, gravimetric quantitation, and long 
term storage, fraction volume was ? rst reduced using 
Amicon Ultra 10000 MWCO Centrifugation devices 
(Millipore, Schwalbach, Germany) and then lyophilised 
using a freeze dryer. Gravimetric quantitation of the 
resulting HMGA2 pellets was performed on an analytical 
balance (Sartorius, Goettingen, Germany), and the pellets 
frozen at -80 °C for long term storage. A stock solution of 
10 ?g/mL HMGA2 was then prepared from the lyophilisate 
for use in the cell proliferation assays.
Cell culture
Chondrocytes were obtained from the knee joint of an 
approximately four month old pig for slaughter, which was 
culled for meat production at a butchery that is subject to 
the German animal protection law and licensed for meat 
production by the Federal Of? ce of Consumer Protection 
and Food Safety, which implies ethical treatment of the 
animals slaughtered. Cartilage was carefully removed 
excluding the calci? ed inner cartilage layer using a punch 
and a scalpel. The cartilage pieces were further chopped 
and digested for 6 h under continuous shaking at 37 °C 
/ 5 % CO2 in 50% v/v 0.26% collagenase NB8 (Serva 
Electrophoresis GmbH, Heidelberg, Germany) and tissue 
culture medium (medium 199 containing Earle’s salts 
and L-glutamine (Invitrogen, Karlsruhe, Germany), 200 
IU Penicillin & 200 mg/mL Streptomycin (Biochrom, 
Berlin, Germany), and 10% foetal bovine serum 
(Invitrogen, Karlsruhe, Germany)) until the chondrocytes 
were released from the extracellular cartilage matrix. 
Following digestion, the released cells were ? ltered from 
the undigested cartilage residue, washed and transferred to 
a 25 cm² tissue culture ? ask (Nunc, Wiesbaden, Germany). 
They were incubated at 37 °C / 5% CO2 / 5 mL tissue 
culture medium as described previously until ¾ con? uency 
of the TC-? ask was reached. This was followed by one 
further passage.
 Canine subcutaneous adipose tissue of the abdominal 
region was taken during surgery from dogs admitted to the 
Fig. 3. HPLC and ESI-MS analysis of the HMGA2-B synthesis product.
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Small Animal Clinic, University of Veterinary Medicine 
(Hanover, Germany). The adipose tissue was transferred 
into sterile Hank’s solution and minced into small pieces 
followed by treatment with 0.26% collagenase NB8. After 
1-2 h, the dissociated cells were transferred into sterile 
? asks containing 5 mL tissue culture medium 199 / 20% 
FCS. The ? asks were incubated at 37 °C / 5% CO2 and 
medium was replaced every 2-3 d. Stem cells were selected 
for by their adherence to the plastic surface of the cell 
culture ? ask (Dominici et al., 2006) and passaged when 
they reached approximately 80% con? uence.
Cell penetration assay and ? uorescence microscopy
Porcine chondrocytes were seeded onto glass plates 
(A=1.76 cm²) positioned in a sterile plastic 12-well 
microtiter plate and incubated for 24 h at 37 °C/5% CO2 
(100,000 cells / well in 1 mL of medium 199/10% FCS). 
Following incubation, the medium was replaced with 0.5 
mL of medium 199/10% FCS (non peptide control), 0.5 
mL of medium 199/10% FCS + 10 ?M HMGA2-CC, 
and 0.5 mL of medium 199/10% FCS + 50 ?M HMGA2-
CC, respectively, and the cells incubated a further 4 h at 
37 °C/5% CO2. Thereupon, the medium was replaced 
with 1 mL of medium199/10% FCS + 25 ?g/mL DAPI 
+ 1 ?g/mL propidium iodide (PI) followed by a further 
incubation time of 5 min at room temperature. Cells were 
washed three times with 1 mL medium 199/10% FCS to 
remove residual stains. The glass plates were removed 
from the 12-well plate and embedded onto glass slides, 
using rubber cement, for analysis. Uptake of ? uorescently 
labelled HMGA2-CC peptides was determined by 
? uorescence microscopy utilising a Carl Zeiss Axioskope 
and documented electronically by Axiovision 4.5 software 
using green (GFP, FITC), blue (DAPI), and red (PI) ? lters 
(Carl-Zeiss-AG, Oberkochen, Germany).
 Canine ADSCs were subjected to a slightly modi? ed 
procedure, where 50,000 cells/well in M199 + 10% FCS 
were seeded into a 24-well plate such that the next day 
a density of about 50% was achieved. The medium was 
removed and for each condition to be tested a solution 
of M199/10% FCS with HMGA2-CC (100 ?M, 50 ?M, 
10 ?M and 0 ?M, respectively), bisbenzimide (0.1 ?g/
mL) and PI (1 ?g/mL) was added to the cells. Cells were 
incubated at 37 ºC for 4 h, washed in M199 and put in 
Hank’s buffered saline solution (HBSS) for immediate 
analysis of ? uorescence. Living cells were checked and 
photographed by ? uorescence microscopy using green 
(GFP, FITC), blue (bisbenzimide), and red (PI) ? lters and 
the 20x objective. Overlay pictures were produced using 
Leica application suite software. 
In vitro cell proliferation assay
The proliferative effects of HMGA2-A and HMGA2-B 
were examined using the BrdU cell proliferation ELISA kit 
(colorimetric) (Roche Diagnostics, Mannheim, Germany) 
according to the manufacturer’s instructions. Conditions to 
be tested for porcine chondrocytes were 10 ?M and 50 ?M 
of HMGA2-A as well as 10 ?M and 50 ?M of HMGA2-B, 
with 10 ?M recombinant HMGA2 and 0 ?M HMGA2 
serving as controls. Chondrocytes were harvested using 
TrypLE Express (Gibco, Karlsruhe, Germany), washed and 
resuspended in fresh tissue culture medium as described 
previously and adjusted to 150,000 cells/mL. For each 
parameter or control, 8 consecutive wells of a 96-well cell 
culture microtiter plate (Nunc, Wiesbaden, Germany) were 
seeded with 7,500 cells/well in 50 ?L of M199/10%FCS. 
Cells were left to settle for three hours at 37 °C / 5% 
CO2. To each test condition, dilutions of HMGA2-A and 
HMGA2-B as well as recombinant HMGA2 solution and 
the non-peptide/protein control were added to the ? nal 
concentrations of 0 ?M, 10 ?M or 50 ?M, respectively, 
in a total volume of 100 ?L. Cells were left at 37 °C / 
5% CO2 for 17 h followed by the addition of BrdU. After 
an incubation period of 7 h at 37 °C / 5% CO2, BrdU 
incorporation was detected with the BioTek Synergy HT 
microtiter plate reader (BioTek Instruments GmbH, Bad 
Friedrichshall, Germany) and interpreted by spreadsheet 
analysis. Data was normalised using the non-HMGA2 
control as reference value.
 The in vitro cell proliferation assay of ADSCs was 
performed with the same BrDU ELISA procedure, with 
some cell type speci? c modi? cations. Conditions to be 
tested were 5 ?M and 50 ?M HMGA2-A, as well as 5 
and 50 ?M HMGA2-B, compared to a non peptide (0 
?M) control. Cells were grown in M199/10% FCS and 
seeded into the wells of a 96 well ? at bottom plate at a 
density of 104 cells in 100 ?L M199 per well. Following 
attachment of cells to the bottom of the wells, the culture 
medium was replaced with M199/1%FCS which was 
left on the cells for 24 h. Finally, this was replaced with 
M199/1%FCS containing the peptides at the concentrations 
mentioned above as well as the non peptide control. After 
6 h of incubation, BrdU was added to each well to a ? nal 
concentration of 10 ?M. Another incubation of 18 h 
followed after which the measurement of cell proliferation 
was performed as described in the chondrocyte section.
Statistics
Statistical analysis was performed with GraphPad Instat 
and GraphPad Prism 5 software (GraphPad Software, La 
Jolla, CA, USA) using the one-way ANOVA (ANalysis 
Of VAriance), with pairs of group means being compared 
using the Tukey-Kramer Multiple Comparisons Test. The 
signi? cance level was set at P<0.01. Identity of standard 
deviations was checked using Bartlett’s test, and Gaussian 
distribution of sample data was tested by the Kolmogorov-
Smirnov method.
Results
Cell penetration assay
By ? uorescence microscopy, a green stain caused by 
the accumulation of ? uorescently labelled HMGA2-CC 
peptides was detected in the nuclei of 51% of chondrocytes 
for both cells incubated with 10 ?m peptide (not shown) 
and 50 ?m peptide (Fig. 4 a-e), respectively, and in 24% 
of ADSCs at 100 ?m peptide (Fig. 4 f-k, 10 ?M and 50 
?M peptide not shown). Green ? uorescence could also 
be detected in the cytoplasm of most chondrocytes and 
ADSCs, even when no intensely stained green nuclei were 
present. Nevertheless, all cells displayed the typical blue 
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DAPI or bisbenzimidine stain in the nucleus. No dead 
cells were detected as revealed by lack of simultaneous 
red ? uorescence (PI) of the nuclei.
Colorimetric Cell Proliferation ELISA
Proliferation of porcine chondrocytes and canine ADSCs 
in response to two different peptides of human HMGA2, 
as well as wild type HMGA2 protein in case of the 
chondrocytes, was examined in in vitro ELISA-based 
assays. For comparability, the absorbance values obtained 
from the microtiter plate reader were normalised to the 
values of the non-HMGA2 control, which was set to a 
value of 1 (Fig. 5).
 To see if the data were suitable for ANOVA, they 
were subjected to the Bartlett’s test which did not show 
signi? cant differences between the standard deviations of 
the different groups in both the chondrocyte and ADSC 
assays. Gaussian distribution of data was tested by the 
Kolmogorov-Smirnov method with all populations passing 
the normality test. Deducing from these test results, data 
were usable for ANOVA. The one way ANOVA resulted 
in a P value <0.0001 for both chondrocytes and ADSCs, 
showing that variation among column means is signi? cantly 
greater than expected by chance. For determination of 
group differences, pairs of group means were compared 
Fig. 4. Transfection of porcine chondrocytes (a-e) and canine ADSCs (f-k) in in vitro monolayer cell culture with the 
? uorescently labelled HMGA2-CC peptide. (a) Overview of porcine chondrocytes showing the green ? uorescence of 
HMGA2-CC in 51% of the cells as well as the blue DAPI stain in the nuclei of all cells. (b) Single chondrocyte with 
combined green HMGA2-CC and blue DAPI stains. (c) Single chondrocyte with green HMGA2-CC stain showing 
the presence of HMGA2-CC in the cytoplasm as well as the nucleus. (d) Single chondrocyte with blue DAPI stain 
in the nucleus. (e) Single chondrocyte showing no signs of cell damage or death as no PI stain could be detected. (f) 
Overview of canine ADSCs showing the green ? uorescence of HMGA2-CC in 24% of the cells as well as the blue 
DAPI stain in the nuclei of all cells (g) two ADSCs with combined green HMGA2-CC and blue DAPI stains (h) 
green channel only (HMGA2-CC) (i) blue channel only (DAPI), (k) red channel only (PI). Scale bars: 100 ?m in a 
and f; 10 ?m in b-e; 20 ?m in g-k.
Fig. 5. Cell pr oliferation of porcine hyaline cartilage cells (a) and canine ADSCs (b) induced by the addition of 
HMGA2 peptides. Values obtained by the microtiter plate reader were normalised to the absorbance of the non-HMG 
control which was set as 1. Error bars: standard deviation.
????????
????????????????????????????????????????????????????????????????????????
?????????????????????????????????????????????????????????????????????????
??????
361 www.ecmjournal.org
A Richter et al.                                                                            HMGA2 fragments stimulate chondrocyte proliferation
using the Tukey-Kramer Multiple Comparisons Test as 
shown in Table 1.
 Compared to the non-HMGA2 control, whose 
proliferative ac tivity was set as 1 for comparability, a 
statistically signi? cant increase in proliferation could be 
detected in chondrocytes treated with either HMGA2-A 
peptides at both 10 ?M (1.94x increase) and 50 ?M 
(1.88x increase), or wild-type HMGA2 protein (10 ?M, 
2.1x increase). However, no dosage-dependency could 
be detected for the HMGA2-A peptide, as there was no 
statistically signi? cant difference of the measured data 
for both 10 ?M and 50 ?M. There was also no signi? cant 
difference in the proliferation inducing activities of wild 
type HMGA2 and 10 ?M or 50 ?M HMGA2-A peptide, 
respectively, indicating a similar proliferation enhancing 
effect of the HMGA2-A peptide to the wild type protein.
 The measured data for the HMGA2-B peptides, 
on the other hand, showed no statistically signi? cant 
differences at both 10 ?M (1.54x increase) and 50 ?M 
(0.90x decrease) compared to the non-HMGA2 control, 
indicating this peptide does not in? uence the proliferation 
of chondrocytes as intended. However, there was also no 
signi? cant difference between HMGA2-B at 10 ?M and 
HMGA2-wt, while HMGA2-B at 50 ?M signi? cantly 
differed from the wild type protein, even leading to a 
slight decrease in proliferative activity. This indicates at 
least some proliferation enhancing effect of the HMGA2-B 
peptide on the cells that is comparable to wild-type 
HMGA2, albeit only at the lower concentration, with the 
effect being diminished or rather reversed at the higher 
concentration of 50 ?M.
 Concerning ADSCs, there was a highly signi? cant 
increase of proliferation compared to the untreated control 
at the higher concentration of 50 ?M HMGA2-A, but not 
at the lower concentration of 10 ?M. In contrast, only the 
treatment of ADSCs with 5 ?M HMGA2-B provided a 
statistically signi? cant increase of proliferative activity 
compared to the control, but not the higher concentration 
of 50 ?M, which even led to a signi? cantly decreased 
proliferation of cells compared to the HMGA2-A peptide 
at 50 ?M.
Table 1. Tukey -Kramer Multiple Comparisons on the effect of different HMGA2 peptides and wild type HMGA2 
protein on the proliferation of porcine chondrocytes (a), as well as HMGA2 peptides on the proliferation of canine 
ADSCs (b). Grey cells indicate signi? cant differences with a P value < 0.01.
(a) Control HMGA2-A 10 ?M
HMGA2-A 
50 ?M
HMGA2-B 
10 ?M
HMGA2-B 
50 ?M
HMGA2-
wt 10 ?M
Control -      
HMGA2-A 
10 ?M < 0.01 -     
HMGA2-A 
50 ?M < 0.01 > 0.05 -    
HMGA2-B 
10 ?M > 0.05 > 0.05 > 0.05 -   
HMGA2-B 
50 ?M > 0.05 < 0.01 < 0.01 > 0.05 -  
HMGA2-wt 
10 ?M < 0.001 > 0.05 > 0.05 > 0.05 < 0.001 -
(b) Control HMGA2-A5 ?M
HMGA2-A 
50 ?M
HMGA2-B
5 ?M
HMGA2-B 
50 ?M
Control
     
HMGA2–A 
5 ?M  > 0.05     
HMGA2–A 
50 ?M  < 0.001  < 0.001    
HMGA2–B 
5 ?M  < 0.01  > 0.05  > 0.05   
HMGA2–B 
50 ?M  > 0.05  > 0.05  < 0.01  > 0.05  
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Discussion
Recombinant proteins of the human High-Mobility-
Group A (HMGA) family including HMGA2 had been 
shown to signi? cantly increase the proliferative activity 
of chondrocytes in a dose-dependent manner in an in 
vitro system utilising cells of porcine origin (Richter et 
al., 2009). These embryonic proteins are usually absent 
in fully differentiated adult cells (Rogalla et al., 1996); 
however, their application to adult chondrocytes led to 
enhanced growth opening up future possibilities e.g. in 
hyaline cartilage repair (Richter et al., 2009). To overcome 
problems caused by e.g. viral delivery of the target gene 
sequence to cells, which is subject to several factors such 
as gene dosage, integration into the host genome, and 
expression of the transgene even after therapy, as well as 
obstacles of recombinant protein expression in bacterial or 
eukaryotic expression systems, we developed two synthetic 
fragments HMGA2-A and HMGA2-B comprising the 
biologically active parts of HMGA2, the so-called AT-
hooks (Reeves and Nissen, 1990; Geierstanger et al., 
1994; Chau et al., 1995; Goodwin, 1998; Reeves, 2000; 
Cattaruzzi et al., 2007; Cleynen and Van de Ven, 2008). 
These peptides can be delivered directly to the affected 
areas and are eliminated over the course of time when 
not re-applied as needed by therapy, solving the problems 
mentioned. For assessing their function, the peptides 
were tested on porcine chondrocytes for their cellular 
localisation as well as their effects on proliferation in 
comparison to a non-HMGA2 control and recombinant 
HMGA2 protein in the same in vitro cell culture system 
as described before (Richter et al., 2009). In addition, 
the new peptides were also evaluated on canine adipose 
tissue derived stem cells, as ADSCs can be differentiated 
into chondrogenic cells in the presence of lineage-speci? c 
induction factors (Zuk et al., 2001; Huang et al., 2004), 
and are thus another important subject in the ? eld of 
cartilage repair. Due to HMGA2 proteins being highly 
conserved between mammals, especially in regard to the 
functional motifs of the AT-hooks, the sequence of the 
human HMGA2 were chosen for both peptide and protein. 
This allows for the use of only one peptide variant across 
several species as e.g. pig, dog, and human.
 Most likely, the detected internalisation of the 
? uorescently labelled variant of the HMGA2-B peptide 
(HMGA2-CC) into the nucleus of chondrocytes as well as 
ADSCs, although the fragment lacks the carboxyterminal 
acidic part of the wild type protein, is due to the nuclear 
localisation signal on the second AT-hook of the HMGA2 
peptide. From this it can be assumed that either the 
complete peptide or at least a fragment thereof comprising 
the labelled N-terminus up to the second AT-hook (this 
would correspond somehow to the shorter HMGA2-A 
peptide which lacks the 20 C-terminal amino acids of 
HMGA2-B including AT-hook 3) are located into the 
nucleus, as the presence of the ? rst AT-hook alone is not 
suf? cient for nuclear transport, while the presence of the 
second AT-hook is necessary (Cattaruzzi et al., 2007). The 
? uorescence found in the cytoplasm would then be caused 
by either or both intact peptides not yet transported into the 
nucleus as well as peptide fragments lacking the nuclear 
transport signal of the second AT-hook.
 However, concerning cell proliferation, the 
administration of recombinant HMGA2 to porcine 
chondrocytes could reproduce the same positive effect on 
proliferation as described before (Richter et al., 2009), as 
there was highly signi? cant difference in proliferation to 
the untreated control. The synthetic HMGA2-A peptide 
led to a comparable effect on proliferation to the wild type 
protein as there was no statistically signi? cant difference 
in cell proliferation at both 10 ?M and 50 ?M HMGA2-A 
compared to HMGA2-wt, leading to the conclusion that it 
is an adequate alternative to the recombinantly produced 
protein. On the other hand, HMGA2-B did not show any 
signi? cant difference to the untreated control group at both 
10 ?M and 50 ?M, and only had comparable effect to the 
wild type protein at 10 ?M, while there was a statistically 
signi? cant lower proliferation at 50 ?M, showing that 
this larger peptide might probably be detrimental to 
chondrocyte proliferation at higher levels. The fact that no 
increase (HMGA2-A) or rather a decrease (HMGA2-B), 
respectively, occurs at 50 ?M compared to 10 ?M, might 
also indicate that there is saturation of cells or their DNA, 
respectively, at higher concentrations of the peptides, which 
in case of HMGA2-B might also inhibit cellular processes 
required for proliferation. As the peptides bind to the minor 
groove of AT-rich DNA, there are probably only a limited 
number of binding sites available for the peptide molecules 
which might be occupied from a certain concentration, 
leading to either no or detrimental effects on the cells.
 Concerning ADSCs, a beneficial effect on the 
proliferation of these cells could be detected as well, at 
least at the higher concentration of 50 ?M HMGA2-A. 
On the other hand, the larger HMGA2-B peptide caused 
a signi? cant increase of proliferative activity only at the 
lower concentration of 5 ?M, while the higher dose of 
50 ?M led to a reduced proliferation compared to 5 ?M 
HMGA2-B, which is similar to the results obtained from 
chondrocytes, albeit at a lower degree. Differences in 
response to HMGA2 peptides between chondrocytes and 
ADSCs – besides comparing distinct cell types – might 
probably be due to possible different chromatin stages of 
these cell types. For example, anti-proliferative activities 
of HMGA2 have been described depending on the cellular 
context (Narita et al., 2006).
 However, the proliferative effects evoked by the 
HMGA2-A peptide open up further possibilities in e.g. 
tissue engineering, comparable to those of HMGA2-wt. 
Due to the presence of two AT-hooks and the nuclear 
localisation signal, this peptide comprises similar functions 
to the recombinant protein, but instead can be synthesised 
up to industrial scale without the need of recombinant 
expression systems. Thus, this peptide as a proliferation 
inducing/enhancing agent is of great importance for future 
applications in e.g. cartilage repair and further tissue 
engineering applications, as well as in further ? elds such 
as e.g., stem cell research.
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Results 
3.3. Cartilage replacement in dogs 
As in humans, the dog is suffering from articular cartilage damage, which may be age 
or injury related, as well as disease induced e.g. in case of Osteochondritis 
dissecans (Newton et al. 1985). Problems occurring in human cartilage regeneration 
such as fibrocartilage formation and the associated onwards degradation of the 
affected areas (Frenkel et al. 1999; Marlovits et al. 2006) also occur. Thus, the 
establishment of a replacement therapy for damaged cartilage in dogs is useful from 
a double perspective, i.e. for both the canine patient as part of its therapy, as well as 
for humans where the dog could act as a model organism for transfer of methods and 
experience gained to human therapy. There are some therapeutical approaches in 
the treatment of damaged cartilage such as lavage, shaving, debridement, (laser) 
abrasion chondroplasty, and Pridie drilling, where damaged tissue is removed and/or 
underlying bone marrow stimulated to enhance the formation of new cartilage to fill 
up the damage. However, they mostly still lead to formation of less resilient areas 
mainly consisting of fibrocartilage (Hunziker 2002). To overcome some of these 
problems, the use of scaffolds seeded with cells amplified in vitro or combined with 
transplanted intact tissue from less heavily loaded areas might be a promising 
approach to replace cartilage in the damaged areas. For this study, a biosynthetic 
structure consisting of beta-tricalcium phosphate (?-TCP) was chosen, as this 
compound was already proven as highly suitable in the treatment of bone defects in 
humans and animal models (Anker et al. 2005; Hirata et al. 2006; Suba et al. 2006; 
Frota et al. 2011), but no data was available at that time for the colonisation with 
canine chondrocytes. 
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Cartilage replacement in dogs - A preliminary  
investigation of colonization of ceramic matrices 
Hauschild et al., Veterinary and Comparative Orthopaedics  
and Traumatology, 2009 
In this study, ?-TCP cylinders were colonised with isolated canine chondrocytes or 
cartilage chips, respectively. As a control, isolated chondrocytes from the same 
donor were kept in cell culture and subjected to the same vitality test as the cells for 
colonisation. The cylinders that were inoculated with a solution of isolated 
chondrocytes showed an even distribution of cells across the cylinder surface and 
within the cylinders’ drilled macropores, as far as could be detected by visible light 
and fluorescence microscopy. Around the macropores’ edges, less cell density, but 
still even distribution of cells could be detected. Vitality staining revealed viability of 
most cells, and the cells showed partial cell-to-cell contact. Scanning electron 
microscopy allowed the detection of cells’ filopodia that anchored onto the construct 
surface and entered the substrate’s micropores, as well as it confirmed the direct cell 
to cell contact. The cell culture control also showed even distribution of mostly viable 
cells and only sporadic cell death in the vitality test. 
In contrast, the cylinders that were studded with cartilage chips showed only little 
colonisation with small groups of cells or individual cells growing around or within the 
drill holes where the cartilage chips were fastened. Nevertheless, vitality staining 
proved the viability of these cells. 
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Summary 
The objective of this study was to examine the 
behaviour of canine chondrocytes following 
colonisation of a β-tricalcium phosphate 
(β-TCP, Cerasorb®, Curasan) matrix. In total, 
five of these cylinders were inoculated with 
1.5 ml of cell suspension and subsequently in-
cubated for about one week. In the second 
part of the experiment, another five  
Cerasorb® cylinders were each studded with 
two cartilage chips of variable size and then 
incubated for about one week. The series of 
experiments were analyzed using cell staining 
and imaging techniques that included scan-
ning electron microscopy. Cell migration onto 
the matrix was proven for both colonisation 
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methods. It was observed that colonising the 
cylinders by pipetting cell suspension on them 
produced far better results, with respect to 
both growth rate and spreading of the cells, 
than did colonisation by studding with carti-
lage chips. A homogenous, surface-covering 
colonisation with predominantly living cells 
was demonstrated by scanning electron 
microscopy in the chondrocyte morphology. In 
comparison to cell-culture controls, there was 
a clearly better colonisation, with cells at-
tached to both the material's primary grains 
and its micropores. The ceramic studied is well 
accepted by canine chondrocytes, and ap-
pears to be fundamentally well-suited as a 
matrix for bio-artificial bone-cartilage re-
placement. Additional qualitative analyses 
and a series of experiments aiming to acceler-
ate cell proliferation are planned for sub-
sequent studies. 
Introduction 
Damage to articular cartilage in canine or 
human patients is a serious orthopaedic 
problem and a therapeutic challenge. The 
tendency of cartilage to self-heal is severely  
limited due to its avascularity, lack of inner-
vation and lymphatic circulation, and 
relatively low cellularity (1). Intrinsic repair 
mechanisms of hyaline cartilage do not bring 
about healing that leads to reconstitution or 
regeneration. Instead, usually only a reduc-
tion of the lesion is achieved, or the deficient 
area is filled with biomechanically weaker  
fibrocartilage, which possesses sufficient ten-
sile strength yet cannot adequately absorb the 
compression loads acting on joints (1–3). 
This inadequate tendency to regeneration is 
further limited by the separation of the chon-
drocytes from the deficient area by the extra-
cellular matrix (4). Conventional therapeutic 
methods, such as lavage and debridement, 
bone-cartilage Pridie drilling, Steadman 
microfracturation, and Johnson abrasion art-
hoplasty, all attempt to promote or improve 
the self-heal potential of the cartilage by 
stimulating mesenchymal stem cells, growth 
factors, and progenitor cells from the bone 
marrow. The result of these various treat-
ments nonetheless remains at best the 
formation of fibrocartilage, for which a 
quarter of all patients leads to no improve-
ment of symptoms, even in the long-term, or 
to renewed deterioration (5–9). 
The use of biological materials and bio-ar-
tificial grafts represents an alternative to these 
techniques. The latter are, as a rule, composite 
materials from a natural or synthetic carrier 
and autologous or heterologous cells. The use 
of natural carriers is limited though by their 
usually low mechanical stability, uncontrol-
lable degradation, and sterilisation difficul-
ties associated with possible pathogen 
transfer. In contrast, synthetic matrices have 
form and surface textures that can be con-
trolled much better and exhibit excellent 
mechanical and physiochemical properties 
(10). For osteochondral grafts, especially as 
they are implemented in the context of a 
modified Autologous Transfer System 
(OATS), the benefits of using a well-estab-
lished bone replacement material as a matrix 
are obvious. The therapeutic concept of 
OATS has been based so far on grafting auto-
logous bone-cartilage cylinders, taken from 
areas of low biomechanical stress of the af-
fected joint, onto the prepared deficient area. 
Significant disadvantages of the procedure 
include not only graft mount complications, 
such as central necrosis, resorption, non-or-
thograde positioning and marrow oedema in 
the subchondral bone area (11, 12), but also 
above all, the limited availability and the mor-
bidity at the donor site. In contrast, there is an 
unlimited availability of synthetic bone  
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replacement materials, including the β-TCP 
tested in the present study, which has been 
successfully used clinically in orthopaedics 
and dental orthopaedics (13–17). In the case 
of proven osteoconductivity and successful 
use as a bone replacement material, the suit-
ability of that bioceramic as a matrix for ca-
nine chondrocytes would currently remain 
unconfirmed to our knowledge. Colonisation 
of the matrix with autologous chondrocytes 
or their progenitor cells in vitro and in vivo is 
imperative for the imitation of autologous 
bone-cartilage cylinders used in OATS with a 
biosynthetic material. Guo et al. (18) were 
able to achieve promising results with respect 
to regeneration by implanting pulverised 
β-TCP colonised with mesenchymal stem 
cells into osteochondral defects in sheep. The 
goal of the present study is to investigate the 
behaviour of canine chondrocytes following 
colonisation of a pure-phase cylindrical 
β-TCP ceramic. 
Methods 
Cylinders 
Five Cerasorb® cylinders were colonised by 
chondrocytes replicated in a cell culture, and 
five other cylinders were studded with carti-
lage chips and then incubated. In each case, 
two of the constructs were stained with 
4’,6-diamidino-2-phenylindole (DAPI) to 
evaluate cell growth. Four additional cylin-
ders (two for each study condition above) 
were stained with Trypan blue to assess cell 
viability and were then treated with DAPI. 
Two of these cylinders (one per study con-
dition) were subjected to scanning electron 
microscopy in order to determine the cell 
morphology. 
Matrix 
β-TCP cylindersa measuring 8.5 x 20 mm 
were used as a matrix. The phase purity of the 
material is over 99%. In addition to the ma-
terial’s intrinsic interconnective porosity, the 
cylinders had vertical and horizontal drill 
holes with a diameter of 1 mm (macropores), 
whereby the horizontal holes ran the entire 
length of the construct, but the vertical holes 
did not penetrate the bottom surface of the 
cylinder (Fig. 1) 
Isolation of cartilage cells 
The canine cartilage used in the study came in 
the form of small cartilage chips from ani-
mals treated at the Veterinary Clinic of the 
Hannover Veterinary College and the Aster-
lagen Veterinary Hospital in Duisburg-
Rheinhausen. The chips were obtained from 
excised femoral heads that were available as a 
result of a therapeutically conducted hip joint 
prosthesis implantation or a femoral head 
and neck excision. They were stored in Hanks’ 
mediumb until further use. To separate the 
cells, the cartilage was briefly centrifuged, and 
the medium was siphoned off using a vacuum 
pumpc . The chips were then washed in 10 ml 
phosphate buffered saline (PBS)b and trans-
ferred to a 25 cm² cell culture flaskd . After ad-
ding 4 ml of equal parts collagenase NB8e and 
Medium 199f , the chips were incubated for at 
least six hours at 37°C in 5% CO2 to free the 
cellsg . During this time, the cell-containing 
supernatant underwent repeated resuspen-
sion by carefully shaking the cell culture flask. 
Following incubation, the cells were washed 
with 10 ml of Medium 199 to remove the col-
lagenase and finally resuspended in 5 ml of 
Medium 199. 
Cell cultivation 
The resuspended cells were transferred to a 25 
cm² cell culture flask, where cell expansion 
took place between three and seven days. The 
culture medium was exchanged twice weekly, 
until approximately three fourths of the flask 
surface was covered with cells (incubation at 
37°C in 5% CO2). To collect the cells, the 
medium was first siphoned off. The cells were 
then washed in 5 ml PBS; 1 ml TrypLE (tryp-
sin replacement)f was added to detach chon-
drocytes from the flask surface, and then the 
cells were washed in 10 ml Medium 199. The 
cell count was determined using a hemacy-
tometerh after resuspension in 2 ml Medium 
199. The final cell count was 1 x 105 cells per 
ml medium. 
Matrix colonisation with cultured 
cells 
Each of the five β-TCP cylinders had a liquid 
intake volume of 1.2 ml. In order to ensure a 
dense cell colonisation and to minimise col-
onisation of the culture flask instead of the 
matrix, the construct inoculation took place 
in a small CryoTubei with a 2 ml capacity. The 
cylinders were transferred into the tube with 
217
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Fig. 1 Cerasorb® cylinder. 
a Cersorb®, Curasan, Kleinostheim, Germany 
c Jürgens Omnilab, Bremen, Germany 
d Nunc, Wiesbaden, Germany 
e Serva Electrophoresis GmbH, Heidelberg, Ger-
many 
f Invitrogen GmbH, Karlsruhe, Germany 
g Thermo Electron Corporation, Waltham, MA, USA 
h Menzel-Gläser, Braunschweig, Germany 
i Nalge Nunc International, Rochester, NY, USA b Biochrom KG, Berlin, Germany 
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the closed base surface facing down. Then, 2 x 
600 μl of cell suspension was pipetted into the 
top macropores (vertical drill holes) of the 
cylinder, so that the matrix was filled and 
covered with cell suspension. To allow gas ex-
change, CryoTube lids were loosely placed. 
The cylinders were then incubated for at least 
six hours at 37°C in 5% CO2 in order to allow 
the cells to anchor themselves to the matrix. 
Next, each construct was transferred to a cell 
culture flask with a special mounting, covered 
with 15 ml Medium 199 and incubated for 
one week at 37°C in 5% CO2. During this 
period, the medium was renewed twice, each 
time after three days. 
Matrix colonisation with canine 
cartilage chips 
In a second group, five β-TCP cylinders were 
each studded with two canine cartilage chips 
of variable size by placing the chips into the 
vertical drill holes of the construct (Fig. 2). 
This group was also covered with 15 ml Medi-
um 199 and incubated for one week at 37°C in 
5% CO2. The medium was renewed as pre-
viously described. 
Analytical process 
The cell viability in culture and after colon-
isation was tested using Trypan blue stainingf 
as previously described by Freshney (19), and 
microscopic analysis and documentation was 
performed using a Zeiss Axioskop 2 Plus and 
an Axiocam HRj . To assess cell growth in cul-
ture and on the surface and inside the cylin-
ders, and to register living cells that were not 
detected by Trypan blue staining, the con-
structs were stained with DAPIk (4’,6-diamid-
ino-2-phenylindole) (20), positioned on a 
microscope slide and subsequently analyzed 
using fluorescent microscopy with a DAPI 
filter. Documentation was carried out as de-
scribed before. Visualization and measure-
ments were performed using a software-pro-
gramme(Axiovision)j. For a more in-depth 
examination of cell behaviour on the cell ma-
trix, the constructs were also examined using 
scanning electron microscopy (REM 
1530VP)j. To do so, the colonised cylinders 
were fixed for six hours using 2% glutaralde-
hyde in phosphate bufferl, dehydrated in a ris-
ing alcohol series, completely evacuated in-
side a Sputter Coaterm, and finally coated 
with an approximately 6 nm thick silver layer. 
Results 
Cell culture controls 
Cell culture controls in 6-well plates showed 
an evenly distributed colonisation of the sur-
face with viable, round or spindle-shaped 
cells, ranging from 10 to 30 μm in size, with 
filopodia extending up to 100 μm (Fig. 3). 
Blue staining of cells indicating cell death oc-
curred only sporadic. 
Colonisation with expanded cells 
On all five cylinders that were inoculated with 
cell suspension, Trypan blue staining and 
subsequent DAPI staining showed evenly dis-
tributed, mainly viable, round cells with a cir-
cumference measuring between 5 and 30 μm. 
Taken together, both visualization methods 
showed a surface-covering colonisation of the 
matrix and, to the extent of their visibility, the 
vertical drill holes. The constructs stained 
only with DAPI likewise showed a homogen-
ous surface colonisation with migration of 
cells into the macropores of the matrix. The 
cells were positioned on the surface next to 
one another, with partial cell-to-cell contact. 
Around the macropores, the cells were 
grouped less densely but were still evenly dis-
tributed (Fig. 4). The scanning electron 
microscopy revealed evenly distributed cells, 
each displaying several filopodia that an-
chored onto the primary matrix structure 
and entered the interconnecting micropores 
of the ceramic. These projections also dem-
onstrated a predominantly direct cell-to-cell 
contact (Fig. 5A-C). 
Fig. 2 Scanning electron microcope Images of a Cerasorb® cylinder showing three vertical macropores (A) and one macropore (B) studded with cartilage 
chips (arrow heads). 
A) B) 
j Zeiss, Jena, Germany 
k Roche Diagnostics GmbH, Mannheim, Germany 
l Merck Eurolab GmbH, Darmstadt, Germany 
m Polaron Equipment, Watford, England
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Studding the matrix 
Studding the vertical drill holes of the matrix 
with cartilage chips produced a different pic-
ture. 
In both the Trypan blue staining and in the 
DAPI staining, mainly viable, round cells 
with a circumference of 5 and 30 μm were ob-
served only in the areas of some of the macro-
pores studded with cartilage chips; some-
times individually or in small groups, some-
times homogenously distributed. With in-
creasing distance from the drill hole, both the 
cell count and the homogeneity of the colon-
isation decreased drastically. Colonisation of 
the matrix could also be observed inside these 
macropores. In the remaining studded ver-
tical drill-holes, no cell migration with subse-
quent colonisation of the matrix surface was 
detected. 
Discussion 
Presently, cartilage defects are treated with 
the goal of achieving the most complete func-
tional recovery of the joint surface possible. 
Among the treatments available, mosaic-
plasty, or OATS, is considered to be highly 
promising in humans as well as in canine pa-
tients (5, 21–27). The extraction of bone-car-
tilage cylinders is associated though with the 
risk of damage to the chondrocytes and mor-
bidity at the donor site. Additionally, the pro-
cedure is restricted by the limited availability 
of the material. Synthetic matrices, such as 
the ceramic β-TCP matrix used in this study, 
are not restricted by this limitation. In order 
to minimise the disadvantages of mosaic-
plasty, a synthetic matrix must first be colon-
ised in vitro with autologous chondrocytes. 
This bioartificial composite material will 
then be grafted onto the defective area ac-
cording to OATS technical procedure. The 
present study investigated the feasibility of 
colonizing β-TCP cylinders with canine 
chondrocytes. Different methods of colon-
isation were compared in respect to their ef-
fect on growth rate and cell spreading.  
The Cerasorb® ceramic matrix acts as a 
bone replacement material and thus forms 
the osteal base for the chondral component of 
the future graft. In addition to the material’s 
osteoconductive properties, its biodegra-
dation concurrent with osteogenesis, its bio-
compatibility, its interconnecting porosity, 
and its phase purity have been confirmed in 
several studies (15–17, 28, 29). Stimulation of 
osteal structures to grow directly into the 
pores of the ceramic usually results in a 
boundary-free integration into the recipient’s 
natural bone without encapsulating the con-
nective tissue (30). During the assimilation of 
the matrix into the deficient area, it is ex-
pected that a vital connection between the 
graft and the recipient organism can be at-
tained, due to the described graft behaviour. 
This is an important prerequisite for the sur-
vival of the chondral component of the graft. 
A further requirement for the graft’s func-
tionality is the adequate connection between 
the subchondral matrix and the cartilage sur-
face. Guo et al. (18) demonstrated that colon-
isation of the ceramic matrix with ovine 
chondrocytes is possible but did not report 
on the morphology of the cell-matrix inter-
face. 
The present study used β-TCB cylinders 
that were colonised with canine chondrocytes 
or studded with cartilage chips. Compared to 
cell culture controls, constructs treated with 
cell suspension exhibited clearly higher cell 
counts with higher viability. The generally 
good cell growth on the matrix points to the 
ceramic’s positive influence on cell adhesion 
and proliferation. The scanning electron 
microscopy showed that the evenly-dis-
tributed cells each had multiple filopodia, 
which both anchored onto the primary grain 
structure of the matrix and also entered into 
the micropores of the ceramic. These projec-
© Schattauer 2009 Vet Comp Orthop Traumatol 3/2009
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Fig. 3  
Cell culture control 
(6-well plate); Trypan 
blue stain (40x mag-
nification, exposure 
229.64 ms) showing 
viable and non- 
viable (arrow heads) 
cells. 
Fig. 4 Left: Cerasorb® cylinder colonised with chondrocytes with pore (Trypan blue staining fol-
lowed by DAPI staining, fluorescent microscopy [10x magnification, exposure 99.5 ms]). Notice sporadi-
cally occurring non-viable cells (arrow heads). Right: Cell culture control (6-well plate) (Trypan blue 
staining followed by DAPI staining, fluorescent microscopy [10x magnification, exposure 39.8 ms]). 
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tions also demonstrated direct cell-to-cell 
contact. The direct interlocking between cells 
and matrix points to the resilience of the 
bond between the graft components, which is 
important for the graft’s long-term stability 
and its vital integration into the recipient or-
ganism. The absence of this strong connec-
tion creates a condition comparable to osteo-
chondrosis dissecans (31, 32), which in-
creases the probability of the in vitro gener-
ated cartilage surface separating from the ce-
ramic, and later the bone base, leading to graft 
failure. 
Cell migration onto the construct was 
demonstrated for both colonisation meth-
ods. Nonetheless, it was apparent that the 
technique of studding the construct with car-
tilage chips was clearly inferior to direct col-
onisation with cell suspension in respect to 
cell growth rate and the spreading of cells. 
Whereas pipetting cell suspension led to cells 
spreading over the surface of the entire cylin-
der including the macropores as far as visible, 
studding the constructs limited cell growth to 
the area immediately surrounding the carti-
lage chips. With increasing distance from the 
drill hole, the cell count and homogeneity be-
came drastically reduced. At a certain dis-
tance from the chip, cell growth could not be 
detected. The expected cell behaviour can 
probably be attributed to the individual 
chondrocytes having to first free themselves 
from the cartilage cell structure. The time loss 
arising from this process and the larger travel 
distances in comparison to planar inocu-
lation with cell suspension can explain the 
significantly lower surface coverage achieved 
by studding. The observation that single cells 
do in fact leave the chip and engage the ce-
ramic matrix is an additional indicator for the 
suitability of β-TCP as a chondral matrix, es-
pecially given that equal proportions of living 
and dead cells appeared in both groups. 
It was not possible with the methods of 
this initial feasibility study (determination of 
cell viability by Trypan blue staining, detection 
of cell growth with DAPI staining, and scan-
ning electron microscopy examination) to pro-
vide indisputable evidence that the cells 
populating the matrix are hyaline cartilage-
producing chondrocytes. Nevertheless, im-
portant clues are provided by cell morphol-
ogy, observed especially with the aid of scan-
ning electron microscopy. Despite the sys-
tem’s inherent disadvantages, that make it im-
possible to rule out a small-scale change in 
cell morphology or deterioration of the im-
aging quality for cell probes (33, 34), the 
examined cells can be classified with a high 
degree of confidence as chondrocytes based 
on their morphology. RT-PCR will be used in 
upcoming experiments to provide qualitative 
identification, and it will be able to differenti-
Fig. 5  
Scanning electron 
microscope Images 
of a Cerasorb® cylin-
der colonised with a 
cell suspension. A) 
Interconnecting cells 
overlapping and 
covering the TCP-sur-
face. B) Notice the 
filopodia anchoring 
the TCP-surface as 
well as entering the 
micropores. C) Cell-
surface-interface in 
detail. 
A) 
B) 
C) 
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ate between cartilage-specific collagens and 
aggrecan and versican proteoglycans, and 
consequently, between hyaline cartilage and 
fibrocartilage. The same method can also be 
used to rule out or confirm chondrocyte de-
differentiation on the matrix.  
To reach the objective of developing a 
bone-cartilage replacement for clinical appli-
cation it is still necessary to determine that 
the colonisation of a β-TCP ceramic ad 
modum Cerasorb® by canine chondrocytes is 
generally possible and that the matrix is well 
accepted by the cells. Furthermore, the colon-
isation process must be made faster for use in 
clinical practice. It is necessary to reduce the 
required amount of extracted material, in 
order to eliminate the risk of morbidity at the 
donor site, which is reduced but not excluded 
in the modified OATS procedure. Further re-
search will focus on examination of induc-
tion of cell replication using the prolifer-
ation-promoting High mobililty group AT-
hook-2 protein (HMGA2). 
References 
1. Metz J. Makroskopie, Histologie und Zellbiologie 
des Gelenkknorpels. In: Gelenkknorpeldefekte. 
Erggelet C, Steinwachs M (eds). Darmstadt: Stein-
kopff 2001; 3–14. 
2. Liebich HG. Knorpelgewebe (Textus cartilagineus). 
In: Funktionelle Histologie der Haussäugetiere. 
Lehrbuch und Farbatlas für Studium und Praxis, 
vol 3. Liebich HG (ed). Stuttgart, New York: Schat-
tauer 1999; 69–72. 
3. Rohen W, Lütjen-Drecoll E. Funktionelle Histolo-
gie. Stuttgart: Schattauer 2001. 
4. Hardingham TE, Fosang AJ, Dudhia J. Aggrecan, 
the chondroitin/keratan sulfate proteoglykan from 
cartilage. In: Articular Cartilage and Osteoarthritis. 
Kuettner KE (ed). New York: Raven Press 1992; 
5–20. 
5. Gaissmaier C, Fritz J, Mollenhauer J et al. Verlauf 
klinisch symptomatischer Knorpelschäden des 
Kniegelenks. Ergebnisse ohne und mit biologischer 
Rekonstruktion. Dtsch Ärztebl 2003; 100: 
2448–2453. 
6. Johnson LL. Arthroscopic abrasion arthroplasty: 
Historical and pathological perspective: Present 
status. J Arthroscopy 1986; 2: 54–69. 
7. Marlovits S, Vécsei V. Möglichkeiten zur chirur-
gischen Therapie von Knorpeldefekten – Teil 1: 
Grundlagen der Knorpelbiologie und der Heilung 
von Knorpeldefekten. Acta Chir Austriaca 2000; 32: 
124–129. 
8. Pässler HH. Die Mikrofrakturierung zur Behand-
lung von Knorpeldefekten. Zentralbl Chir 2000; 
125: 500–504. 
9. Schmidt H, Hasse E. Arthroskopische operative Be-
handlung von umschriebenen Knorpelschäden 
mittels Spongialisation oder Pridie-Bohrung. Beitr 
Orthop Traumatol 1989; 36: 35–37. 
10. Wang Y, Kim UJ, Blasioli DJ et al. In vitro cartilage 
tissue engineering with 3D porous aqueous-derived 
silk scaffolds and mesenchymal stem cells. Bio-
materials 2005; 26: 7082–7094. 
11. Sanders TG, Mentzer KD, Miller MD et al. Autogen-
ous osteochondral “plug” transfer for the treatment 
of focal chondral defects: postoperative MR appear-
ance with clinical correlation. Skeletal Radiol 2001; 
30: 570–578. 
12. Imhoff AB, Öttl GM, Burkart A et al. Osteochon-
drale autologe Transplantation an verschiedenen 
Gelenken. Orthopäde 1999; 28: 33–44. 
13. Foitzik C, Staus H. Phasenreines β-Tricalciumphos-
phat zum Knochenersatz bei parodontaler Indi-
kation. Quintessenz 1999; 10: 1049–1058. 
14. Gruber AJ. Erfahrungen mit Cerasorb® in der Pra-
xis des niedergelassenen Chirurgen. Der niedergel-
assene Chirurg 1999; 14: 1–3. 
15. Hauschild G, Merten HA, Bader A et al. Bioartificial 
bone grafting: Tarsal joint fusion in a dog using a 
bioartificial composite bone graft consisting of 
ß-tricalciumphosphate and platelet rich plasma – A 
case report. Vet Comp Orthop Traumatol 2005; 1: 
52–54. 
16. Hauschild G, Bader A, Uhr G et al. Klinischer Eins-
atz von ß-Tricalciumphosphat – Erfahrungen mit 
einem matrixorientierten Ansatz zur Osteoregener-
ation. Tierärztl Prax (K) 2007; 35: 5–13. 
17. Szabo G, Suba Z, Hrabak K et al. Autogeneous bone 
versus beta-tricalcium phosphate graft alone for bi-
lateral sinus elevations (2– and 3-dimensional com-
puted tomographic, histologic, and histomorpho-
metric evaluations): preliminary results. Int J Oral 
Maxillofac Implants 2001; 5: 681–692. 
18. Guo X, Wang C, Duan C et al. Repair of osteochon-
dral defects with autologous chondrocytes seeded 
onto bioceramic scaffold in sheep. Tissue Engineer-
ing 2004; 10 (11/12): 1830–1840. 
19. Freshney R. Culture of Animal Cells: A Manual of 
Basic Technique. Alan R. Liss, Inc., New York 1987; 
117. 
20. Lydon MJ, Keeler KD, Thomas DB. Vital DNA stain-
ing in cell sorting by flow microfluorometry. J Cell 
Phys 1980; 102: 175–181. 
21. Frank M. Einsatz der osteochondralen Transplan-
tation (Mosaicplasty®) in der Therapie der Osteo-
chondrosis dissecans (OCD) des Kniegelenkes 
beim Hund. Tierärztl Prax (K) 2003; 31: 346–355. 
22. Huntley JS, Bush PG, MC Birnie JM et al. Chondro-
cyte death associated with human femoral osteo-
chondral harvest as performed for mosaicplasty. J 
Bone Joint Surg Am 2005; 87: 351–360. 
23. Marlovits S, Vécsei V. Möglichkeiten zur chirur-
gischen Therapie von Knorpeldefekten – Teil 2: 
Chirurgische Behandlungsoptionen zur biol-
ogischen Knorpelreparatur. Acta Chir. Austriaca 
2000; 32 (4): 185–195. 
24. Wagner H. Operative Behandlung der Osteochon-
drosis dissecans des Kniegelenkes. Z Orthopädie 
1964: 62–64. 
25. Matsusue Y, Yamamuro T, Hma H. Case report: 
Arthroscopic multiple osteochondral transplan-
tation to the chondral defect in the knee associated 
with cruciate ligament disruption. Arthroscopy 
1993; 9: 318–321. 
26. Bobic V. Arthroscopic osteochondral autograft 
transplantation in anterior cruciate ligament re-
construction: a preliminary clinical study. Knee 
Surg Sports Traumatol Arthosc 1996; 3: 262–264. 
27. Hangody L, Karpati Z, Szerb I et al. Autologous os-
teochondral mosaic-like graft technique for replac-
ing weight bearing cartilage defects. Abstract, 7th 
Congress of the ESSKA 1996, Budapest, Hungary 
((author: please complete)). 
28. Foitzik C, Stamm M. Einsatz von phasenreinem 
ß-Tricalciumphosphat zur Auffüllung von ossären 
Defekten – Biologische Materialvorteile und klin-
ische Erfahrungen. Quintessenz 1997; 48: 
1365–1377. 
29. Heide H, Karbe E, Kling HG et al. Entwicklung und 
tierexperimentelle Untersuchungen von implan-
tierbaren, porösen keramischen Werkstoffen. Zwei 
Teilberichte für das Bundesministerium für For-
schung und Technologie, Bonn, Referat III B 3–7/12 
(1973). 
30. Soost F. (2000): Validierung des Knochenumbaus 
von Knochenersatzmaterialien in der Mund-, 
Kiefer- und Gesichtschirurgie. Berlin 2000; Hum-
boldt-Universität, Habilitationsschrift  
31. Dämmrich K, Loppnow H. Knorpelgewebe. In: All-
gemeine Pathologie für Tierärzte und Studierende 
der Tiermedizin, vol 8. Stünzi H, Weiss E (eds). Ber-
lin, Hamburg: Verlag Paul Parey 1990; 134–136. 
32. Fox SM, Walker AM. The etiopathogenesis of osteo-
chondrosis. Vet Med 1993; 88: 116–118. 
33. Goodhew PJ, Humphreys FJ. Elektronenmikrosko-
pie: Grundlagen und Anwendung, vol 1. London: 
McGraw-Hill Verlag 1991. 
34. Schmidt PC, Weyhing K. Pulverinhalte aus der 
Nähe betrachtet. Dtsch Apoth Ztg 2005; 145, Nr. 20: 
68–75.
© Schattauer 2009 Vet Comp Orthop Traumatol 3/2009
221 G. Hauschild et al.: Cartilage replacement in dogs
????????
???????????????????????????????????????????????????????????????????????????????????
????????????????????????????????????????????????????????????????????????????????????
??????
Results 
3.4. Canine genetics 
As was mentioned in the previously described work and in many recent papers 
(Ostrander et al. 1997; Kuska 1999; Ostrander et al. 2000; Ostrander et al. 2000; 
Starkey et al. 2005), the dog is a suitable model organism for the research and 
treatment of human disease including cancer, while at the same time it benefits from 
the knowledge gained for its own therapy (Shearin et al. 2010). Therefore, knowledge 
about canine genetics is a prerequisite for research on dogs and the transfer of the 
respective results to human medicine. As the canine genome had not been 
sequenced completely at the beginning of conducted research, and even after 
completion certain genes were not sequenced successfully in total, own sequencing 
and analyses of canine genes or parts thereof was performed for genes involved in 
both canine and human diseases, i.e. the canine HMG and RAS genes. In addition, 
expression plasmids for canine HMG proteins were constructed, allowing for 
research into gene therapeutic approaches of diseases involving this protein family 
as well as tissue engineering utilising these genes. Supplementing the previously 
presented work, the following papers resulted from research into the canine genome. 
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Abstract
Ultrashort pulsed laser ablation in liquids represents a powerful tool for the generation of pure gold
nanoparticles (AuNPs) avoiding chemical precursors and thereby making them especially
interesting for biomedical applications. However, because of their electron accepting properties,
laser-generated AuNPs might affect biochemical properties of biomolecules, which often adsorb
onto the nanoparticles. We investigated possible effects of such laser-generated AuNPs on
biological functionality of DNA molecules. We tested four differently sized and positively charged
AuNPs by incubating them with recombinant eGFP-C1-HMGB1 DNA expression plasmids that
code for eGFP fusion proteins and contain the canine architectural transcription factor HMGB1.
We were able to show that successfully transfected mammalian cells are still able to synthesize and
process the fusion proteins. Our observations revealed that incubation of AuNP with the plasmid
DNA encoding the recombinant canine HMGB1 neither prevented the mediated uptake of the
vector through the plasma membrane in presence of a transfection reagent nor had any effect on
the transport of the synthesized fusion proteins to the nuclei. Biological activity of the recombinant
GFP-HMGB1 fusion protein appears to have not been affected either, as a strong characteristic
protein accumulation in the nucleus could be observed. We also discovered that transfection
efficiencies depend on the size of AuNP. In conclusion, our data indicate that laser-generated
AuNPs present a good alternative to chemically synthesized nanoparticles for use in biomedical
applications.
Findings
Gold nanoparticles (AuNPs) are used widely for various
biomedical applications including cell imaging [1], diag-
nostics [2], targeted drug delivery [3], and sensing [4]. Var-
ious methods have been established for AuNP generation.
Many of these rely on several chemical reactions or gas
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pyrolysis, showing the risk of impurities or agglomeration
[5]. Laser ablation in liquids showed to be a powerful tool
with many advantages, having almost no restriction in the
choice of source material and the ability of yielding highly
pure colloidal particles[6-11]. These pure AuNPs are char-
acterised by their unique surface chemistry free of sur-
factants, a feature unattainable by other methods [12-14].
X-ray photoelectron spectroscopy of such AuNPs revealed
the presence of the oxidation states Au+ and Au3+ at the
AuNP surface [15]. In previous studies we demonstrated
that unmodified DNA oligonucleotides adsorb easily
onto these positively charged nanoparticles [16,17], prob-
ably via amino- and keto-groups, which interact with the
electron accepting surface of the generated AuNPs. How-
ever, these findings raised the possibility that more com-
plex biomolecules could also be attracted and bound to
such nanoparticles' surfaces, if incubated intentionally or
unintentionally with colloidal laser-generated gold nano-
particles, even if no additional conjugation is envisaged.
Such binding could have a strong effect on the properties
of biomolecules and should be characterised with a view
of their potential toxicity [18].
We therefore decided to analyse the possible effects of
laser-generated AuNPs on DNA functionality. For this rea-
son we incubated the charged particles with recombinant
eGFP-C1-HMGB1 expression plasmids and subsequently
transfected them into mammalian cells. As the HMGB1
protein is normally highly abundant in the cell nuclei, we
were able to show that the treated expression plasmids are
still functional and suitable for use as transcription
matrix, because the transfected cells were still able to syn-
thesize the fusion proteins, to process them and to trans-
port them to their biofunctional destination. The effect of
four differently sized nanoparticles on the activity of the
eGFP-C1-HMGB1 plasmid was investigated by fluores-
cence microscopy. We additionally performed a binding
assay to investigate structural effects on the plasmid due to
AuNP co-incubation.
Nanoparticle generation
AuNPs were generated by laser ablation in water, as
recently reported in detail [17]. Briefly, the beam of a fem-
tosecond laser system (Spitfire Pro, Spectra-Physics),
delivering 120 fs laser pulses at a wavelength of 800 nm,
was focused with a 40 mm lens on a 99.99% pure gold tar-
get placed at the bottom of a Petri dish filled with 2 mL of
bidistilled water. A pulse energy of 200 ?J at 5 kHz repeti-
tion rate was employed for 12 min. According to observa-
tions of Kabashin et al. [9] the focal position was lowered
from one generation experiment to the other (0 mm, -2
mm, -4 mm relative to the focus in air) in order to obtain
colloidal suspensions containing AuNPs with mean
hydrodynamic diameters of dh = 89 nm, dh = 59 nm and
dh = 24 nm. The remaining small particles were removed
by centrifugation at 15000 rpm for 10 min. To generate 14
nm AuNPs, laser ablation was carried out at a focal posi-
tion of -4 mm, followed by a second irradiation for 5 min
at 1 mJ with an Nd-YLF laser system (pulse length: 27 ns,
1047 nm, 5 kHz), as was described recently [19,20]. Char-
acterization of nanoparticle suspensions was performed
by dynamic light scattering using a Malvern Zetasizer and
by UV-Vis spectroscopy using a Shimadzu 1650. The
hydrodynamic number distributions and the average zeta
potential of the colloids are shown in Figure 1. The zeta
potential seems to be independent of the nanoparticle
size, which might be explained by a similar surface charge
density.
The particle mass concentration in the suspensions was
determined by weighing the sediment after water evapora-
tion.
Au-NP and eGFP-C1-HMGB1 vector in vitro transfection 
assay
The synthesised Au-NP suspensions were sterilized by fil-
tration through a 0.2 ?m filter device (Millex-GV Steriliz-
ing Filter Unit, Millipore, Billerica, USA). Subsequently,
250 ng of each differently sized Au-NPs were incubated
for 24 h at room temperature with 1 ?g of recombinant
plasmid eGFP-C1-HMGB1 in a total volume of 47 ?l of
ddH2O. The time of co-incubation was intentionally kept
that long as we aimed to investigate possible effects on the
vector due to nanoparticle interferences. This was only
possible as the circular double-stranded plasmid is not
susceptible to rapid degenerative processes.
The recombinant plasmid encodes an eGFP-HMGB1
fusion protein. The HMGB1 coding sequence was derived
from canine cDNA using PCR amplification (primer pair
EcoR1_B15'CGGAATTCACCATGGGCAAAGGAGA3'/
KpnI_B1 (5'GCGGTACCTTATTCATCATCATC-3'). The
obtained PCR products were separated on a 1.5% agarose
gel, recovered with QIAquick Gel Extraction Kit (QIAGEN,
Hilden, Germany), cloned into the pEGFP-C1 vector plas-
mid (BD Bioscience Clontech) and sequenced. Twelve
hours prior to transfection, 3 × 105 cells from canine
mammary cell line MTH53a were seeded into 12 multi
well plates. The cells were grown at 37°C and 5% CO2 in
medium 199 (Invitrogen, Karlsruhe, Germany) supple-
mented with 20% FCS, penicillin, and streptomycin. For
transfection, 3 ?l aliquots of Fugene HD (FHD) reagent
(Roche, Mannheim, Germany) were added to 47 ?l of dif-
ferent Au-NP/eGFP-C1-HMGB1 plasmid suspensions in a
total volume of 50 ?l and incubated for 15 min. The three
control sample sets were: (i) 1 ?g of eGFP-C1-HMGB1
DNA without nanoparticles, (ii) 250 ng of Au-NPs with-
out any plasmid DNA, and (iii) a set of Au-NPs with DNA,
but without the FHD.
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Following 15 min incubation at 23°C, the respective 50 ?l
transfection mixtures were added to cell cultures. The cells
were incubated for 48 hours in medium 199 (20% FCS)
at 37°C and 5% CO2. The uptake of plasmid DNA and
expression of the eGFP-C1-HMGB1 fusion protein were
verified by fluorescence microscopy. All experiments were
performed in quadruples.
Fluorescence microscopy
Transfected cells were washed with PBS, fixed in a 4%
paraformaldehyde/PBS solution (pH 7.5) for 30 min at
room temperature and washed again with PBS. After-
wards, the cells were incubated with 10 ?l of mounting
medium containing DAPI (4',6-diamidino-2-phenylin-
dole) for fluorescent visualization of nucleic DNA (Vecta
Laboratories, Burlingame, USA). Fluorescence microscopy
was performed using the Carl Zeiss Axioskop 2 and
images were recorded with the Axiovision Software. eGFP
fluorescence was measured employing wavelength filter
set 10 (Carl Zeiss MicroImaging, Göttingen, Germany),
while DAPI fluorescence was measured employing wave-
length filter set 2 (Figure 2A to 2M). Both fluorescence
images were taken with a Zeiss 2-channel Axiocam MRm
camera. Both images were then merged in a single image.
Full colour images were taken with a Zeiss Axiocam HRc
(Figure 2M and 2N). The uptake of plasmid DNA (effi-
ciency of transfection) was estimated taking into account
the quantity of cells within an ocular's visual field. Thus
the estimation was done comparing the number of cells
showing green fluorescence protein expression (green
Size distribution and surface charge of laser generated gold nanoparticlesFigure 1
Size distribution and surface charge of laser generated gold nanoparticles. Gold nanoparticles (Au-NP) were gener-
ated by laser ablation in water using a femtosecond laser system (Spitfire Pro, Spectra-Physics) delivering 120 fs laser pulses at 
a wavelength of 800 nm (working pulse energy: 200 ?J per pulse, beam diameter: 4 mm). In order to generate four suspensions 
containing differently sized nanoparticles, the focal position was lowered from one generation experiment to the other (0 mm, 
-2 mm, -4 mm relative to the focus in air) resulting in the colloidal suspensions containing nanoparticles with mean hydrody-
namic diameters of dh = 89 nm, dh = 59 nm and dh = 24 nm. For the generation of 14 nm sized nanoparticles, laser ablation was 
carried out at a focal position of -4 mm and then reirradiated for 5 min at 1 mJ with an Nd-YLF laser system (pulse length: 27 
ns, 1047 nm, 5 kHz). The hydrodynamic size distribution was analysed by Dynamic Light Scattering.
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The effect of co-transfecting plasmid DNA and laser generated gold nanoparticles on the bioactivity of GFP-HMGB1 fusion prot inFigure 2
The effect of co-transfecting plasmid DNA and laser generated gold nanoparticles on the bioactivity of GFP-
HMGB1 fusion protein. Images A to I (vertical) show a 100 fold magnification and B to J (vertical) a 400 fold 
magnification. Images A and B represent the positive control I: a transient transfection of MTH53a cells by Fugene HD rea-
gent with the eGFP-C1-HMGB1 plasmid without Au-NP incubation. Cells in images C to J are treated like control I but include 
incubation of the plasmid with 14 nm sized Au-NP (C and D), 24 nm sized Au-NP (E and F), 59 nm sized nanoparticles (G and 
H) and 89 nm sized Au-NP (I and J), respectively. Image K and L represent the negative controls II and III. M and N are full 
color images of DAPI and GFP fluorescence.
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staining) and cells showing blue DAPI fluorescence dye
staining.
Co-transfection of plasmid DNA and laser-generated gold 
nanoparticles
As the HMGB1 protein is a transcription factor, it binds
strongly to nuclear DNA. We therefore may assume that
cell nuclei containing strong eGFP fluorescence represent
successful functional transfection events. All cells trans-
fected with AuNP-incubated plasmid DNA showed strong
colocalised eGFP and DAPI staining (Figure 2), whilst the
negative controls, cells treated with Au-NP and FHD
(AuNP of dh = 24 nm), showed no eGFP fluorescence (Fig-
ure 2K). We therefore conclude that co-incubation of
AuNP with the plasmid DNA encoding the recombinant
canine HMGB1 neither prevents the mediated uptake of
the vector in presence of a transfection reagent nor has any
visible effect on the transport and biological functionality
of the synthesised fusion proteins.
By comparing fluorescence images of the cells co-incu-
bated with the AuNPs of different sizes and to cells incu-
bated without AuNPs, we were able to compare
transfection efficiencies in each case. We estimate that the
achieved efficiency of DNA transfection for the sample
containing 14 nm AuNPs was approx. 15 ± 5% (Figure 2C
and 2D).
The highest observed transfection efficiencies were
achieved using 24 nm and 59 nm Au-NPs (50 ± 5% and
50 ± 10% respectively, see Figure 2E to 2H). The Au-NPs
showed size dependent effects concerning the observed
transfection efficiencies (see Table 1). Exemplarily, Au-
NPs of a medium size (dh: 24 and 59 nm) showed the
highest effects. Thus, the observed GFP fluorescence of the
respective fusion proteins was so intense that it even
leaked into the DAPI channel (Fig 2M and 2N respectively
for AuNP of dh = 59 nm). Further negative control samples
containing DNA- co-incubated AuNPs missing FHD,
showed no recombinant protein expression, proving that
our AuNPs did not act as transfection reagent themselves.
(Figure 2L). The cell population seems to go along with
transfection efficiency, as the observed seeding density
was in all wells similar prior to transfection.
Shift assay
We performed binding experiments with plasmid DNA
(eGFP-C1-HMGB1) and respective Au-NPs of different
sizes and with various concentrations. We digested the co-
incubated batches with a NcoI restriction enzyme (Fer-
mentas, St Leon Rot, Germany) and separated the result-
ing DNA fragments in a 1.5% agarose gel. No significant
shift alterations could be observed in the DNA mobility
pattern. To ensure that this phenomenon is also valid in
presence of proteins we added purified HMGB1 protein
(Centre for Human Genetics, Bremen, Germany) to the
Au-NPs/DNA and HMGB1 protein mobility shift assaFigure 3
Au-NPs/DNA and HMGB1 protein mobility shift 
assay. M: GeneRuler 1 kb Plus (Fermentas), lane 1: 170 ng 
plasmid (NcoI digested); lane 2: 170 ng plasmid (NcoI 
digested) and 1.5 ?g HMGB1; lanes 3-6: 170 ng plasmid 170 
(NcoI digested) and 1.5 ?g HMGB1 in 0.1 nM, 0.5 nM, 1.0 nM 
and 2.5 nM AuNPs suspensions, size dh 24 nm; lane 7: 170 ng 
plasmid (NcoI) digested and 1.5 ?g HMGB1 and 90 ng pure 
Au suspension, size dh 24 nm; lanes 8-11: 170 ng plasmid 
(NcoI digested) and 1.5 ?g HMGB1 in 0.1 nM, 0.5 nM, 1.0 nM 
and 2.5 nM AuNPs suspensions, size dh 59 nm; lane 12: 170 
ng plasmid (NcoI) digested and 1.5 ?g HMGB1 and 50 ng 
pure Au suspension, size dh 59 nm.
Table 1: Summary of estimated transfection efficiencies
Size
Au-NP (dh)
Estimated Transfection Efficiency (%) Figure
Positive controls 10 ± 2 A and B
14 nm 15 ± 5 C and D
24 nm 50 ± 5 E and F
59 nm 50 ± 10 G and H
89 nm 8 ± 3 I and J
Negative controls - K and L
Differently sized Au-NPs were incubated with plasmid DNA and transfected into the canine MTH53a cellline
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batches. Akin to the DNA mobility pattern of digested
Plasmid DNA and HMGB1 without Au-NPs (lane 2, Fig-
ure 3) we could not detect any significant change in the
shift pattern (see lanes 3 to 12, Figure 3). Consequently
the DNA/Au-NPs complexes serve as substrates for the
DNA-bindig protein HMGB1.
Conclusion
In conclusion, incubation of uncoated, positively charged
AuNPs with a DNA plasmid that encodes recombinant
eGFP-C1-HMGB1 fusion protein for 24 hours before cel-
lular transfection does not seem to alter the protein
expression and the protein functionality (DNA binding),
while the presence of AuNPs seems to have a significantly
positive effect on the transfection efficiencies. The
observed effect was size-dependent: medium sized AuNPs
enhanced transfection efficiency nearly 6 fold. These
results support the hypothesis that laser-generated AuNPs
present a good alternative to chemically synthesized nan-
oparticles and are especially suitable for biomedical appli-
cations.
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Abstract
Background: The high mobility group A1 proteins (HMGA1a/HMGA1b) are highly conserved
between mammalian species and widely described as participating in various cellular processes. By
inducing DNA conformation changes the HMGA1 proteins indirectly influence the binding of
various transcription factors and therefore effect the transcription regulation. In humans
chromosomal aberrations affecting the HMGA1 gene locus on HSA 6p21 were described to be the
cause for various benign mesenchymal tumours while high titres of HMGA1 proteins were shown
to be associated with the neoplastic potential of various types of cancer. Interestingly, the absence
of HMGA1 proteins was shown to cause insulin resistance and diabetes in humans and mice.
Due to the various similarities in biology and presentation of human and canine cancers the dog
has joined the common rodent animal model for therapeutic and preclinical studies. Accordingly,
the canine genome was sequenced completely twice but unfortunately this could not solve the
structure of canine HMGA1 gene.
Results: Herein we report the characterisation of the genomic structure of the canine HMGA1
gene consisting of 7 exons and 6 introns spanning in total 9524 bp, the in vivo localisation of the
HMGA1 protein to the nucleus, and a chromosomal assignment of the gene by FISH to CFA12q11.
Additionally, we evaluated a described canine HMGA1 exon 6 SNP in 55 Dachshunds.
Conclusion: The performed characterisations will make comparative analyses of aberrations
affecting the human and canine gene and proteins possible, thereby providing a basis for revealing
mechanisms involved in HMGA1 related pathogenesis in both species.
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Background
The high mobility group A (HMGA) proteins are small
chromatin associated non-histone proteins named
according to their characteristic motility in acid-urea poly-
acrylamide gel electrophoresis. The protein family con-
sists of the three proteins HMGA1a, HMGA1b and
HMGA2 which are encoded for by two different genes
(HMGA1 and HMGA2). The functional motifs of these
proteins, named AT-hooks, bind to the minor groove of
DNA causing conformational changes of the DNA mole-
cule. On genomic level these structural changes influence
the binding of various transcription factors and thus indi-
rectly influence the transcription regulation, which classi-
fies the HMGA proteins as so called architectural
transcription factors (for detail see [1]).
In previous studies we characterised the canine HMGA1
cDNAs and proteins and in comparative analyses of these
molecules showed that they are highly conserved between
different mammalian species. The observed number of
amino acid changes seen across mammalian species (cat-
tle, dog, hamster, horse, mouse, pig, and rat) vary between
0 to 3 when compared to the human molecules [2-10].
Interestingly, only the canine HMGA1 proteins are 100%
identical to their respective human counterparts [11].
The HMGA1 proteins are well known to play a significant
role in the pathogenesis of various diseases including can-
cer. In humans, chromosomal aberrations affecting the
HMGA1 gene locus on HSA 6p21 were described for vari-
ous benign mesenchymal tumours, e.g. endometrial pol-
yps, lipomas, pulmonary chondroid hamartomas, and
uterine leiomyomas [12-14]. The observed aberrations are
supposed to lead to an up-regulation of the HMGA1 gene
in the affected tumours, as opposed to adult healthy tis-
sues where HMGA gene expression is low or hardly meas-
urable [9,15,16]. In malignant neoplasias HMGA1
expression is reported to be associated with an aggressive
behaviour of tumours. Accordingly, HMGA1 overexpres-
sion was detected in various malignancies including thy-
roid, lung, prostatic, pancreatic, uterine cervical, and
colorectal carcinoma [17-22]. Thus HMGA expression is
supposed to present a powerful diagnostic and prognostic
molecular marker due to the described correlation
between HMGA expression and tumour aggressiveness.
Whilst overexpression of HMGA1 is clearly associated
with cancerogenesis the disruption of the HMGA1 gene
and thus induced loss of HMGA1 expression shows signif-
icant pathogenic effects. Heterozygous and homozygous
Hmga1 knock-out mice develop cardiac hypertrophy
combined with hematologic malignancies e.g. B cell lym-
phoma and myeloid granuloerythroblastic leukemia [23].
Additional research with Hmga1 knock-out mice targeting
diabetes presented by Foti et al. (2005) showed that loss
of Hmga1 expression is clearly associated with signifi-
cantly decreased insulin receptor expression and thus
causes a characteristic diabetes type 2 phenotype in mice
[24].
The various similarities in presentation and biology of
numerous canine and human diseases including cancer
suggest similar mechanisms to be involved in the respec-
tive pathogenic events. Accordingly, at least a dozen dis-
tinct canine cancers are hypothesized to be appropriate
models for their human counterparts, among those oste-
osarcoma, breast carcinoma, oral melanomas, lung carci-
nomas and malignant non-Hodgkin's lymphomas [25].
The characterization of disease related genes and their
protein biology will allow for comparative studies to
reveal the molecular mechanisms involved therein and
serve as a basis for future clinical studies.
Results and discussion
The HMGA1 gene and its proteins HMGA1a and
HMGA1b are described as regulating multiple cellular
processes and are widely reported to be associated with
various diseases including diabetes and cancer. In previ-
ous studies we characterised the canine HMGA1 cDNAs
and proteins completely and did comparative analyses of
these molecules to the respective counterparts of different
species and showed high evolutionary conservation. The
fact that several canine and human cancer types show
striking similarities in presentation and biological behav-
iour, e.g. spontaneous occurrence and metastasis patterns,
strongly suggests similar mechanisms to be involved in
the respective pathogenic events of both species. Thus,
various canine tumours are currently used as models for
several human cancer types. Accordingly, comprehension
of the canine gene and its gene products is precondition
for comparative analyses, allowing the revelation of
molecular effects involved in these pathogenic presenta-
tions. Understanding and comparison of the respective
genes will thus benefit both species. The exact mechanism
for the emergence of the pathogenic effects caused by
chromosomal aberrations affecting the human HMGA1
gene in benign mesenchymal tumours, e.g. endometrial
polyps, lipomas, pulmonary chondroid hamartomas, and
uterine leiomyomas [12-14] are not completely under-
stood. However, it is currently supposed that the aberra-
tion causes up-regulation of the HMGA1 gene in the
affected neoplasias. The principal aim of the study was to
characterize the genomic structure of the canine HMGA1
gene allowing the comparison of its genomic structure to
the counterparts of other mammals and thus allowing a
further evaluation of evolutionary conservation of the
gene and a comparative analysis of chromosomal aberra-
tions in both species. Additional aims were the in vivo
localization of the canine HMGA1 protein and the evalu-
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ation of a previously described point mutation which
causes a disrupted protein.
Genomic structure, BAC Screening and FISH
A canine HMGA1 genomic PCR reaction was established
and used for screening of a canine BAC for identification
of the canine HMGA1 gene locus by FISH. The verified
BAC 572 P20 K12 RC was used for FISH experiments. Ten
well spread metaphases were analysed and showed signals
on both chromatides of both chromosomes CFA 12q11
(Figure 1). The chromosomal localisation was done fol-
lowing the nomenclature established by Reimann et al.
[26]. Existing painting probe based synteny studies and
RH analyses [27] indicated that the canine CFA 12 shares
homology with the human chromosome 6 on which the
HMGA1 gene is located at HSA 6p21. Chromosomal aber-
rations affecting CFA 12 are not or barely reported to be
significantly associated with canine neoplasias [28,29].
While previous studies reported the localization of a
HMGA1 gene positive BAC to CFA 23 [30], the performed
in silico analyses and the recently published canine
genome assembly [31] support the herein described
assignment of the canine HMGA1 gene to CFA 12q11 by
FISH described in this study. Comparative chromosomal
in silico analyses using the "Evolutionary Highway" http:/
/evolutionhighway.ncsa.uiuc.edu/results.html showed
similar results.
The genomic structure of the canine HMGA1 gene consists
in total of the 7 exons and 6 introns. Overall the canine
HMGA1 gene spans 9524 bp. The exon/intron structure,
size and the homologies to their human counterparts
were analysed and defined (Figure 2, Table 1). The total
identity to the corresponding human region is 62.8%. In
detail, the identities of the exons vary between 74.6% and
97.8% to their human counterpart, while the introns
show identities between 58.9% and 92.4% (for details see
Table 1). The newly characterized sequences combined
with the analyses performed in silico revealed that the
exon 4, which exists in humans, is missing on genomic
level in the canine genome. This exon 4 deletion also
exists in the mouse genome and affects the respective
mRNAs of both species in their 5' UTR. As the genomic
characterization of the canine HMGA1 gene was not avail-
able when the exons were named previously, the number-
ing at that time was based on the respective human exon
numbers as defined by Friedmann et al. [32]. Conse-
quently, as it is now known that the canine genomic
sequence is lacking an equivalent to human exon 4, the
previously used canine exon numbering should be revised
with the then named canine exon 5 now being canine
exon 4 and so on (Figure 2, Table 1). However, a part of
intron 2 remains unsequenced due to an extensive CG
repeat which also exists in the human counterpart
(90%CG), and only the number of nucleotides (311 bp)
could be identified. The genomic sequences were submit-
FISH-Mapping of the canine HMGA1igure 1
FISH-Mapping of the canine HMGA1. Canine metaphase spread after GTG-banding (left) and the same metaphase after 
fluorescence in situ hybridisation with BAC MGA 572 P20 K12 RC showing signals on both chromosomes 12 (right).
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ted to the NCBI database (bankit1078465,
bankit1078536, bankit1078968).
Exon 6 SNP evaluation
While characterising the canine HMGA1 gene we screened
twelve different canine breeds for point mutations affect-
Genomic structure of the canine HMGA1 geneFigure 2
Genomic structure of the canine HMGA1 gene. Detailed structure of the genomic organisation of the canine HMGA1 
gene.
Canine HMGA1
Human HMGA1
E1 E3 E4 E5 E6 E7
5`
E2
            
I1 I2 I3 I4 I5 I6 I7
E8
CDS
UTR
Intron
E1 E3 E4 E5 E6 E7E2
            
I1 I2 I3 I4 I5 I6
500bp
HSA6 GenBank NC_000006 
Region: 34312628-34321986 
CFA12 GenBank NW_876254
Region: 3531321-3541043 5`
Table 1: Detailed analysis of the canine HMGA1 gene genomic elements
Element of canine HMGA1 gene Size in bp Identity to human counterpart in % (GenBank NC_000006))
Total gene 9524 62.8
Detail exons/introns (revised numbering)*
Exon 1 94 97.8
Intron 1 196 92.4
Exon 2 164 95.8
Intron 2 311 -
Exon 3 162 74.6
Intron 3 3096 58.9
Exon 4 (5) 179 93.9
Intron 4 (5) 1761 51.1
Exon 5 (6) 84 96.4
Intron 5 (6) 584 57.5
Exon 6 (7) 51 94.1
Intron 6 (7) 1459 58.1
Exon 7 (8) 1386 75.4
Identity comparison of the genomic elements of the canine HMGA1 gene with its respective human counterparts.
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ing the protein coding region. A Dachshund sample
showed a transition from A to G in exon 6 (according to
revised exon numeration) leading to an amino acid
exchange from threonine to alanine causing a mutated
HMGA1 protein [9]. To elucidate if the observed exchange
is frequently existent in the Dachshund population we
screened 55 Dachshunds for the respective mutation (Fig-
ure 3). The results obtained by sequencing and restriction
fragment analysis clearly showed that the previously
found mutation is a rare event, as none of the screened 55
Dachshunds showed the mutation. Thus our findings sug-
gest that the previously found aberrant HMGA1 allele
leading to a mutated protein form is unlikely to play a
major role in HMGA1 pathogenesis in Dachshunds.
In general, different species show significant differences
considering the number and probability of described
SNPs. This fact surely is directly dependent on total num-
bers of studies and sequencing reactions performed for
the different species. While in 2001 Sachidanandam et al.
[33] detected 1.42 million SNPs in the human genome
with one SNP per 1.9 kb the currently estimated total
number reported SNPs in the public databases is approx.
9 million for the human genome [34]. For the dog Lind-
blad-Toh et al. reported 2.5 million SNPs, whereas the
probability differs depending on the breed between one
SNP per 1500 bp and 900 bp [31]. Comparable to the
human genome the total numbers of reported SNPs in the
other different species is expected to increase significantly
according to the performed research efforts, leading to
increased knowledge of effects caused by SNPs in general.
HMGA1 in vivo localization
The in vivo localization of the canine HMGA1 proteins via
expression of a canine HMGA1a-GFP fusion protein
showed that equivalently to its human counterpart the
protein is located in the nucleus (Figure 4). Proteins of the
HMGA family are described to be architectural transcrip-
tion factors, and thus a localisation in the nucleus seems
obvious. However, further localisation and function of
these proteins seem to be very likely, due to the fact that
application of recombinant HMGA1 proteins to porcine
cartilage cells in vitro showed significant increase of cell
proliferation (Richter et al. accepted for publication). For
a further member of the HMG proteins called HMGB1 the
existence of an extracelluar function was recognised only
a long time after its initial characterisation as an architec-
tural transcription factor, revealing a direct influence of
Position of the evaluated Dachshund point mutationFigure 3
Position of the evaluated Dachshund point mutation. Strategic position of the evaluated point mutation screened in 55 
Dachshunds.
Exon 6
51 bp
part of
Intron6
part of
Intron 5
A1 In 5 Up
18 bp
A1 In 6 Lo
19 bp
point mutation
Part of the canine HMGA1a gene
SNP
Acc. No. 
NC_006594
TTT
AAA
T
A
GATGGTGTTGAGGTCCCTCCTTTGGCTCCCCGTCTGGGTTTTTTGAC
CTACCACAACTCCAGGGAGGAAACCGAGGGGCAGACCCAAAAAACTG
C
G
????????
???????????????????????????????????????????????????????????????????????????????????
????????????????????????????????????????????????????????????????????????????????????
??????
BMC Genetics 2008, 9:49 http://www.biomedcentral.com/1471-2156/9/49
Page 6 of 9
(page number not for citation purposes)
extracellular HMGB1 on metastatic events [35-37]. Thus,
we suppose that a similar mechanism could also exist for
HMGA proteins and are currently working towards its
identification.
Conclusion
Knowledge about the structure of genes and proteins is
precondition to use them as potential therapeutic targets,
markers or for revealing mechanisms involved in relevant
pathogenic events. The canine and human HMGA genes
and proteins have widely been shown to be involved in
various diseases especially in cancer. Due to the numerous
reasons for using the dog as a model system for human
cancer research the characterisation of canine genes and
proteins is of special interest. The performed characterisa-
tions of the canine HMGA1 gene and proteins will allow
performing comparative analyses of aberrations affecting
the human and canine genes and proteins as basis for
revealing mechanisms involved in HMGA1 related patho-
genesis in both species.
Methods
BAC library screening
A PCR reaction for the use in PCR-based screening of the
Canis familiaris DogBAC library (Schelling et al., 2002)
(Institute of Animal Genetics, Nutrition and Housing,
University of Berne, Berne, Switzerland) for a BAC clone
containing HMGA1 was established using canine genomic
DNA derived from blood. The primers A1In5up (5'
GGCATCCGGTGAGCAGTG 3') and A1In6lo (5' CAG-
GCAGAGCACGCAGGAC 3') were designed using
GeneBank sequences AY366395 &NW_876254. PCR
parameters were: 95°C for 5 min, followed by 30 cycles of
95°C 30 sec, 59.3°C 30 sec, 72°C 30 sec, and a final elon-
gation of 72°C for 10 min. The corresponding 201 bp
PCR product was cloned into the pGEM-T Easy vector sys-
tem (Promega, Mannheim, Germany) and verified by
sequencing. The DNA contigs and alignments were done
with Lasergene software (DNAstar, Madison, USA) and
various sequences from the NCBI database (AY366395,
NW_876254). The verified BAC clone MGA 572 P20 K12
RC was used as probe for the following FISH experiments.
Slide Preparation
1 ml of canine whole blood was incubated for 72 h in
Chromosome Medium B (Biochrom, Berlin, Germany).
Subsequently, colcemide (0.1 ?g/ml) (Biochrom, Berlin,
Germany) was added for 2 hours. The cells were centri-
fuged at 135 × g for 10 min and incubated for 20 min in
0.05 M KCl. Finally the cells were fixed with methanol/
glacial acetic acid. This suspension was dropped on ice-
cold slides and dried for at least 7 days at 37°C. The chro-
mosomes were stained by GTG banding for karyotype
description. Prior to use in FISH investigations, the slides
were destained with 70% ethanol.
Fluorescence in situ Hybridization
MGA 572 P20 K12 RC BAC-DNA was digoxigenin
labelled (Dig-Nick-Translation-Kit, Roche, Mannheim,
Germany). The hybridization mixture contained 200 ng
probe, 40 ng ssDNA, 600 ng sonicated dog DNA, 2 × SSC,
2 × SSPE, 50% formamide and 10% dextran sulfate. 50 ?l
of this mixture were applied to each slide and the cover
slips were sealed with rubber cement. Probe and chromo-
somes were denatured at 75°C on an Eppendorf Thermo-
cycler gradient, using the in situ adapter. Afterwards, the
slides were incubated in a moist chamber at 37°C over
night. Cover slips were carefully removed and the slides
were incubated in 0.1 × SSC at 61°C and 1 × PBS at RT.
Slides were then covered with 100 ?l non fat dry milk
(NFDM) for 20 min. at 37°C in a moist chamber. For sig-
nal detection 100 ?l NFDM containing 3 ?g of Anti-Dig-
oxigenin-Rhodamine, Fab fragments (Roche, Mannheim,
Germany), were added to each slide and again incubated
for 20 min at 37°C in a moist chamber, followed by
washes with 1 × PBS, 3 × 3 min. at RT. Slides were air dried
In vivo localisation of the canine HMGA1 proteinFigure 4
In vivo localisation of the canine HMGA1 protein. In vivo localization of a canine HMGA1a-GFP fusion protein in culture 
canine MTH53A cells, 24 h posttranslational. a) GFP expression in canine mammary cell line MTH53A, b) DAPI fluorescent 
staining of cell nuclei, merged GFP and DAPI image, c) merged GFP and transmitted light image (magnification ×400).
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before chromosomes staining was performed with 25 ?l
of Vectashield Mounting Medium with DAPI (Vector Lab-
oratories, Burlingame, CA, USA)
Ten well spread metaphases were examined indicating a
signal on CFA 12q11 on both chromatids of both chro-
mosomes CFA 12q11 (Fig. 1). The determination of chro-
mosomes follows the nomenclature of the canine
karyotype as described previously [26].
Genomic characterisation
For genomic characterisation of the canine HMGA1 gene
the missing parts were amplified by PCR on the screened
BAC clone MGA 572 P20 K12 RC. For the missing part 1
a 858 bp fragment (bankit 1078968) was generated with
primer pair A1_6640-6997_upa (5'-GGCGCGGCTCCAA-
GAA-3'), A1_6_lo_2 (5'-CCAACAGAGCCCTGCAAA-3'), a
1879 bp fragment (bankit 1078465 for the missing part 2
was generated by the primer pair A1_8864-10549_upa
(5'-GTCTCACCGTCTGGAGAAT-3'), A1_8864-10549_loa
(5'-TCACCGGAGGCTGCTT-3') and for the third missing
part a 979 bp fragment (bankit 1078536) was generated
with primer pair A1_11223-11834_upa (5'-
CTGAGCCCATGCCAGATAA-3'), A1_11223-11834_loa
(5'-AGAGATCCCTGCCGTAGT-3'). The obtained PCR
products were separated on a 1.5% agarose gel, recovered
with QIAquick Gel Extraction Kit (QIAGEN, Hilden, Ger-
many), cloned in pGEM-T Easy vector system (Promega,
Mannheim, Germany) and sequenced for verification.
The final genomic canine HMGA1 contig and the identity
alignments were created with Lasergene software (DNAS-
tar, Madison, USA) with the generated sequences from the
cloned cDNAs described previously and various
sequences from the NCBI database derived from the
canine genome sequencing (AY366394, AY366395,
AY366396, NM_001003387, NW_876254).
SNP screening
Genomic DNA was isolated from the collected 55 Dachs-
hunds samples using the QiaAmp kit (QIAGEN, Hilden,
Germany). A specific genomic PCR using the primer pair
A1In5up (5' GGCATCCGGTGAGCAGTG 3') and A1In6lo
(5' CAGGCAGAGCACGCAGGAC 3') was established
allowing the amplification of the complete exon 6 and
flanking regions of intron 5 and 6, respectively (Figure 3).
In detail the PCRs were performed in a 25 ?l volume con-
taining 0.5 ?M of both primers (MWG Biotech, Martin-
sried, Germany), 0.1 mM of each dNTP (Invitrogen,
Karlsruhe, Germany) 0.6 units Taq-DNA polymerase
(Promega, Mannheim, Germany), 1.5 mM MgCl2
(Promega, Mannheim, Germany), PCR buffer (Promega,
Mannheim, Germany) and 2.5 ?l template DNA, contain-
ing averaged 26.5 ng/?l.
After an initial denaturation step of 5 min at 95°C, the
amplification followed in 30 cycles (30 sec. at 95°C, 30
sec at 59.3°C and 30 sec at 72°C). To complete, a final
elongation step for 10 min. at 72°C completed the proc-
ess. The obtained PCR products were purified using the
QIAquick PCR Purification Kit (Qiagen, Hilden, Ger-
many), directly sequenced by MWG Biotech (Martinsried,
Germany), and additionally digested enzymatically with
AluI (Fermentas, St. Leon-Rot, Germany). The occurrence
of the described SNP creates a new restriction site for the
enzyme AluI (5' AGtCT 3'). Thus, a digestion with AluI
cuts the 201 bp PCR product in two fragments of 69 bp
and 132 bp, respectively allowing a verification of the
sequencing results.
HMGA1 in vivo localisation
For the HMGA1 in vivo localisation the protein coding
sequence of the canine HMGA1a was amplified by PCR
using primer pair EcoR1_IY-upATG (5'-CGGAATTCCAC-
CATGAGCGAGTCGAGCTCGA-3'), BamH1_IY-loSTOP
(5'-CGGGATCCTCACTGCTCCTCTTCGGAGGACT-3').
The obtained PCR products were separated on a 1.5% aga-
rose gel, recovered with QIAquick Gel Extraction Kit (QIA-
GEN, Hilden, Germany), ligated into the pEGFP-C1
vector plasmid (BD Bioscience Clontech) and sequenced
for verification.
Cells from canine mammary tumour cell line MTH53a
were cultivated using medium 199 (Invitrogen, Karlsruhe,
Germany) supplemented with 20% FCS, penicillin, and
streptomycin. The transfection was performed according
to the manufacturer's instructions using 3 ?l FugeneHD
reagent (Roche, Mannheim, Germany) in 100 ?l PBS
(without Mg2+) containing 2 ?g of recombinant pEGFP-
C1-HMGA1a. After treatment, the cells were incubated for
48 hours in the culture media. The uptake and expression
of DNA was verified by fluorescence microscopy.
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Abstract
Point mutations in the cellular homologues HRAS, KRAS2, and NRAS of the viral Harvey and Kirsten rat sarcoma virus
oncogenes are commonly involved in the onset of malignancies in humans and other species such as dog, mouse, and rat. Most
often, three particular hot-spot codons are affected, with one amino acid exchange being sufficient for the induction of tumor
growth. While RAS genes have been shown to play an important role in canine tumors such as non-small lung cell carcinomas,
data about RASmutations in canine fibrosarcomas as well as KRAS2mutations in canine melanomas is sparse. To increase the
number of tumors examined, we recently screened 13 canine fibrosarcomas and 11 canine melanomas for point mutations,
particularly within the mutational hot spots. The results were compared to the already existing data from other studies about
these tumors in dogs.
A family of genes often involved in human tumors are the
well-characterized RAS genes, which comprise HRAS,
KRAS2, and NRAS, coding for closely related, small, 189
amino acid, 21 kDa, membrane-bound, intracellular proteins.
The human cellular HRAS and KRAS2 genes were identified
to be homologues of the Harvey and Kirsten rat sarcoma
virus oncogenes v-Ha-ras and v-Ki-ras2, respectively (Der
et al. 1982; Parada et al. 1982), withNRAS being only weakly
homologous to both v-Ha-ras and v-Ki-ras2 (a v-N-ras gene has
not been described) (Shimizu et al. 1983). Ras genes have
been found in a variety of mammals, showing high sequence
similarity across species, with sequence variation most often
not affecting the amino acid sequence of the encoded pro-
teins (Watzinger et al. 1998).
The RAS proteins function in relaying mitogenic growth
signals into the cytoplasm and nucleus, influencing prolifer-
ation, differentiation, transformation, and apoptosis of cells
(Watzinger andLion 1999). Regulation ofRASprotein activity
occurs through intrinsicGTPase activity in thewild-typeRAS,
which switches the protein from an active (guanosine triphos-
phate [GTP]-bound) to an inactive (guanosine diphosphate
[GDP]-bound) state. Point mutations in a number of partic-
ular hot-spot codons in exon 1 (mostly codons 12 and 13) and
exon 2 (mostly codon 61) lead to diminished GTPase activity,
bringing about constant signal transduction and facilitating
uncontrolled cell division and tumor growth (Park 1995).
Alterations in RAS genes are among the most important
incidents in the onset of malignancies in humans (Arber
1999; Hahn et al. 1994), and have been described in dog,
mouse, and rat, among others. Studies indicate that in man,
up to 13% of brain tumors, 30% of lung tumors, 30% of liver
tumors, 30%of acutemyelogenous leukemia, 53%of follicular
and 60% of undifferentiated papillary thyroid tumors, 50% of
tumors of the gastrointestinal tract, and 90% of pancreatic
tumors are affected by a mutation in the hot-spot codons
of one of the three known RAS genes (Bos 1989; Knapp
and Waters 1997; Spandidos et al. 2002; Tang et al. 2002).
Studies about the involvement of RAS genes in canine
tumors have been performed by a number of groups inves-
tigating several types of tumors. Gumerlock et al. (1989) de-
scribed the formation of activated NRAS through the
substitution of glycine by aspartartic acid at position 12 of
the protein in a case of a gamma radiation-induced canine
acute nonlymphocytic leukemia.
KRAS2 activation was observed in non-small cell lung
cancer of the dog (Kraegel et al. 1992). Out of 21 tumors,
which included adenocarcinomas, adenosquamous carcino-
mas, and one large cell carcinoma, 5 were shown to be af-
fected by mutations mostly of codon 12 of the KRAS2
gene, being similar to the overall frequency of KRAS2 in-
volvement in non-small cell lung cancer in man (25%). This
was confirmed by a later study investigating a wide range of
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canine lung tumorswhere 19 out of 117 tumors (16%) showed
KRAS2 alterations in the hot-spot codons (Griffey et al. 1998).
On the other hand, NRAS was shown to be infrequently
activated in canine malignant lymphomas, with only 1 from
28 examined cases showing an amino acid substitution from
glycine to aspartate at position 13 (Edwards et al. 1993).
Similar to malignant lymphomas, RAS gene mutations at
the hot-spot loci were shown to be rarely or not involved in
canine mammary tumors (Castagnaro 1995; Mayr et al. 1998).
Furthermore,Watzinger et al. (1998) have shown in avariety of
canine tumors thatRASgenes are, compared tohumans, rather
infrequently involved in the onset of malignancies. In that
study, only three fibrosarcomas were included, none of which
showed RAS gene alterations. Since Guerrero et al. (2002)
showed that fibrosarcomas can be induced in nude mice by
subcutaneously injecting transfected fibroblasts with KRAS2
point mutations in codon 12, we recently screened a larger
number of 13 canine fibrosarcomas for KRAS2 and NRAS
mutations in the particular hot-spot codons. In addition, we
also recently screened 11 canine melanomas for KRAS2 and
NRASmutations (MuruaEscobar et al. 2004).However, none
of the screened tumors showed the characteristic RAS alter-
ations in the hot-spot codons. A low rate of NRAS involve-
ment in canine melanomas has been shown before, with 2 of
16 tumors showing NRAS mutations (Mayr et al. 2003).
In summary, the data from the available studies on canine
fibrosarcomas and melanomas (Mayr et al. 2003; Murua
Escobar et al. 2004; Watzinger et al. 2001) strongly indicate
that KRAS2 and NRAS mutations at the hot-spot loci are
essentially very rare in the investigated canine tumor entities.
To the best of our knowledge, from the total number of 32
screened canine fibrosarcomas and 17 screened canine mel-
anomas, only 2 melanoma samples have been found to have
exon 61 of the NRAS gene affected. For KRAS2, no muta-
tions in the hot-spot codons have been found. However, to
allow for a comparison of these canine tumors with research
results from, for example, man and mouse, with vast amounts
of data being available, a larger number of canine tumors will
have to be screened in the future, as it is still too early to draw
conclusions from the relatively small number of canine
tumors examined.
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Abstract
HMGA1 nonhistone proteins are reported to participate in various cellular processes including regulation of inducible gene
transcription, integration of retroviruses into chromosomes, and the induction of neoplastic transformation and promotion
of metastatic progression of cancer cells. Overexpression of HMGA1 was shown to be characteristic for various malignant
tumors, suggesting a relation between the neoplastic phenotype and a high titer of the protein. Also chromosomal
aberrations affecting the human HMGA1 gene at 6p21 were described in several tumors, e.g., uterine leiomyomas,
pulmonary chondroid hamartomas, and follicular thyroid adenomas. We characterize the molecular structure of the canine
HMGA1 cDNA, its splice variants, and predicted proteins HMGA1a and HMGA1b. Furthermore, we compared the CDS
of both splice variants for 12 different breeds, screened them for SNPs, characterised a basic expression pattern, and
mapped the gene via FISH. Additionally, we compared the known human, canine, murine, rat, hamster, bovine, pig, Xenopus,
and chicken HMGA1 transcripts.
High mobility group proteins named according to their
characteristic mobility in gel electrophoresis are small
chromatin-associated nonhistone proteins, which can be
subdivided into three families because of their functional
sequence motives: the HMGA (functional motive ‘‘AT-
hook’’), HMGB (functional motive ‘‘HMG-box’’), and
HMGN (functional motive ‘‘nucleosomal binding domain’’)
protein families (for review see Bustin 2001). By binding
DNA with their functional motives, the HMG proteins
induce DNA conformation changes influencing the binding
of various transcription factors and thus taking indirect
influence on transcription regulation as so-called architec-
tural transcription factors (for detail see Bustin and Reeves
1996).
The proteins HMGA1a, HMGA1b, and HMGA2 of the
human HMGA genes are associated with various human
diseases, including cancer. Members of the human HMGA1
protein family presently known are HMGA1a and
HMGA1b, which by modifying chromatin structure take
influence on transcription and up- and down-regulation of
a number of target genes, for example, ATF2, IFN-b, NF-
jB, Interleukin-2 receptor, E-Selektin, Interleukin-4, Interfeone-A,
ERCC1, and Cyclin A (Chuvpilo et al. 1993; Du and Maniatis
1994; Thanos and Maniatis 1992; Lewis et al. 1994; John
et al. 1995, 1996; Klein-Hessling et al. 1996; Yie et al. 1997;
Borrmann et al. 2003).
The expression pattern of the HMGA genes in human
adult tissues shows only very low levels or even absent
expression, whereas it is abundantly expressed in embryonic
cells (Rogalla et al. 1996; Chiappetta et al. 1996). In humans
the HMGA1 gene is located on HSA 6p21, a region often
affected by aberrations leading to an up-regulation of this
gene in various benign mesenchymal tumors, for example,
endometrial polyps, lipomas, pulmonary chondroid hamar-
tomas, and uterine leiomyomas (Williams et al. 1997;
Kazmierczak et al. 1998; Tallini et al. 2000). This suggests
that transcriptional activation due to these chromosomal
alterations is probably an early and often even primary event
of cancer development. Recently, the canine HMGA1 gene
has been mapped to CFA 23. This cytogenetic assignment
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indicates that the canine HMGA1 gene does not map to
a hotspot of chromosomal breakpoints seen in canine
tumours (Becker et al. 2003).
HMGA1 expression in human malignant epithelial
tumors is reported to be associated with an aggressive
behavior of the tumors. Overexpression of HMGA1 was
Figure 1. Species comparison of HMGA1a and HMGA1b transcripts. Exon 5 is enlarged by factor fife for better
visualization.
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detected in a number of malignancies, including thyroid,
prostatic, pancreatic, uterine cervical, and colorectal cancer
(Tamimi et al. 1993; Chiappetta et al. 1995; Fedele et al. 1996;
Bandiera et al. 1998; Abe et al. 1999, 2000; Czyz et al. 2004;
Takaha et al. 2004). The correlation betweenHMGA expres-
sion and tumor aggressiveness in some of these malignancies
has led to the conclusion that HMGA expression may pres-
ent a powerful diagnostic and prognostic molecular marker.
Due to the similarities of various human and canine
cancer entities, the characterization of the canine HMGA
genes could open new fields for experimental and
therapeutic approaches. We recently characterized the canine
HMGA1a and HMGA1b transcripts, deduced their proteins,
evaluated them as targets for therapeutic approaches, and
characterized a basic expression pattern in healthy tissues
(Murua Escobar et al. 2004). Sequence comparison showed
a 100% identity between the human and canine protein
molecules. Although both species showed the identical two
proteins, the number of found cDNA transcripts varies. For
the human HMGA1 seven different cDNA transcripts
(Figure 1: SPV1–SPV7) were described (Johnson et al. 1988)
of which SPV1 and SPV2 are the commonly found variants.
The characterized dog variants showed the same composi-
tion structure as the mentioned human variants SPV1 and
SPV2. Canine counterparts of the human transcript variants
SPV3–SPV7 could not be detected using polymerase chain
reaction (PCR) amplification approaches. Comparison of the
human cDNAs to the known transcripts of other species
shows that the dog is the only species showing similar
transcripts to those commonly found in humans referring to
exon structure and distribution. In detail, human and dog are
the only known species showing the presence of exon one
and two in both HMGA1a or HMGA1b transcripts,
respectively (Figure 1). Both isoforms (HMGA1a and
HMGA1b) were found in mouse (BC013455, NM_016660),
hamster (AF1893762, AF193763), and rat (NM_139327,
AF511040), of which for the last two species the described
transcripts are limited to the protein coding sequences and
the mouse transcripts show either exon one (HMGA1a) or
exon two (HMGA1b) in the respective transcripts (Figure 1).
For the HMGA1 transcripts of horse (CD535395), pig
(AU296646), chicken (AY303673), bovine (CK951567), and
Xenopus (BC084025), either the HMGA1a or the HMGA1b
isoform are currently (2004) present at the NCBI database.
For CDS (coding sequence) and protein identity analysis, we
used the described sequences and deduced, if necessary, the
corresponding parts for analyses. The in silico analyses were
done using Lasergene software programs (DNASTAR,
Madison). The coding sequence identities of the canine
HMGA1 transcripts to the sequences from other species
vary between 72.0% (chicken AY303673) and 95.7% (pig
AU296646, horse CD535395) (Table 1). Identity comparison
of the deduced proteins revealed similarities between 69.7%
(chicken AY303673) and 100.0% (human: P17096, X14957,
horse CD535395) (Table 1). The proteins of all species
showed strong conservation in the functional AT-Hook
DNA binding domains. Common for all species analysed is
that the protein coding sequences are composed of four
exons (Figure 1). The described proteins of the different
species are composed of 107 amino acids and 96 amino
acids, respectively, for HMGA1a and HMGA1b. Also
common for those species where both protein isoforms
were described is that the difference between the splicing
variants is the ‘‘typical’’ 33-bp deletion in the HMGA1b
transcripts resulting in the lack of 11 amino acids.
Previous results describing the comparison of the protein
coding sequences in 12 canine breeds revealed that the
mentioned deletion is also conserved in the analyzed breeds.
SNP screening in these breeds resulted in detection of one-
amino-acid change in a single breed. A Teckel showed
a nucleotide transition from A to G at the first base of codon
64 in its HMGA1b transcript leading to an amino acid
replacement from threonine to alanine (Murua Escobar et al.
2004). As far as we know, no other canine HMGA1
polymorphisms have been described. Summarizing the
HMGA1 transcript and protein comparison data emphasizes
the relevance of the canine species as a model organism for
the research and development of therapeutic approaches for
human disorders.
Due to the mentioned properties of the HMGA1 gene,
its proteins HMGA1a/HMGA1b, and its reported role in
development of cancer, future studies targeting HMGA1
proteins could be of significant value.
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Abstract. Point mutations within ras proto-oncogenes,
particularly within the mutational hot-spot codons 12, 13 and 61,
are frequently detected in human malignancies and in different
types of experimentally-induced tumours in animals. So far little
is known about ras mutations in naturally occurring canine
fibrosarcomas or K-ras mutations in canine melanomas. To
elucidate whether ras mutations exist in these naturally occurring
tumours in dogs, in the present study we screened 13 canine
fibrosarcomas, 2 feline fibrosarcomas and 11 canine melanomas
for point mutations, particularly within the mutational hot-spots,
making this the first study to investigate a large number of canine
fibrosarcomas. None of the samples showed a K- or N-ras hot
spot mutation. Thus, our data strongly suggest that ras mutations
at the hot-spot loci are very rare and do not play a major role in
the pathogenesis of the spontaneously occurring canine tumours
investigated.
Dogs and humans often share the same genetic pathways in
the development of cancer, as has been described in the
literature. Point mutations affecting genes of the ras- family are
assumed to be among the most important alterations in human
tumourigenesis (1). Ras proteins play an important role as
signal transmitters. The binding of growth factors activates the
ras protein and thus initiates cell division. Mutations in ras
genes are assumed to lead to enduring activation of pathways
that stimulate cell growth, which results in uncontrolled cell
division (2). Especially mutations in K-ras have been described
in human pancreatic cancers and tumours of the gastro-
intestinal tract, as well as in tumours of the skin (3-5). K-ras
screening for hot-spot point mutations in dogs has been
described in different types of lung cancer, pancreatic cancer
and breast cancer (6-12), showing that the canine gene is also
affected by the typical ras mutations observed in humans but at
a much lower ratio.
Guerrero et al. (13) were able to induce fibrosarcomas in
nude mice by subcutaneously injecting transfected fibroblasts
with K-ras point mutations affecting codon 12. So far little is
known about ras mutations in canine fibrosarcomas. Just one
report of a ras mutation screening including three canine
fibrosarcoma samples has been described (11). There is also a
lack of studies about K-ras mutations in canine melanomas. In
canine melanomas virtually no hot-spot N-ras mutations were
described with one exception: Mayr et al. (14) found 2 out of
16 melanomas to be affected by mutations in codon 61. 
In the present study, we screened 13 canine fibrosarcomas,
2 feline fibrosarcomas and 11 canine melanomas for point
mutations, particularly within the mutational hot-spot codons
of the K-ras and N-ras genes, to analyze whether these changes
could be detected in these naturally occurring tumours. 
Materials and Methods
The tissues used in this study were provided by the Small Animal
Clinic, School of Veterinary Medicine, Hanover, Germany. Thirteen
canine fibrosarcoma, 2 feline fibrosarcoma and 11 canine melanoma
samples were taken and used for analyses. The breeds represented
were German Shorthaired Pointer, Irish Terrier, Fox Terrier,
Schnauzer, Kuvasz, Berger de Brie, German Shepherd, Standard
Poodle, Irish Red Setter, Rottweiler, Cairn Terrier, Beagle and canine
and feline crossbreed.
The DNA of the twenty-six canine and feline fibrosarcoma and
melanoma samples (10 - 25 mg each) was isolated using QIAamp
DNA Kit (QIAGEN, Hilden, Germany) following the manufacturer’s
tissue protocol. The two feline samples served as internal controls,
since they show specific point mutations compared to dogs (15). The
PCRs for the screening of the hot-spot exons were performed using
the following primer pairs. K-ras: primer pair KEx1up / KEx1lo (5’
cgatataaggcctgctgaaa 3’ / 5’ tgtaggatcatattcatcca 3’) and primer pair
KEx2up / KEx2lo (5’ caggattcctacaggaaaca 3’ / 5’ aacccacctataatggtgaa
3’). N-ras: primer pair NEx1up / NEx1lo (5’ gactgagtacaaactggtgg 3’ /
5’ gggcctcacctctatggtg 3’) and primer pair NEx2up / NEx2lo (5’
tcttaccgaaaacaggtggttatag 3’ / 5’ gtcctcatgtattggtctctcatggcac3’). The
PCR products were directly sequenced in the forward and reverse
direction and additionally cloned in pGEM-T Easy Vector System
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(Promega, Madison, USA) and sequenced once more. The DNA
sequences and the homology alignments were created with various
sequences from the NCBI database (accession numbers CFU62093,
X02751, U62094, S42999, M54968, S64261). In case of single
nucleotide exchanges being present, the procedures were repeated for
verification.
Results
Four of the twenty-six analysed samples showed nucleotide
exchanges in the screened canine exons. None of the exchanges
found affected the ras hot-spot codons 12, 13 and 61. One
fibrosarcoma sample (Berger de Brie) showed three changes
affecting K-ras exon 1 codon 23 (CTA→TTA, no amino acid
exchange), exon 2 codon 53 (TTG→TAG, Leu→stop codon)
and N-ras exon 1 codon 10 (GGA→GAA, Gly→Glu). Two
other fibrosarcomas (Kuvasz and Poodle) each showed one
nucleotide exchange in K-ras exon 2 affecting codon 48
(GGA→GAA, Gly→Glu) and codon 70 (CAG→CTG,
Gln→Leu), respectively. N-ras exon 1 codon 22 (CAG→CTG,
Gln→Leu) was affected in a melanoma sample (crossbreed)
(Table I). The screening of N-ras exon 2 revealed no
nucleotide exchanges among the canine sequences. The
described nucleotide differences between the canine and feline
sequences (15) in N-ras exon 2 and K-ras exon 2 were detected.
Discussion
Our data strongly suggest that K- and N-ras mutations at the
hot-spot loci are very rare and do not play a major role in the
pathogenesis of the spontaneously occurring canine tumours
investigated. These results are in accordance with the  sparse
data available for canine melanomas (twenty-four samples) and
fibrosarcomas (three samples) (11, 14). In both studies a total of
three mutations at the hot-spot codons could be detected.
Compared to the data obtained from different studies in
humans that show up to 30% of lung tumours, 90% of
pancreatic tumours and 50% of tumours of the gastrointestinal
tract to be affected by specific point mutations in the ras gene
hot-spot codons (16, 17), the data seen in dogs apparently
indicate that ras mutations do not play a major role in the
pathogenesis of these spontaneously occurring canine tumours. 
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Table I. Detected gene base substitutions in N-ras exon 1 and K-ras exons
1 and 2.
Gene /Exon SampleCodon Substitution Amino Acid Exchange
K-ras Exon 1 3 23 CTA→TTA No AA exchange (Leu)
K-ras Exon 2 3 53 TTG→TAG Leu→Stop
13 70 CAG→CTG Gln→Leu
14 48 GGA→GAA Gly→Glu
N-ras Exon 1 3 10 GGA→GAA Gly→Glu
24 22 CAG→CTG Gln→Leu
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Introduction: The dog is an emerging model organism for the
investigation of mechanisms involved in human disease,
including cancer. Several parallels in human and canine
tumours have been described, with comparable environmental
living conditions and age of tumour onset in both human and
canine patients as well as similarities in development and his-
tology of tumours in both species.1 NRAS is a member of the ras
proto-oncogene family of proteins that act in growth-related
signal transduction and are frequently involved in the devel-
opment of human tumours, with ras point mutations being one
of the most important alterations in the onset of malignancies.2
Ras genes show high sequence similarity across different
mammalian species such as human, cat, dog, cattle and
rodents, with most nucleotide differences representing syn-
onymous changes not affecting the amino acid sequence.3 In
malignancies, most amino acid exchanges in ras genes are
caused by alterations of the so-called hot spot codons 12, 13,
and 61 in exons 1 and 2, respectively, leading to constitutively
active ras proteins that bring about constant signal transduc-
tion, facilitating uncontrolled cell division. These hot-spot
codons have been described to be affected in other mammalian
species as well. In dogs, NRAS mutations were found in
lymphomas4 and malignant melanomas.5
The canine NRAS gene had not been mapped so far, there-
fore, in this study we localized the chromosomal location of the
canine NRAS gene by fluorescence in situ hybridization (FISH).
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BAC library screening: In order to isolate a FISH probe, the
DogBAC canine BAC library6 (http://www.dogmap.ch/) was
polymerase chain reaction (PCR)-screened. Primers were
designed using canine mRNA sequence GenBank accession no.
U62093 (primer UP: GACTGAGTACAAACTGGTGG and primer
LO: GGGCCTCACCTCTATGGTG). The PCR conditions were
established on canine blood genomic DNA, the corresponding
PCR product cloned and verified by sequencing. The positive
BAC clone (DogBAC library ID S050P24H09) was verified by
PCR and sequencing.
Gene mapping: For mapping the chromosomal location of the
canine NRAS gene, metaphase preparations and FISH were
performed as described previously.7 Ten well spread metaphases
exhibited a signal on CFA 17 on both chromatids of both
chromosomes (Fig. 1), following the nomenclature of the canine
karyotype as established by Reimann et al.8
Comments: NRAS mutations in humans have been found in
30% of liver tumours, 40% of myelodysplastic syndrome, 30%
of acute myelogenous leukaemia, 13% of brain tumours and in
53% of follicular and 60% of undifferentiated papillary thyroid
tumours.9 In dogs, depending on tumour type, comparable
occurrences exist in malignant melanomas,5 while fibrosarco-
mas showed no amino acid alteration of the NRAS protein
(H. Murua Escobar, K. Gu¨nther, A. Richter, J. T. Soller,
S. Winkler, I. Nolte & J. Bullerdiek 2004, personal communi-
cation). Overall, data available on involvement of ras proto-
oncogenes in tumours of dogs are still insufficient. Knowledge
of the cytogenetic properties of NRAS will further the under-
standing of this important gene. The mapping results obtained
in this study are in accordance with the known homology be-
tween canine chromosome 17 and the centromer-proximal
regions 11.1–13.3 of the p-arm of human chromosome 1.10
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Figure 1 Metaphase spread after fluorescence
in situ hybridization showing signals on both
chromosomes 17 (right) and the same meta-
phase after GTG-banding (left).
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Introduction: Dogs and human beings often share the same
genetic pathways in development of cancer. Point mutations
affecting genes of the ras family are assumed to be among the
most important alterations in human tumourigenesis.1 Ras
proteins play an important role as signal transmitters. The
binding of growth factors activate the ras protein and thus
initiates cell division. Mutations in ras genes are assumed to
remove the time limit of the cell stimulating signals which
results in uncontrolled cell division.2 Mutations in KRAS2 have
been described in human pancreatic cancers and tumours of
the gastrointestinal tract as well as in tumours of the skin.3–5
Hot spot point mutations in KRAS2 described in different types
of human lung tumours and breast cancers are also present in
the corresponding canine gene.6 For further characterization of
the gene, we have mapped the canine KRAS2 gene.
BAC clone and probe: A KRAS2 DNA probe was generated
by polymerase chain reaction (PCR) spanning part of
the exon 2 (primer up: 5¢-caggattcctacaggaaaca-3¢/lo:
5¢-aacccacctataatggtgaa-3¢ based on NCBI sequence M54968)
using genomic canine DNA. The resulting amplicon was
cloned and sequenced for verification. These PCR conditions
were also used to screen a canine BAC library7 (URL: http://
www.dogmap.ch). To rule out false-positive BAC screening
results, a PCR using the initial primer pair was performed,
and the resulting amplicon cloned and sequenced for verifi-
cation. BAC S069P22D02 was positive for KRAS2 and was
used for fluorescence in situ hybridization (FISH) analysis.
FISH: Metaphase preparations and FISH were performed as
described previously.8 Ten well spread metaphases were
examined and all showed a signal on both chromatids of
chromosome 22s (CFA 22) (Fig. 1).
Comments: Different investigations show that 30% of human
lung tumours, 90% of human pancreatic tumours and 50%
of tumours of the gastrointestinal tract depend on specific
point mutations in genes of the ras gene family.9–11
Molecular investigations of the ras family are rare in dogs,
but existing publications point to the fact that there are the
same point mutations affecting hotspot codons 12, 13 and
61, as they are in human malignancies.6 Up to 24% of cases
investigated in dogs showed point mutations in those codons.
The canine chromosome to which KRAS2 was mapped has
been involved in a centric fusion of CFA 8/22.12 According
to Yang et al.13 the canine chromosome 22 shares homol-
ogy with HSA13, whereas the human KRAS2 gene is located
on HSA12. In our FISH studies, there were no metaphase
signals on the corresponding canine chromosomes, 29
and 10.
Acknowledgements: We thank Norbert Drieschner for his helpful
advice in FISH techniques.
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Figure 1 Metaphase spread after fluorescence in situ hybridization with signals on both chromosomes 22 (right) and the same metaphase after GTG
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Abstract
Due to the emerging advantages of numerous canine diseases as a genetic model for their human orthologs, the dog could join the mouse
as the species of choice to unravel genetic mechanisms, e.g. of cancer predisposition, development and progression. However, precondition
for such studies is the characterisation of the corresponding canine genes.
Human and murine HMGA1 non-histone proteins participate in a wide variety of cellular processes including regulation of inducible gene
transcription, integration of retroviruses into chromosomes, and the induction of neoplastic transformation and promotion of metastatic
progression of cancer cells.
Chromosomal aberrations affecting the human HMGA1 gene at 6p21 were described in several tumours like pulmonary chondroid
hamartomas, uterine leiomyomas, follicular thyroid adenomas and others. Over-expression of the proteins of HMGA1 is characteristic for
various malignant tumours suggesting a relation between high titer of the protein and the neoplastic phenotype.
In this study, we characterised the molecular structure of the canine HMGA1 cDNA, its splice variants and predicted proteins HMGA1a
and HMGA1b. Furthermore, we compared the coding sequence(s) (CDS) of both splice variants for 12 different breeds, screened them for
single nucleotide polymorphisms (SNPs) and characterised a basic expression pattern.
D 2004 Elsevier B.V. All rights reserved.
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1. Introduction
As witnessed by a number of recent articles (Kuska,
1996; Kingman, 2000; Ostrander et al., 2000; Vail and
MacEwen, 2000), a growing number of scientists predict
that human genetics will focus on the dog in this century
(Kuska, 1996). Due to the emerging advantages of numer-
ous canine diseases as a genetic model for their human
counterparts, the dog could join the mouse as the species of
choice to unravel genetic mechanisms, e.g. of cancer pre-
disposition, development and progression.
The proteins of the human HMGA1 gene HMGA1a and
HMGA1b are associated with various human diseases
including cancer. Due to the similarities of various human
and canine cancer entities, the characterisation of the canine
HMGA1 gene could open new fields for experimental and
therapeutic approaches.
Four human members of the HMGA protein family
are presently known: the HMGA1a, HMGA1b, HMGA1c
and HMGA2 proteins, which can modify chromatin
structure by bending DNA, thus influencing the tran-
scription of a number of target genes. The human
HMGA1 gene on 6p21 encodes the well characterised
0378-1119/$ - see front matter D 2004 Elsevier B.V. All rights reserved.
doi:10.1016/j.gene.2004.01.009
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HMGA1a and HMGA1b proteins (formerly known as
HMGI and HMGY) derived by alternative splicing and
the barely characterised HMGA1c variant, while the
HMGA2 protein is encoded by a separate gene on
chromosome 12 (12q14–15) (for review, Reeves and
Beckerbauer, 2001).
Expression of HMGA1 is detectable only at very low
levels or is even absent in adult tissues, whereas it is
abundantly expressed in embryonic cells (Chiappetta et
al., 1996). In humans, 6p21 is often affected by aberra-
tions leading to an up-regulation of HMGA1 in benign
mesenchymal tumours, e.g. lipomas, uterine leiomyomas,
pulmonary chondroid hamartomas and endometrial polyps
(Williams et al., 1997; Kazmierczak et al., 1998; Tallini
et al., 2000). Transcriptional activation due to a chromo-
somal alteration of HMGA1 is probably an early and
often even primary event of cancer development. In
contrast, HMGA1 expression in malignant epithelial
tumours seems to be a rather late event associated with
an aggressive behaviour of the tumours. Thus, an over-
expression of HMGA1 was reported for a number of
malignancies including thyroid, prostatic, pancreatic, cer-
vical and colorectal cancer (Tamimi et al., 1993; Chiap-
petta et al., 1995, 1998; Fedele et al., 1996; Bandiera et
al., 1998; Abe et al., 1999, 2000). The correlation
between HMGA expression and tumour aggressiveness
in these malignancies has led to the conclusion that
HMGA expression may present a powerful prognostic
molecular marker. The causal role of HMGA1 expression
in the progression of carcinomas has been elucidated by a
set of in vitro experiments involving HMGA1 sense and
antisense transfection assays (Reeves et al., 2001). An
experimental approach aimed at the down-regulation of
HMGA protein in tumours has been presented by Scala et
al. (2000) who were able to show that an HMGA1
antisense strategy using an adenoviral vector treatment
of tumours induced in athymic mice caused a drastic
reduction in tumour size.
Recently, the canine HMGA1 gene has been mapped to
CFA 23. This cytogenetic assignment indicates that the
canine HMGA1 gene does not map to a hotspot of
chromosomal breakpoints seen in canine tumours (Becker
et al., 2003). However, despite the emerging role of
HMGA1 gene expression in malignancies, the molecular
characterisation of the canine HMGA1 gene had not been
carried out before. The characterisation of the molecular
structure could permit new therapeutic approaches using
the dog as model organism.
In this study, we characterised the molecular structure
of the canine HMGA1 gene on cDNA level, its splice
variants and proteins HMGA1a and HMGA1b, and a basic
expression pattern. Furthermore, for 12 different canine
breeds the coding sequence(s) (CDS) of both splice var-
iants were characterised and screened for SNPs to find out
if changes at protein level exist between the different
breeds.
2. Materials and methods
2.1. Tissues
The tissues used in this study were provided by the Small
Animal Clinic, Veterinary School, Hanover, Germany. The
breeds represented were Alsatian, Bull Terrier, Collie,
Dachshund, Doberman Pinscher, German Shorthaired Point-
er, Golden Retriever, Jack Russell Terrier, Kangal, Munster-
land, West Highland Terrier and Yorkshire Terrier. From
each breed up to three samples of testis tissue were taken
and used for analyses.
2.2. cDNA characterisation
Total RNA was isolated from 150 mg canine testis tissue
using TRIZOL LS (Invitrogen, Karlsruhe, Germany) fol-
lowing the manufacturer’s protocol. To avoid genomic
DNA contamination a DNase digest of each sample was
performed using DNA-free (Ambion, Huntingdon, Cam-
bridgeshire, UK). cDNA was synthesised using 3V-RACE
adaptor primer AP2 (AAGGATCCGTCGACATC(17)T), 5
Ag total RNA and M-MLV (Invitrogen) reverse transcrip-
tase according to the manufacturer’s instructions. The
polymerase chain reactions (PCRs) for the molecular clon-
ing of the cDNA were done using the primer pairs Ex1up
and Ex8lo (5V GCTCTTTTTAAGCTCCCCTGA 3V/5V
CTGTCCAGTCCCAGAAGGAA 3V) and primer pair
Ex8up and 3VUTRlo (5V AGGGCATCTCGCAGGAGTC
3V/5V ATTCAAGTAACTGCAAATAGGA 3V) which were
derived from human cDNA sequences (accession no.
X14957). The PCR products were separated on a 1.5%
agarose gel, recovered with QIAEX II (QIAGEN, Hilden,
Germany), cloned in pGEM-T Easy vector system (Prom-
ega, Madison, USA) and sequenced. The cDNA contig and
the homology alignments were created with Lasergene
software (DNAStar, Madison, USA) and various sequences
from the NCBI database (GenBank accession nos. X14957,
X14958, NM_002131, NM_145899, NM_145900,
NM_145901, NM_145902, NM_145903, NM_145904,
NM_145905).
2.3. Characterisation of splice variants
The splice variants HMGA1a and HMGA1b were
detected by amplifying a fragment spanning the CDS with
primer pair Up (5VCATCCCAGCCATCACTC 3V) and Lo
(5V GCGGCTGGTGTGCTGTGTAGTGTG 3V) using the
canine testis cDNA samples as template. The primer pair
was designed using the cDNA cloned as described in
Section 2.2. The obtained PCR products were separated
on a 4.0% agarose gel, recovered with QIAEX II (QIA-
GEN), cloned in pGEM-T Easy vector system (Promega)
and sequenced. The contigs and the homology alignments
were created with two sequences from the NCBI database
(GenBank accession nos. X14957, X14958).
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2.4. CDS comparison between breeds
The CDS of both splice variants were characterised for
all breeds as described previously in Section 2.3. The
contigs and the homology alignments were created using
two sequences from the NCBI database (GenBank accession
nos. X14957, X14958). In case of single nucleotide
exchanges, the samples were sequenced again in both
forward and reverse direction. Exchanges causing no amino
acid (aa) substitution were not taken into account for further
analyses. For all samples with aa substitutions the initial
PCR was repeated and the exchange verified by sequencing
the product in both forward and reverse direction. If
possible, a restriction enzyme digestion was performed
additionally.
2.5. Protein sequences
The canine HMGA1a and HMGA1b protein sequences
were derived from the open reading frames (ORFs) of the
characterised cDNA sequences described previously in
Section 2.2. The protein homology alignments were created
with two sequences from the NCBI database (GenBank
accession nos. X14957, X14958).
2.6. Northern blot
Total RNAs were isolated from canine heart, lung,
muscle, kidney and spleen tissue using RNeasy system
(QIAGEN). An additional sample of total RNAwas isolated
from canine heart tissue by TRIZOL LS acid guanidine
isothiocyanate–chloroform method (Invitrogen) in order to
figure out whether this isolation method would lead to any
difference in hybridisation. Further on poly A RNA was
purified from canine spleen total RNA with OLIGOTEX
(QIAGEN) and total RNA was prepared from human
cultured fibroblasts by RNeasy system (QIAGEN). Spleen
poly A RNA was placed on the blot in case that HMGA1
was not detectable in the total RNA samples.
For Northern Blot hybridisation, 20 Ag of total RNA
from each sample with the exception of 10 Ag of muscle and
3.6 Ag of spleen poly A RNA were separated on a 1.2%
denaturing agarose gel containing 0.65% formaldehyde.
RNAs were transferred onto Hybond-N+ positive nylon
membrane (Amersham Pharmacia Biotech, Freiburg, Ger-
many) by capillary blot.
A 489-bp cDNA fragment derived from the canine
HMGA1a sequence (exon 5/exon 8) served as a molecular
probe for hybridisation. The probe was generated by PCR
with the primer set Up and Lo (5V CATCCCAGCCAT-
CACTC 3V/5V GCGGCTGGTGTGCTGTGTAGTGTG 3V)
using the cloned cDNA described in Section 2.2. Probe
labelling was performed by random primed labelling (Amer-
sham Pharmacia Biotech) as described in the manufacturer’s
protocol with 50 ACi(a32P)dCTP (Amersham Pharmacia
Biotech). Purification of the labelled probe was performed
using Sephadex G-50 Nick Columns (Amersham Pharmacia
Biotech) and the probe was stored at 20 jC before use.
Using the PERFECTHYB PLUS hybridisation solution
(Sigma-Aldrich, Saint Louis, MO, USA) prehybridisation
was carried out for 30 min and hybridisation for 2.5 h at 68
jC. The membrane was washed for 5 min at room temper-
ature in 2SSC/0.1% SDS, and twice for 20 min at 68 jC in
0.5SSC/0.1% SDS. Signals were visualised using a
STORM phosphorimager (Molecular Dynamics, Sunnyvale,
USA).
3. Results and discussion
3.1. The canine HMGA1 cDNA transcripts
For the human HMGA1 gene various transcripts were
described for both splicing variants (HMGA1a and
HMGA1b) that differ in their 5V-UTR. The characterisation
of the canine HMGA1 cDNAs revealed that the complete
canine HMGA1 cDNA spans six exons and codes for two
splicing variants HMGA1a with 1836 bp and HMGA1b with
1803 bp which are similar to the human transcripts
(HMGA1a GenBank accession no. AY366390 and
HMGA1b GenBank accession no. AY366392). The exon
structure, the UTRs and the ORFs of both splice variants
were defined and their homologies to their human counter-
parts analysed (Fig. 1, Table 1). The splicing variants
showed the ‘‘typical’’ 33 bp gap which is conserved across
various species such as human, mouse, hamster and rat
(GenBank accession nos. BC013455, NM_016660,
A7193763, NM_139327, A7511040). The homology of
the canine cDNAs to their human counterparts is 80.6%
for both splice variants. The 5V-UTR, CDS and the 3V-UTR
showed homologies of 95.6%, 95.1% and 74,7%, respec-
tively (Table 1). Homologies of the canine CDS with the
CDS from mouse, hamster and rat on nucleotide level vary
from 90.4% to 93.1%. The cDNA sequences were submitted
to the NCBI database: HMGA1a, GenBank accession no.
AY366390 and HMGA1b, GenBank accession no.
AY366392.
3.2. The canine HMGA1a and HMGA1b proteins
The canine HMGA1a and HMGA1b protein sequences
were deduced from the respective cDNA sequences. The
canine HMGA1a protein is a 107-amino acid molecule with
a calculated weight of 11,674.97 D and HMGA1b a 96-
amino acid molecule with a calculated weight of 10,677.85
D (Fig. 2). Homology comparison to the human counter-
parts (GenBank accession nos. P17096, X14957) showed
100% homology of the molecules including the three ‘‘AT-
hooks’’ and the acidic carboxy-terminal domain.
Comparison of the canine and human HMGA1a and
HMGA1b proteins with the described mouse, rat and
hamster molecules showed aa changes in positions 5, 34,
H. Murua Escobar et al. / Gene 330 (2004) 93–99 95
????????
???????????????????????????????????????????????????????????????????????????????????
????????????????????????????????????????????????????????????????????????????????????
??????
69, 75 and 78 of HMGA1a and positions 5, 34, 58, 64 and
67 of HMGA1b, respectively (Fig. 2) (Johnson et al., 1988,
1989; Friedmann et al., 1993; Aldrich et al., 1999; Sgarra et
al., 2000; Strausberg et al., 2002; Sgarra et al., 2003).
According to the definition of the AT-hooks (HMGA1a: I
aa 21–31, II aa 53–63, III aa 78–89; HMGA1b: I aa 21–
31, II aa 42–52, III aa 67–78) by Reeves and Nissen (1990)
and Reeves (2000), none but the aa exchange at position 78
(HMGA1a) or 67 (HMGA1b), respectively, do affect the
AT-hooks in either species. The exchange at position 78
leads to a difference in the third AT-hook of mouse and
hamster when compared to the other species. According to
the definition of the AT-hooks (HMGA1a: I aa 23–31, II aa
55–70, III aa 81–89; HMGA1b: I aa 23–31, II aa 44–59,
III aa 70–78) by Huth et al. (1997), this aa exchange does
not affect the third AT-hook. Following this definition, the
second AT-hook is affected by the aa exchange at position
69 (HMGA1a) or 58 (HMGA1b), respectively.
The canine protein sequences were submitted to the
NCBI database with GenBank accession nos. HMGA1a
AY366390 and HMGA1b AY366392.
Due to the identical structure of the canine HMGA
proteins to the respective human molecule, therapeutic
approaches applied in dogs could be more suitable in terms
of transferability for the development of human therapies
than to approaches tested in other organisms.
3.3. HMGA1a and HMGA1b CDS comparison between
canine breeds
For twelve different canine breeds the splicing variants
HMGA1a and HMGA1b were detected by amplification of a
fragment spanning the CDS using the canine testis cDNA
samples as template. The comparison of the characterised
protein coding sequences for these twelve canine breeds
Fig. 1. Structure of the canine HMGA1a and HMGA1b transcripts and partial genomic structure.
Table 1
Detailed analysis of the canine HMGA1a and HMGA1b cDNA
Element of canine
HMGA1 cDNAs
Size in bp Homology to human
counterpart in %
Total cDNA HMGA1a 1836 80.6
Total cDNA HMGA1b 1803 80.6
5V-UTR 231 95.6
CDS HMGA1a 324 95.1
CDS HMGA1b 291 95.1
3V-UTR 1332 74.7
Exon 1 94 97.8
Exon 2 114 96.5
Exon 5 HMGA1a 179 93.9
Exon 5 HMGA1b 146 93.9
Exon 6 84 96.4
Exon 7 51 94.1
Exon 8 1386 75.4
Homology comparison of the cDNA elements of the canine HMGA1 to its
human counterpart (characterisation of the UTRs, the ORF and the exon
sizes).
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revealed one amino acid change in a single breed. Nucle-
otide exchanges causing no amino acid substitution were not
taken into account in further analyses. Sample 2 (Teckel)
showed in its HMGA1b transcript a nucleotide transition
from A to G at the first base of codon 64 leading to an aa
replacement from threonine to alanine and a new restriction
recognition site for AluI causing four (58, 100, 158 and 176
bp) instead of three fragments (58, 100 and 334 bp) to
appear in an AluI digest. (data not shown). The substitution
was missing in the corresponding HMGA1a transcript of the
dog suggesting a heterozygous genotype. A possible PCR
artifact seems rather unlikely since the nucleotide transition
was verified as described in Section 2.4. The CDS cDNA
sequences of the twelve breeds were submitted to the NCBI
database with GenBank accession nos. AY363606,
AY363605, AY363607, AY363604, AY363608,
AY363610, AY363609, AY363600, AY363603,
AY363599, AY363601, AY363602, AY363994,
AY363995, AY363611, AY363999, AY364000,
AY364002, AY364001, AY363998, AY363996,
AY363997, AY364003.
3.4. Canine HMGA1 expression analysis
Expression of human HMGA1 is detectable at very low
levels or is even absent in adult tissues whereas it is
abundantly expressed in embryonic cells (Chiappetta et
al., 1996). To elucidate a basic HMGA1 gene expression
pattern in dogs, a canine Northern blot was generated
containing total RNA from canine spleen, heart, lung,
muscle and kidney tissue samples. In order to detect a
possible low level expression of HMGA1 as reported in
adult human tissues, a poly A RNA sample from canine
spleen was additionally added to the blot. Hybridisation was
performed with a a32P-labelled canine HMGA1a cDNA
probe. Except for the kidney total RNA and one of two
heart samples (Trizol method) all total RNA samples
showed a weak signal of approximately 1.8 kb (Fig. 3,
Trizol sample not shown), while the poly A RNA spleen
sample revealed a distinct signal. After stripping, rehybrid-
isation with a canine GAPDH probe showed signals
corresponding to approximately 1.3 kb in all but the Trizol
method (data not shown) samples, indicating a degradation
of the Trizol-prepared RNA.
In humans, HMGA1 expression in malignant epithelial
tumours seems to be associated with an aggressive behav-
iour of the tumours. Over-expression of HMGA1 was
reported for a number of malignancies including thyroid,
prostatic, pancreatic, uterus cervical and colorectal cancer
(Tamimi et al., 1993; Chiappetta et al., 1995, 1998; Fedele
et al., 1996; Bandiera et al., 1998; Abe et al., 1999, 2000).
The correlation between HMGA expression and tumour
Fig. 2. Comparison of the canine, human, mouse, rat and hamster HMGA1a and HMGA1b proteins.
Fig. 3. Northern blot showing 1.8-kb HMGA1 and 1.3-kb GAPDH
transcripts. Lanes: (1) canine kidney total RNA, (2) canine spleen total
RNA, (3) canine spleen poly A RNA, (4) canine heart total RNA, (5) canine
lung total RNA, (6) canine muscle total RNA and (7) human fibroblasts
total RNA.
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aggressiveness in some of these malignancies has led to the
conclusion that HMGA expression may present a powerful
prognostic molecular marker.
So far no studies analysing the HMGA1 expression
pattern in canine tumours have been carried out. Since these
tumours occur spontaneously in dogs as well as in humans a
canine in vivo analysing system could have significant value
for research and drug development.
The causal role of HMGA1 expression in the progression
of carcinomas has been elucidated by a set of in vitro
experiments involving HMGA1 sense and antisense trans-
fection assays (Wood et al., 2000a,b; Reeves et al., 2001). A
proof of concept for a therapy aimed at the down-regulation
of HMGA protein in tumours has been presented by Scala et
al. (2000) who were able to show that an HMGA1 antisense
strategy using an adenoviral vector treatment of tumours
induced in athymic mice caused a drastic reduction in
tumour size.
Due to the similarities of human and canine tumours, the
transfer of such experimental approaches could benefit
cancer research in either species.
The comprehension of the canine HMGA1 gene and its
gene products could be the precondition for future new
experimental approaches and for evaluating the canine gene
product as potential target for therapeutic strategies using
the dog as model system.
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Abstract. Background: The human high mobility group protein
B1 (HMGB1) has attracted considerable interest among
oncologists because it sensitises cancer cells to the anticancer
drug cisplatin by shielding cisplatin-DNA adducts from
nucleotide excision repair. Materials and Methods: Since
cisplatin is the cornerstone of adjuvant systemic therapy for
osteosarcomas, in both humans and dogs, the expression pattern
of the HMGB1 gene in seven canine sarcomas was investigated
by Northern blot analysis and semi-quantitative RT-PCR.
Results: A strong intertumoural variation of HMGB1 expression
was detected by Northern blot analysis and confirmed by the
semi-quantitative RT-PCR established herein. Conclusion: The
observed variations of HMGB1 expression in canine sarcomas
emphasises the role of HMGB1 as a potential marker of clinical
interest as its expression level may predict the clinical outcome of
therapies based on cisplatin. The semi-quantitative RT-PCR
established allows a quick and convenient determination of the
HMGB1 expression level as necessary for clinical applications.
The related platinum compounds cisplatin and carboplatin
are widely used antitumour drugs for the treatment of a
number of malignancies. The main cytotoxic effect of
cisplatin/carboplatin is the formation of cisplatin/carboplatin-
DNA adducts characterised by intrastrand cross-links and
significantly bended and distorted DNA.
Gel mobility shift assays revealed a selective affinity of
high mobility group (HMG) proteins for cisplatin-DNA
adducts (1). The recognition of cisplatin damage by HMG
is assumed to mediate cisplatin cytotoxicity. HMG proteins
are chromatin-associated non-histone proteins characterised
by low molecular weight, acid-solubility and a high content
of charged amino acids. According to their molecular size,
sequence and DNA binding capacity, three families have
been distinguished: HMGB (formerly HMG1/2), HMGN
(formerly HMG14/17) and HMGA (formerly HMGI(Y))
(2,3). The HMGB family, comprising HMGB1, HMGB2
and HMGB3, is characterised by its two DNA-binding
domains called the "HMG-Box" (4,5).
One of the best analysed members of the group of HMG-
Box proteins is HMGB1 (synonymously known as HMG1 or
amphoterin). Both DNA-binding domains selectively bind
with a very high affinity to major cisplatin-DNA adducts (6-
8) and interaction between HMGB1 and cisplatin-damaged
DNA contributes to its biological activity, as it sensitises
cancer cells to cisplatin by shielding its major DNA adducts
from nucleotide excision repair (9,10).
Interestingly, HMGB1 gene expression can be induced by
oestrogens in breast cancer cells probably due to an up-
regulation of the gene, so that HMGB1 itself can be
considered an oestrogen-responsive gene (11). Recently, we
were able to explain this observation by the identification of
two oestrogen responsive elements within the first intron of
HMGB1 (12). He et al. (10) have shown that, in oestrogen
receptor-positive human breast cancer cells, oestrogen can
significantly increase the effect of cisplatin by causing an
overexpression of HMGB1. This finding has led to the
conclusion that oestrogen treatment prior to cisplatin
therapy may sensitise the cancer cells against that drug.
Accordingly, a clinical trial for the treatment of
gynaecological tumours with cisplatin has already been
approved by the Food and Drug Administration (FDA)
(10). On the other hand, the former experiment clearly
shows that the quantitation of the intratumoural HMGB1
expression level may be of high impact for a
cisplatin/carboplatin therapy for two reasons. Firstly, it may
predict the clinical outcome of the therapy; secondly, it may
influence the therapy protocol as, for example, tumours
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showing a high HMGB1 expression level may be treated
with a lower amount of this antitumour drug.
Due to the close similarities of numerous canine diseases
to their human counterparts, the role of the dog as a model
organism for therapeutic approaches is justified.
Furthermore, genes and proteins known to be of high
diagnostic and therapeutic impact in man can also be
considered to play an important role in the dog.
Osteosarcomas and several types of carcinomas belong to
the group of canine malignancies often treated with cisplatin
or carboplatin. So far no data are available analysing the
expression pattern of the HMGB1 gene in canine sarcomas.
Thus, in this study we analysed the HMGB1 expression level
in five canine osteosarcomas, one fibrosarcoma and one
leiomyosarcoma by Northern blot experiments. Based on
the observed strong intertumoural variation of HMGB1
expression, we further established a quick RT-PCR-based
diagnostic system for future studies.
Materials and Methods 
Tissue samples. All canine tumour samples used in this study (Table
I) were provided by the Clinic for Small Animals, Hanover,
Germany. Samples were taken during surgery, immediately frozen
in liquid nitrogen and stored at -80ÆC.
RNA isolation. Total RNA extraction of the canine sarcoma samples
was performed according to the RNeasy midi protocol for isolation
of total RNA from heart, muscle and skin tissue (Qiagen, Hilden,
Germany) including a Proteinase K digest. Enrichment of poly A+
mRNA was carried out using the Oligotex mRNA kit (Qiagen). 
Northern blot hybridisation. For Northern blot analysis, 5 Ìg of
mRNA from each sample were separated on a 1.2% denaturing
agarose gel containing 0.65% formaldehyde. RNAs were
transferred onto a Hybond-XL charged nylon membrane
(Amersham Biosciences, Buckinghamshire, England) by capillary
blot overnight. As a probe for hybridisation, a 603 bp cDNA
fragment derived from the ORF (exon 2-5) of the canine HMGB1
gene was generated by PCR using the primer pair ToastUP (5’
GGGCAAAGGAGATCCTAAGAAG 3’) (13) and Ex5lo (5’
TCTTCCTCCTCCTCCTCATCC 3’). A 445 bp cDNA probe
detecting the 1.3 kb transcript of the canine GAPDH gene was
amplified by PCR with the primer set GAPDH2up (5’
GTGAAGGTCGGAGTCAAC 3’) and GAPDHdog5do (5’
AGGAGGCATTGCTGACAAT 3’). Probes were labelled with 50
ÌCi(·-32P)dCTP (Amersham Biosciences) using the Megaprime
Labelling Kit (Amersham Biosciences) for random-primed
labelling (14). Hybridisation was performed for 3 h at 68ÆC in 10
ml of PerfectHyb Plus Hybridisation Buffer (Sigma-Aldrich, Saint
Louis, USA). The membranes were washed for 5 min with low
stringency at RT in 2x SSC, 0.1% SDS and twice for 20 min with
high stringency at 68ÆC in 0.5x SSC, 0.1% SDS. Signals were
visualised using a Storm PhosphorImager (Molecular Dynamics,
Sunnyvale, USA). Quantitation of the transcripts of HMGB1 and
GAPDH was performed using the software program ImageQuant
(Molecular Dynamics).
Semi-quantitative RT-PCR. cDNA synthesis was performed using
primer AP2 (5’ AAGGATCCGTCGACATCT(17) 3’) with 500 ng of
mRNA with SuperScript Reverse Transcriptase (Invitrogen,
Karlsruhe, Germany) according to the manufacturer’s instructions. In
order to determine the expression of HMGB1 in relation to that of
the housekeeping gene GAPDH, a duplex PCR was established using
the primer sets ToastUP/Ex5lo and GAPDH2up/GAPDHdog5do
(see above). PCR reactions were set up according to the "basic PCR
protocol" of Taq DNA Polymerase (Invitrogen) using the following
PCR program: initial denaturation for 5 min at 94ÆC, 28 cycles of
denaturation for 30 sec at 94ÆC, primer annealing for 30 sec at 55ÆC
and extension for 45 sec at 72ÆC, followed by a final extension for 10
min at 72ÆC. The appropriate number of cycles was previously
determined so that for both PCR-products amplification was in the
exponential range (data not shown). PCR-products were separated
on a 1.2% agarose gel stained with VistraGreen (Amersham) and
visualised using a Storm PhosphorImager (Molecular Dynamics).
Quantitation of the PCR-fragments of HMGB1 and GAPDH was
performed using the software program ImageQuant (Molecular
Dynamics) measuring pixel intensities.
Results
Northern blot hybridisation on a series of 5 osteosarcomas,
one fibrosarcoma and one leiomyosarcoma sample of the
dog (Table I), using a cDNA probe derived from the ORF
(Exon 2-5) of the canine HMGB1 gene, resulted in the
detection of two HMGB1 mRNA transcripts of
approximately 1.4 and 2.4 kb (Figure 1), which are similar
to that observed in human tissues (15-17) and various
canine tissues (18). In order to quantify the expression of
HMGB1, the blot was rehybridised with a canine GAPDH-
specific cDNA probe (Figure 1). Summing up the intensities
of the 1.4 and 2.4 kb HMGB1 signals, the HMGB1-RNA /
GAPDH-RNA ratios were calculated. As shown in Figure 1,
the analysed canine sarcoma samples revealed a strong
intertumoural variation in the relative expression of
HMGB1. Values obtained by Northern blot analysis for the
osteosarcoma samples varied between 0.52 and 1.31, while
the fibrosarcoma and the leiomyosarcoma showed ratios of
0.73 and 0.24, respectively (Table II).
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Table I. Sarcoma samples analysed in this study.
Sarcoma Tumour Breed Sex Age
sample
OS1 Osteosarcoma Rottweiler f 1 yr
OS2 Osteosarcoma Crossbreed f 4 yrs
OS3 Osteosarcoma German Shepherd m 6 yrs
OS4 Osteosarcoma Crossbreed m 9 yrs
OS5 Osteosarcoma German Shepherd m n.r.1
FS Fibrosarcoma Bobtail m 5 yrs
LMS Leiomyosarcoma Crossbreed f 10 yrs
1n.r. = not reported
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In order to confirm the results and to develop a less time-
and material-consuming technique, we established a semi-
quantitative duplex RT-PCR suitable for detecting
intertumoural variation of HMGB1 expression in relation to
expression of the house-keeping gene GAPDH (Figure 2).
After quantitation of the signals obtained by RT-PCR, the
HMGB1-RNA / GAPDH-RNA ratios were calculated. The
values for the osteosarcoma samples varied between 0.72
and 1.28, while the ratios for the fibrosarcoma and the
leiomyosarcoma were 0.73 and 0.42, respectively (Table II).
In order to determine the comparability of the results
obtained by the Northern blot hybridisation and RT-PCR
analyses, mean values for each test series were calculated,
set to one, and relative expression levels were determined
(Table II, Figure 3). Statistical analysis using the Pearson’s
Correlation Test revealed a significant correlation between
the relative HMGB1 expression level obtained by Northern
blot hybridisation and the level obtained by the established
RT-PCR (r=0.8919, p=0.0071).
Discussion
Cisplatin and carboplatin are widely used anticancer drugs,
manifesting their cytotoxicity to tumour cells by damaging
DNA, generating a distorted DNA duplex. HMGB1 proteins
selectively bind with high affinity to cisplatin or carboplatin-
DNA adducts and several investigations revealed that this
interaction contributes to tumour death by blocking excision
repair of the major cisplatin-DNA adducts (9,10).
No features have been identified yet allowing clinicians to
predict the response to cisplatin or carboplatin therapies in
dogs with osteosarcomas at the time of diagnosis or during
treatment (19). Hence, it was the aim of this study to analyse
the expression level of HMGB1 in canine sarcomas.
Based on Northern blot and RT-PCR analyses, we were
able to show an intertumoural variation of HMGB1
expression levels among canine sarcomas. Very recently,
comparable results were obtained for human breast cancer
samples (17,20) and a clinical trial designed to increase
HMGB1 expression by oestrogen treatment has been
approved by the FDA (10). The observed intertumoural
variances of HMGB1 expression in seven sarcomas analysed
in this study may be of importance for therapeutic
approaches based on cisplatin/carboplatin treatment as, for
example, tumours showing a high HMGB1 expression level
may be treated with a lower amount of this antitumour
drug. However, future clinical studies including a greater
number of tumours have to be performed to correlate the
Meyer et al: HMGB1 and Canine Sarcomas
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Table II. Absolute and relative HMGB1-mRNA / GAPDH-mRNA ratios.
Sarcoma Absolute HMGB1 / Relative HMGB1 /
sample GAPDH-RNA ratios GAPDH-RNA ratios1
RT-PCR Northern blot RT-PCR Northern blot
OS1 0.95 0.52 1.09 0.7
OS2 0.99 0.79 1.13 1.06
OS3 1.02 1.05 1.17 1.41
OS4 1.28 1.31 1.47 1.75
OS5 0.72 0.60 0.83 0.79
FS 0.73 0.73 0.84 0.97
LMS 0.42 0.24 0.48 0.32
Mean value 0.87 0.75 1.0 1.0
1 Calculated with the mean values of the absolute HMGB1 / GAPDH-
RNA ratios set to one.
Figure 1. Northern blot analysis of five osteosarcomas (OS1-5), one
fibrosarcoma (FS) and one leiomyosarcoma (LMS) of the dog hybridised
with a HMGB1-specific cDNA probe detecting the two canine HMGB1
transcripts of approximately 1.4 and 2.4 kb (upper part). Co-hybridisation
of the same membrane with a GAPDH-specific cDNA probe detecting a
1.3 kb transcript (lower part).
Figure 2. Semi-quantitative duplex RT-PCR products of HMGB1 (603
bp) and GAPDH (445 bp) using canine cDNAs of five osteosarcomas,
one fibrosarcoma and one leiomyosarcoma after electrophoresis and
VistraGreen staining (Amersham Biosciences). Lane 1: DNA molecular
weight standard 1 Kb Plus DNA Ladder (Invitrogen). Lanes 2-6:
osteosarcoma samples 1-5 (OS1-5). Lane 7: fibrosarcoma sample (FS).
Lane 8: leiomyosarcoma sample (LMS). Lane 9: H2O, negative control.
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HMGB1 expression level with clinical outcome of
cisplatin/carboplatin chemotherapy. The statistically
significant correlation of the relative HMGB1 expression
levels obtained by Northern blot analyses as well as duplex
RT-PCR makes the established PCR approach a quick and
convenient method to determine the intratumoural HMGB1
expression.
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Figure 3. Variation of relative HMGB1 expression in five osteosarcomas
(OS1-5), one fibrosarcoma (FS) and one leiomyosarcoma (LMS) of the
dog as revealed by Northern blot analysis (dark grey bars) and semi-
quantitative RT-PCR (light grey bars). In order to compare the results
obtained by the two methods, mean values for each test series were
calculated, set to one and relative expression levels were determined.
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Introduction: Parallels between human and canine tumours
have often been described. Human chromosomal rearrange-
ments on 6p21 involving the HMGA1 gene have been described
in various benign mesenchymal tumours like pulmonary
chondroid hamartomas, uterine leiomyomas, endometrial pol-
yps and lipomas1,2. So far, it is not clear if comparable trans-
locations occur in the corresponding canine tumour as well. To
further elucidate that question, we have mapped the canine
HMGA1 gene.
BAC clone and probe: A HMGA1 DNA probe was generated by
PCR spanning part of the exon 6, the complete intron 6 and
part of exon 7 (primer up: AGC GAA GTG CCA ACA CCT AAG
AGA/Lo: CCT TGG TTT CCT TCC TGG AGT TG) on DNA derived
from the canine cell line MTH52 (Center for Human Genetics,
Bremen, Germany), cloned, sequenced and used for screening
of a canine BAC library. Filters were obtained from the BAC-
PAC RESOURCES/Childrens Hospital, Oakland, CA, USA
(http://www.chori.org/bacpac). BAC-screening was performed
following manufacturers’ instructions. To rule out false-positive
results, a PCR using the initial primer pair used for the
screening probe was preformed, cloned and sequenced.
Fluorescence in situ hybridization: Metaphase preparations and
fluorescence in situ hybridization (FISH) were performed as
described previously3. Ten well-spread metaphases were
examined all showing a signal on CFA 23 on both chromatids
of both chromosomes CFA 23 (Fig. 1).
Comments: Chromosomal rearrangements of HSA 6p21 invol-
ving HMGA1 represent the second most frequent specific
translocations in human tumours. The assignment of the
canine HMGA1 gene to CFA 23 clearly shows that the chro-
mosomal region to which the canine HMGA1 gene has been
Figure 1 An example of a metaphase spread after fluorescence in situ hybridization with signals on both chromosomes 23 (right) and the same
metaphase after GTG-banding (left).
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mapped, is not a hotspot of chromosomal breakpoints seen in
canine tumours. The hotspots that have been found in the dog
genome so far, include chromosomes 1, 19 and 25 which are
preferentially involved in chromosomal fusions4. The X-chro-
mosome of the dog, in contrast, is frequently affected by
structural aberrations. Therefore, in contrast to humans, the
activation of HMGA1 as a result of chromosomal translocations
does not seem to play a considerable role in canine tumours.
This may be due to the fact that the corresponding changes are
not able to induce benign tumours in the dog or to stimulate
their growth. Alternatively, there may be factors favouring the
occurrence of the structural changes in humans which are
lacking in dogs.
No homology has been found between human chromo-
some 6, to which the HMGA1 is mapped, and canine chro-
mosome 23, rather human chromosome 6 shares homology
with canine chromosome 22 and 85. In our FISH studies no
metaphase shows signals on these dog chromosomes.
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Abstract. Due to the close similarities of numerous canine
diseases to their human counterparts, the dog could join the
mouse as the species of choice to unravel the genetic back-
ground of complex diseases as e.g. cancer and metabolic dis-
eases. Accordingly, the role of the dog as a model for therapeut-
ic approaches is strongly increasing. However, prerequisite for
such studies is the characterization of the corresponding canine
genes. Recently, the human high mobility group protein B1
(HMGB1) has attracted considerable interest of oncologists
because of what is called its “double life”. Besides its function
as an architectural transcription factor HMGB1 can also be
secreted by certain cells and then acts as a ligand for the recep-
tor for advanced glycation end products (RAGE). The binding
of HMGB1 to RAGE can activate key cell signaling pathways,
such as p38MAPK, JNK, and p42/p44MAPK emphasizing the
important role of HMGB1 in inflammation and tumor metas-
tasis. These results make HMGB1 a very interesting target for
therapeutic studies done in model organisms like the dog. In
this study we characterized the molecular structure of the
canine HMGB1 gene on genomic and cDNA levels, its pre-
dicted protein, the gene locus and a basic expression pattern.
Copyright © 2003 S. Karger AG, Basel
As witnessed by a number of recent articles (Kuska, 1999;
Kingman, 2000; Ostrander et al., 2000; Vail and MacEwen,
2000) a growing number of scientists predict that human genet-
ics will be “going to the dogs” in this century (Kuska, 1999).
Due to the emerging advantages of numerous canine diseases as
a genetic model for human orthologs, the dog could join the
mouse as the species of choice to unravel genetic mechanisms
e.g. of cancer predisposition, development, and progression.
A very interesting group of genes in terms of oncology are
the high mobility group (HMG) protein genes. High mobility
group proteins named according to their electrophoretic mobil-
ity in the electric field are small chromatin-associated nonhis-
tone proteins which can be subdivided into three families
because of their functional sequence motifs: the HMGA,
HMGB, and HMGN protein families. Three human members
of the HMGB protein family are presently known: the
HMGB1, HMGB2, and HMGB3 proteins. The best analyzed
member of this group, HMGB1 (synonymously known as
HMG1 or amphoterin), can modify chromatin structure by
bending DNA thus influencing the transcription of a number of
target genes (for review see Muller et al., 2001). Recently,
HMGB1 has attracted additional interest of oncologists be-
cause of what was called its “double life”. Besides its function
as an architectural transcription factor, HMGB1 can also be
secreted by certain cells, e.g. macrophages (Wang et al., 1999).
As an extracellular protein HMGB1 is a ligand for the receptor
for advanced glycation end products (RAGE) (Parkkinen and
Rauvala 1991; Parkkinen et al., 1993; Hori et al., 1995) thus
activating key cell signaling pathways, such as p38MAPK, JNK,
and p42/p44MAPK and playing an important role in inflamma-
tion and tumor metastasis (Liotta and Clair, 2000; Taguchi et
al., 2000).
The high mobility group protein HMGB1 has a number of
features particularly related to the development and progres-
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sion of gynaecological cancers. As an example HMGB1 has
been shown to interact with and modify the binding affinity of
several transcription factors, e.g. TATA-binding protein (TBP),
Hox D9 protein, and steroid hormone receptors (Ge and Roe-
der, 1994; Zappavigna et al., 1996; Verrier et al., 1997; Boonya-
ratanakornkit et al., 1998; Romine et al., 1998; Das and Scov-
ell, 2001). Interestingly, HMGB1 gene expression can be in-
duced by estrogens in breast cancer MCF-7 cells probably due
to an upregulation of the gene so that HMGB1 itself can be
considered an estrogen-responsive gene (Chau et al., 1998).
Additionally, it has been shown that HMGB1 is able to bind to
cisplatin-DNA adducts (Pil and Lippard, 1992) and sensitizes
cancer cells to cisplatin by shielding its major DNA adducts
from nucleotide excision repair (He et al., 2000). He et al.
(2000) have shown that in estrogen receptor-positive human
breast cancer cells estrogen can significantly increase the effect
of cisplatin by causing an overexpression of HMGB1. This
finding has led to the conclusion that estrogen treatment prior
to cisplatin therapy may sensitize the cancer cells against that
drug. Accordingly, a clinical trial for the treatment of gynaeco-
logical tumors with cisplatin has already been approved by the
Food and Drug Administration (He et al., 2000).
However, the canine HMGB1 gene had not yet been charac-
terized molecularly. The enlightenment of the molecular struc-
ture could permit new therapeutic approaches using the dog as
model organism.
Materials and methods
cDNA characterization
Total RNA was isolated from 50 mg canine testis tissue using TRIZOL
LS (Invitrogen) following the manufacturer’s protocol. cDNA synthesis was
performed using AP2 primer (AAGGATCCGTCGACATC(17)T), 5 Ìg total
RNA and M-MLV (Invitrogen) reverse transcriptase according to the manu-
facturer’s instructions. The PCRs for the molecular cloning of the cDNA
were done using the following primer pairs: 5)-AGCTCCATAGAGACAG-
CACC-3)/5)-TCTTCCTCCTCCTCCTCATCC-3) and primer pair 5)-AGG-
CCTCTTGGGTGCATT-3)/5)-AGTATCATCCAGGACTCAGAT-3). 
PCR products were separated on a 1.5% agarose gel, recovered with
QIAEX II (QIAGEN), cloned in pGEM T-easy vector system (Promega)
and sequenced. The cDNA contig and the homology alignments were created
with two sequences from the NCBI database (acc. nos. AF281043,
U51677).
Protein sequence
The canine HMGB1 protein sequence was derived from the ORF of the
characterized cDNA sequence described previously. The protein homology
alignments were created with sequences from the NCBI database (acc. nos.
AF281043, U51677).
Northern blot
Total RNAs were isolated from canine heart, lung, muscle, kidney, and
spleen tissue using RNeasy system (QIAGEN). An additional sample of total
RNA was isolated from canine heart tissue by TRIZOL LS acid guanidine
isothiocyanate-chloroform method (Invitrogen) in order to figure out wheth-
er this isolation method leads to any difference in hybridization. Further-
more, mRNA was purified from canine spleen total RNA with OLIGOTEX
(QIAGEN) and total RNA was prepared from human cultured fibroblasts by
RNeasy system (QIAGEN). Spleen mRNA was placed on the blot in case
that HMGB1 was not detectable in the total RNA samples.
For Northern blot hybridization 20 Ìg of total RNA of each sample (ex-
cept muscle 10 Ìg and spleen mRNA 3.6 Ìg) were separated on a 1.2% dena-
turing agarose gel containing 0.65% formaldehyde. RNAs were transferred
onto Hybond-N+ positive nylon membrane (Amersham Pharmacia Biotech)
by capillary blot.
A 292-bp cDNA fragment derived from the coding sequence (exon 2/
exon 3) of the canine HMGB1 served as a molecular probe for hybridization.
The probe was generated by PCR with the primer set 5)-AGGCCTCTTGG-
GTGCATT-3)/5)-GGGCAAAGGAGATCCTAAGAAG-3) (Jiang et al.,
1998) on the cloned cDNA described previously. Labeling was performed by
random primed labeling (Roche Diagnostics) as described in the manufactur-
er’s protocol with 50 ÌCi [·32P]dCTP (Amersham Pharmacia Biotech). Puri-
fication of the labeled probe was done using Sephadex G-50 Nick Columns
(Amersham Pharmacia Biotech) and the probe was stored at –20 °C before
use.
Using the PERFECTHYB PLUS hybridization solution (Sigma-Aldrich)
prehybridization was carried out for 30 min and hybridization for 2.5 h at
68 °C. The membrane was washed for 5 min at room temperature in 2× SSC,
0.1% SDS, and twice for 20 min at 68 °C in 0.5× SSC, 0.1 % SDS. Signals
were visualized by using a STORM imager (Molecular Dynamics, Sunny-
vale, USA).
BAC screening and FISH
An HMGB1 canine genomic DNA probe was used for hybridization of
canine RPCI 81 BAC/PAC filter (BACPAC RESOURCES, Children’s Hos-
pital Oakland Research Institute, Oakland, USA). The 531-bp probe was
generated by PCR (Primer 5)-AGGCCTCTTGGGTGCATT-3)/5)-AGAG-
GCCTCCGTGAGTATCTTG-3)) on genomic DNA of the canine pleomor-
phic adenoma cell line ZMTH3 (Center for Human Genetics, Bremen, Ger-
many). The obtained PCR product was separated on a 1.5 % agarose gel,
recovered with QIAEX II (QIAGEN), cloned in pGEM T-easy vector system
(Promega) and sequenced for verification. The probe labeling was performed
by random primed labeling (Roche Diagnostics) as described in the manufac-
turer’s protocol with 50 ÌCi [·32P]dCTP (Amersham Pharmacia Biotech).
Purification of the labeled probe was done using Sephadex G-50 Nick Col-
umns (Amersham Pharmacia Biotech) and the probe was stored at –20 °C
before use.
The filters were placed in a minimum volume of Church Buffer
(0.15 mM BSA, 1 mM EDTA, 0.5 M NaHPO4, 7% SDS) and transferred into
hybridization bottles. The filters were prehybridized at 65 °C for 1 h in 25 ml
Church Buffer. Hybridization was performed at 65 °C overnight (16–18 h) in
the same solution. All further steps were performed according to manufactur-
er’s protocol. Signals were visualized using a STORM imager (Molecular
Dynamics, Sunnyvale, USA).
Metaphase preparations were obtained from blood samples of two differ-
ent dogs. The samples were stimulated with PHA and cultured for 96 h at
37 °C. After 1.5 h colcemide (0.1 Ìg/ml) incubation, the lymphocytes were
harvested according to routine procedures. Prior to FISH, chromosomes
were stained using the GTG-banding method. After taking photographs of
the metaphases, the slides were destained in 70% ethanol for 15 min and air
dried.
FISH was performed using the protocol of Reimann et al. (1996) with
some modifications. BAC DNA was digoxigenin labeled (Dig-Nick-Transla-
tion-Kit, Roche Diagnostics). The hybridization mixture contained 125–
175 ng probe, 43.2 Ìg salmon sperm DNA, 1,000–1,200 ng sonicated dog
DNA, 2× SSC, 2× SSPE, 50 % formamide and 10 % dextran sulfate. The
chromosomes were stained with propidium iodide and G-bands were identi-
fied according to Reimann et al. (1996).
Genomic characterization
For genomic characterization of the canine HMGB1 gene the introns
were amplified by PCR on the screened BAC 24-A16 (BACPAC RE-
SOURCES, Children’s Hospital Oakland Research Institute, Oakland, USA)
and on genomic DNA of the canine pleomorphic adenoma cell line ZMTH3
(Center for Human Genetics, Bremen, Germany). For intron 2 a 517-bp frag-
ment was generated with primer pair 5)-AGGCCTCTTGGGTGCATT-3)/
5)-GGGCAAAGGAGATCCTAAGAAG-3), a 579-bp intron 3 fragment was
generated by the primer pair 5)-GATCCCAATGCACCCAAGAG-3)/5)-
GGGGATACTCAGAACAAAACA-3) and the fourth exon 1,224-bp frag-
ment was generated with pair 5)-GAAGGCTGCTAAGCTGAAGGA-3)/5)-
TCTTCCTCCTCCTCCTCATCC-3). The obtained PCR products were sep-
arated on a 1.5 % agarose gel, recovered with QIAEX II (QIAGEN), cloned in
pGEM T-Easy vector system (Promega) and sequenced for verification. The
final genomic canine HMGB1 contig and the homology alignments were
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Fig. 1. Structure of the genomic elements and
the cDNA of the canine HMGB1.
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created with Lasergene software (DNAStar, Madison, USA) with the gener-
ated sequences from the cloned cDNA described previously and various
sequences from the NCBI database (acc. nos. AF 281043, U 51677,
NM_002128).
Results
Herein, we describe the genomic and the cDNA structure,
the predicted protein sequence, a basic expression pattern, and
the chromosomal locus of the canine HMGB1 gene.
cDNA sequence
The canine cDNA sequence consists of 2,236 bp spanning
five exons. The exon structure, the UTRs, and the ORF were
defined and their homologies to their human counterpart ana-
lyzed (Fig. 1, Table 1). The cDNA sequence was submitted to
the NCBI database acc. no. AY135519.
Protein sequence
The canine HMGB1 protein sequence was deduced from
the composite cDNA sequence. The protein is a 215-amino-
acid (AA) molecule with a calculated weight of 24,892.67 Dal-
tons (Fig. 3, Table 2). The sequence was submitted to the NCBI
database acc. no. AY135519. Homology comparison to the
human counterpart showed 100% homology of the molecules
including the two “HMG boxes” and the acidic carboxy-termi-
nal domain, while mouse and bovine molecules showed differ-
ences in the acidic tail.
Genomic structure
The genomic structure of the canine HMGB1 gene consists
of the previously described five exons and four introns. Due to
the fact that intron 1 could not be cloned a contig spanning
exon 2 to exon 5 consisting of 3,959 bp was created. The exon/
intron structure, size and the homologies to their human coun-
terparts were analyzed and defined (Fig. 1, Table 1). The ge-
nomic sequences were submitted to the NCBI database (acc.
nos. AY135520, AY135521).
Northern blot
To elucidate a basic expression pattern, a canine Northern
blot was performed using RNA and mRNA from canine spleen,
Fig. 2. Northern blot showing 1.4-kb and 2.4-kb HMGB1 transcripts.
Lanes: canine: (1) kidney, (2, 3) spleen, (4, 5) heart, (6) lung, (7) muscle;
human: (8) fibroblasts.
Table 1. Detailed analysis of the canine HMGB1 cDNA and genomic
elements: Homology comparison of the genomic and cDNA elements of the
canine HMGB1 to its human counterpart (Characterisation of the UTRs, the
ORF and the exon/intron sizes)
Element of canine HMGB1 Size in bp Homology to human 
counterpart in % 
cDNA elements   
 Total cDNA 2236 90.8 
 5’ UTR 89 95.6 
 cds 648 95.4 
 3’ UTR 1499 88.6 
Genomic elements 
  
 Total Exon 2–5 3959 73.3 
 Exon 1 76 98.7 
 Intron 1 - - 
 Exon 2 163 95.2 
 Intron 2 225 20.3 
 Exon 3 146 95.2 
 Intron 3 518 59.0 
 Exon 4 175 93.7 
 Intron 4 1056 61.8 
 Exon 5 1676 89.4 
heart, lung, muscle, and kidney tissue samples and hybridized
with a 32P-labeled canine HMGB1 cDNA probe. Except for the
kidney tissue that showed no detectable signal, all samples
revealed two transcripts similar to the signals obtained in
human fibroblasts (Fig. 2) of about 1.4 and 2.4 kb. One of two
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Fig. 3. Comparison of canine, human, mouse, and bovine HMGB1 proteins.
Table 2. Detailed in silico analysis of the ca-
nine HMGB1 protein Amino Acids (AA) Molecular Weight in Da Isoelectric Point Charge at pH 7.0 
215 24892.67 5.591 -4.629 
Strongly Basic (+) AA Strongly Acidic (-) AA Hydrophobic AA Polar AA 
51 56 43 32 
canine heart samples showed weak signals probably due to the
Trizol sample quantification difficulties. Human HMGB1
transcripts of this size had been detected in multiple normal
tissues and several breast cancer samples.
BAC screening and FISH
A canine HMGB1 genomic DNA probe was generated and
used for screening a canine BAC for localization of the canine
HMGB1 gene locus by FISH.
The screened BAC 24-A16 was first verified according to
the manufacturer’s protocol which requires two hybridization
signals to appear in a specific orientation on the filter spotting
panel. Second verification was done by PCR using primer pair
UP: 5)-GAAGGCTGCTAAGCTGAAGGA-3)/LO: 5)-TCT-
TCCTCCTCCTCCTCATCC-3) spanning intron 4. For final
verification the obtained PCR product was separated on aga-
rose gel, recovered, cloned and sequenced as described pre-
viously.
????????
???????????????????????????????????????????????????????????????????????????????????
????????????????????????????????????????????????????????????????????????????????????
???????
Cytogenet Genome Res 101:33–38 (2003) 37
Fig. 4. An example of a metaphase spread
after FISH with signals on both chromosomes 25
(a) and the same metaphase after GTG-banding
(b).
The verified BAC was used for FISH experiments. Sixteen
well spread metaphases were examined for analysis. Signals
were detected on both chromatides of both chromosomes. The
obtained signals mapped the canine gene to CFA25 (Fig. 4).
Discussion
The human HMGB1 is considered to have a “double life”
with impact on several diseases including tumorigenesis (Tagu-
chi et al., 2000; Flohr et al., 2001). First, by acting as an archi-
tectural transcription factor, HMGB1 influences the formation
of transcription factor complexes of several target genes. Sec-
ond, HMGB1 can be released from some cells allowing its bind-
ing to the cell surface receptor RAGE. Blockade of RAGE-
HMGB1 interaction in rat C6 glioma cells significantly inhibits
their growth, motility, and local invasion as well as metastasis
(Liotta and Clair, 2000; Taguchi et al., 2000).
The aim of the present study was to characterize the cDNA,
protein, genomic structure, gene locus, and a basic expression
pattern of the canine HMGB1 gene. Knowledge of its structure
would be the precondition to evaluate the canine gene product
as a potential target for therapeutic approaches using the dog as
model system.
The complete canine HMGB1 cDNA consists of 2,236 bp
encoded by five exons similar to the human transcript (acc. no.
AY135519). The homology of the complete molecule to its
human counterpart is 90.8% whereas the ORF is 95.4%. The
derived canine protein consists of 215 AA with a molecular
weight of 24,892.67 Da. Comparison to the human protein
showed 100% homology of the canine counterpart. Differences
between human HMGB1 and the mouse protein were described
as two or three AA changes in the acidic carboxy-terminal
domain (Paonessa et al., 1987; Ferrari et al., 1994). The bovine
molecule (acc. no. P10103) shows one AA change compared to
its human and canine counterpart. Due to the previously
described properties of the canine HMGB1 and the identical
structure to the human molecule, therapeutic approaches in dogs
likely can be performed with identical compounds.
Northern blot analysis was performed to define a basic
expression pattern in canine heart, lung, muscle, kidney, and
spleen tissue. Except for the kidney tissue that showed no
detectable signal, all samples revealed two transcripts similar to
the signals obtained in human fibroblasts of about 1.4 and
2.4 kb. One of two canine heart samples showed weak signals
probably due to the Trizol sample quantification difficulties.
Human HMGB1 transcripts of this size had been detected in
multiple normal tissues (Rogalla et al., 1998) and several breast
cancer samples (Flohr et al., 2001).
At the genomic level the canine HMGB1 gene exon/intron
structure is similar to the human ortholog consisting of five
exons and four introns. While the homologies of the exons,
ranging between 89.4 and 98.7%, are extremely high, the
homologies of the amplified introns 2–4 vary between 20.3 and
59.0%. Approaches to amplify the canine intron 1 resulted in
unspecific PCR products which were probably due to the puta-
tive existence of various CpG islands found in human intron 1
(Borrmann et al., 2001).
Mapping of the canine HMGB1 gene resulted in assignment
to CFA25. The G-bands were identified according to Reimann
et al. (1996).
Yang et al. (1999) found no conservation of synteny be-
tween the human chromosome 13 where the human HMGB1 is
located and the canine chromosome 25 where we mapped
canine HMGB1.
Nevertheless the molecular characterization of the canine
HMGB1 gene and protein showed clearly that man and dog
share an identical HMGB1 protein. Considering the similari-
ties of genesis and development of diseases in both species
molecular targeting of HMGB1 in dogs can be of significant
importance for therapeutic approaches in humans as well.
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Discussion 
4. Discussion 
High-mobility-group AT-hook (HMGA) proteins are non-histone components of 
chromatin that function as architectural transcription factors, influencing the activation 
and transcription of genes in the developing embryo. Initially a target of tumour 
biology, as re-expressed HMGA proteins are involved in a large number of benign 
and malignant tumours, recent research led to knowledge on HMGA2 in chromatin 
structure and pluripotency of stem cells (Pfannkuche et al. 2009). Thus, as HMGA 
proteins are involved in processes including embryonic cell growth and maintenance 
of cell stemness (Li et al. 2007), their growth-inducing properties are thought to have 
the potential of being utilised in applications where enhanced cell growth is an issue, 
including tissue engineering of cartilage. The connection between HMGA2 and 
cartilage had been proven before, as the complete HMGA2 and the HMGA2/LPP 
(LIM domain containing preferred translocation partner in lipoma) fusion protein were 
demonstrated to positively influence expression of the chondrogenous COL11A2 
gene (Kubo et al. 2006). In addition, Hmga1 (+/-) and (-/-) murine knock-out 
embryonic stem cells showed decreased expression of the COL1A2 (Collagen, type 
I, alpha 2) mRNA coding for the collagen alpha-2(I) chain (Martinez Hoyos et al. 
2004), indicating function of HMGA1a and HMGA1b proteins in chondrogenesis. 
Even earlier, HMGA proteins were shown to be involved in the focal differentiation of 
areas of articular cartilage in benign tumours of the lung (Kazmierczak et al. 1995; 
Kazmierczak et al. 1996; Kazmierczak et al. 1996; Wanschura et al. 1996; 
Kazmierczak et al. 1999; Rogalla et al. 2000; Tallini et al. 2000; Lemke et al. 2002). 
The connection between HMGA presence and chondrocyte growth was thus the 
main aspect of the work conducted during this thesis. 
Cartilage damage is a common disease present at almost all ages and not limited to 
humans, as it is also diagnosed in pet as well as production animals. Tissue 
engineering of cartilage e.g. in the form of autologous chondrocyte transplantation 
has been the focus of treating cartilage damages in recent years. It is based on 
amplifying chondrocytes taken from a small biopsy sample and reimplanting the 
multiplied cells into the defect, either with or without the aid of scaffolds that may be 
based on biomaterials such as chitosan or synthetic materials as for example 
polylactic acid. One crucial aspect is thus the growth rate of the explanted 
chondrocytes, aiming at keeping the time span between explantation and 
reimplantation as short as possible. While this might be achieved using cartilage-
specific growth factors as well as specific growth media, the work conducted in this 
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thesis was aimed at the investigation of the potential growth inducing effects of the 
HMGA proteins on chondrocytes. Improved cell growth due to application of HMGA 
proteins to chondrocytes grown in vitro for autologous chondrocyte transplantation, or 
a combination of HMGA supplemented chondrocytes and scaffolds could thus be a 
possible enhancement for tissue engineering. For assessing the growth inducing 
potential of HMGA protein on chondrocytes, it was chosen to supply the cells with 
recombinantly produced HMGA proteins, as their dosage can be adjusted and 
proteins will be degraded over time being thus completely removed from the cell, if 
not re-applied. This is in opposition to gene therapeutic methods by either viral or 
non-viral gene delivery with limited influence on gene and thus protein dosage and 
even unwanted side effects such as constitutive transgene expression as well as 
transactivation of host genes. Thus with viruses, depending on the type chosen, 
genotoxic effects due to integration into the host genome leading to possible 
interference with host genes as well as enhancer and promoter sequences have to 
be taken into consideration. For example, in a patient who underwent gene therapy 
of human ?-thalassaemia, amongst others, the ?-globin vector incidentally integrated 
into the third intron of HMGA2 introducing a cryptic splice site that resulted in 
constitutive expression of a truncated HMGA2 variant insensitive to degradation by 
let-7 miRNAs due to missing miRNA binding sites (Cavazzana-Calvo et al. 2010). 
Integration of viruses into regulative or promoter elements of murine retrovirus-
induced interleukin-3 dependent myeloid leukaemia cells caused the activation of 
Mecom (MDS1 and EVI1 complex locus; synonymous with Evi-1) due to either the 
insertion of viral promoter sequences into the 5’ non-coding region of the Mecom 
gene (Morishita et al. 1988), or into the genetically linked Cb-1/fim-3 locus that is 
located 90 kb 5’ of Mecom, activating the normal promoter (Bartholomew et al. 1991). 
Finally, in gene-therapy of human X-linked severe combined immunodeficiency (X-
SCID), initially normal high-affinity interleukin-2 receptor expression and function 
could be achieved (Hacein-Bey-Abina et al. 2002) in a total of 9 from 10 patients 
treated. However, in two of these patients, uncontrolled exponential clonal mature 
T-cell proliferation occurred due to retrovirus vector integration in proximity to the 
LMO2 (LIM domain only 2 (rhombotin-like 1)) proto-oncogene promoter, leading to 
aberrant transcription and expression of LMO2 probably due to retrovirus enhancer 
activity (Hacein-Bey-Abina et al. 2003). 
As undamaged human hyaline cartilage is difficult to obtain, porcine cartilage was 
chosen as a model for the experiments conducted. The growth inducing properties of 
HMGA proteins were examined in an in vitro system utilising isolated porcine 
chondrocytes grown in monolayer cell culture that were removed from cartilage of the 
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elbow joint of a pig for slaughter. Sequence similarity allowed the use of human 
HMGA proteins on porcine cells, and recombinantly produced human HMGA1a, 
HMGA1b, and HMGA2 proteins were chosen as potential growth inducing agents. 
While the actual protocol for recombinant HMGA expression and purification was 
described in a previous publication (Schwanbeck 2000), it needed some adaptation 
to provide for efficient production of higher amounts of protein, as the protein yield 
and purity was not sufficient. Background expression of the HMGA transgenes during 
expression culture preparation proved to be inhibitory to bacterial growth, probably 
due to abundant HMGA binding to the bacterial DNA disturbing vital processes within 
the cells. Furthermore, codon usage of the HMGA proteins proved to be 
unfavourable in the initially described bacterial host, so that an overall adaptation to a 
more suitable expression system was necessary. Therefore, a more robust and 
efficient bacterial strain was chosen that allowed for more stringent background 
expression control and expressed additional rare transfer ribonucleic acids (tRNAs) 
not present in the previously used strain. Protein purification also needed some 
adaptation, as the method had to be adjusted to the HPLC equipment present at that 
time. In the end, a highly pure fraction of recombinant HMGA1a, HMGA1b, and 
HMGA2 could be produced for the experiments whose results were published in the 
Tissue Engineering A journal (Richter et al. 2009). 
Administration of HMGA1a and HMGA1b as well as HMGA2 showed a highly 
significant effect on cell proliferation at levels of 10?g/ml or 100?g/ml protein, 
respectively, compared to the non-HMGA treated control group, nearly doubling the 
proliferation rate in case of 100?g/ml HMGA2. HMGA1b was the only variant causing 
a significant impact on proliferation already at the lower concentration of 1?g/ml 
protein, but no difference to HMGA1a or HMGA2 could be observed at the higher 
amounts of protein. Concerning dosage, a statistically significant difference was 
deduced between 1?g/ml and 100?g/ml for both HMGA1a and HMGA2, but not 
HMGA1b. 
The stimulation of chondrocyte proliferation induced by HMGA proteins is probably 
related to their proper function in the developing embryo, albeit with different starting 
conditions in cells derived from fully differentiated adult tissue. HMGA2 was shown to 
have direct influence on chromatin state in human embryonic stem cell lines (Li et al. 
2006), regulating key developmental genes and thus having influence on stemness 
and proliferation (Li et al. 2007). HMGA1 function in stem cells has been studied to a 
lesser degree than HMGA2, but, amongst others, involvement in embryonic stem cell 
lympho-haematopoietic differentiation (Battista et al. 2003) and adipocyte 
differentiation (Esposito et al. 2009) was demonstrated. Application of HMGA to 
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chondrocytes derived from adult tissue might thus influence the cells in these 
regards. Uptake of extracellular HMGA resulting in higher intracellular concentration 
and subsequent nuclear transport might shift the cells’ chromatin into a more 
embryonic, de-differentiated or stem cell like state, facilitating cell growth usually not 
found in differentiated cells. A similar mechanism was observed in tumours with re-
expression of HMGA2 and further oncofoetal genes, leading to de-differentiation and 
cell growth in a process subsequently termed reverse embryogenesis (Johnson et al. 
2005; Park et al. 2007; Peter 2009). On this account, the tumourigenic potential of 
HMGA proteins has to be taken into account in a putative therapeutic use. In stem 
cells, HMGA2 presence has been associated with stemness, i.e. growth- and 
differentiation potential, which is precondition for volitional steering of cell growth and 
regeneration of tissues. In tumours however, reversed HMGA2 expression has been 
associated with genomic instability and unwanted tumour growth. One factor 
accounting for the tumourigenic potential of HMGA2 is the suppression of non-
homologous end joining repair (NHEJ) of DNA double strand breaks (DSBs). HMGA2 
overexpression led to accumulation of DNA damage and dysregulation of NHEJ by 
stimulating phosphorylation of the catalytic subunit of DNA-PKc (DNA-dependent 
protein kinase) and reducing end binding of the DNA targeting Ku80 subunit, leading 
to delayed release of DNA-PKcs at DSB sites which is associated with impaired 
repair (Li et al. 2009). Double strand breaks may result from exogenous sources 
such as ionising radiation or endogenously generated reactive oxygen species and 
mechanical stress on the chromosomes, as well as lesions that are encountered by 
DNA replication forks (Khanna et al. 2001). Furthermore, intended DSBs occur in 
recombination of homologous chromosomes during meiosis and further cellular 
processes (Khanna et al. 2001). Increased HMGA2 presence in cells undergoing 
these processes may thus lead to hampered DNA repair resulting in chromosomal 
damage that may result in further degradation of cellular integrity. This is proven by 
results from Li et al. (2009), where ectopic expression of HMGA2 in normal human 
lung fibroblast WI-38 cells led to spontaneous chromosome aberrations including 
tetraploidy, nonclonal chromosome breaks and gaps and a translocation. Similar to 
HMGA2, genome instability has also been associated with ectopic presence of 
HMGA1 proteins. In human prostate cancer cell lines, induced overexpression of full-
length HMGA1a led to enhanced presence and heterogeneity of unbalanced 
chromosomal rearrangements, which are common in solid human tumours (Takaha 
et al. 2002). In human transfected MCF-7 (Michigan Cancer Foundation - 7) cells 
overexpressing HMGA1a, presence of the protein led to increased UV sensitivity by 
inhibiting global genomic nucleotide excision repair of UV-induced cyclobutane 
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pyrimidine dimer (CPD) lesions (Adair et al. 2005). This was later attributed to 
negative regulation of XPA (Xeroderma pigmentosum complementation group A) 
through HMGA1 interacting with the XPA promoter (Adair et al. 2007). Further 
involvement of HMGA proteins in cellular repair processes was shown in the 
interaction of HMGA1 and ATM (Ataxia-telangiectasia mutated) kinase. In cellular 
response to DNA damage such as DSBs, ATM induces cell cycle arrest and DNA 
repair by phosphorylating several substrates intended to reduce chromosomal 
breakage and enhancing cell survival, including HMGA1b (Pentimalli et al. 2008). 
Later it was reported that HMGA2 as well interacts with and gets phosphorylated by 
ATM in irradiated HEK (human embryonic kidney) 293 cells. Both HMGA1 and 
HMGA2 proteins were demonstrated to positively regulate ATM expression by 
binding to the ATM promoter (Palmieri et al. 2011). 
However, in treating cells with HMGA proteins to induce cell growth, as opposed to 
tumours with constant HMGA presence e.g. due to loss of let-7 regulation, the 
application of recombinant HMGA for growth enhancement of normal cells is a 
temporary process exposing the cells to HMGA only for a short period of time. This 
might just provide an initial growth enhancing “start signal” bringing forward 
enhanced cell growth without the unwanted consequences of constitutive HMGA 
expression. 
Additionally, as opposed to facilitated growth of differentiated cells, the observed cell 
proliferation might also be caused by stem or progenitor cells present in adult hyaline 
cartilage. While hyaline cartilage was initially thought to be a post-mitotic tissue 
without considerable cellular turn-over (Hulth et al. 1972; Aigner et al. 2001), it was 
later shown that it contains mesenchymal progenitor cells (MPCs) (Alsalameh et al. 
2004) that are differentially distributed across the superficial, middle, and deep zones 
of articular cartilage (Dowthwaite et al. 2004; Grogan et al. 2009), with the highest 
number present in the superficial zone. Exclusive to the superficial zone are side 
population cells (SPCs) (Goodell et al. 1996) exhibiting stem cell properties (Hattori 
et al. 2007). The distribution of both MPCs and SPCs is thus consistent with the 
postulated appositional mechanism of cartilage growth subsequent to the formation 
of the secondary centre of ossification (Archer et al. 1994; Hayes et al. 2001). HMGA 
presence might thus enhance proliferation of these cells leading to increased 
chondrocyte growth through their influence on stemness of stem or progenitor cells 
as was proposed above for differentiated chondrocytes, involving processes that are 
related to stem cell aging or rather stem cell self renewal and subsequent 
chondrocyte formation. While younger stem cells are generally able to self-renew, 
stem cells are susceptible to aging as was shown in murine haematopoietic stem 
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cells (Morrison et al. 1996). In murine neural stem cells, this process could be linked 
to regulation of p16Ink4a and p19Arf by Hmga2 (Nishino et al. 2008). Hmga2 promoted 
neural stem cell self renewal by reducing p16Ink4a and p19Arf expression in young 
mice. Decreased Hmga2 levels in old mice, i.e. due to increase of let-7 miRNAs, thus 
led to an increase of p16Ink4a and p19Arf, which in turn inhibited self-renewing cell 
divisions (Nishino et al. 2008). However, recent research conducted on uterine 
fibroids overexpressing HMGA2 (Markowski et al. 2010) as well as on human and 
canine adipose tissue derived stem cells (ADSCs) expressing HMGA2 via induction 
with FGF1 (fibroblast growth factor 1 (acidic)) (Markowski et al. 2011) revealed 
opposite results showing increased expression of p14Arf, the human orthologue of 
murine p19Arf, in the presence of HMGA2. Upregulation of p14Arf was postulated an 
endogenous protection mechanism in activated stem cells linking self-renewal with 
protection of their genome (Markowski et al. 2011), as p14Arf has positive influence 
on TP53 (tumour protein p53) by interacting with MDM2 (Mdm2 p53 binding protein 
homolog (mouse)) (Pomerantz et al. 1998; Zhang et al. 1998). 
HMGA2 application to cartilage might thus improve stem cell self renewal leading to 
improved cell growth and regeneration, while at the same time a potential increase of 
p14Arf-expression might prove beneficial for the genomic stability of the proliferating 
cells. In addition to these processes, the chondrogenic properties of HMGA2 as 
shown by Kubo et al. (2006), or HMGA1 as indicated by Martinez Hoyos et al. 
(2004), might also direct the growing cells to remain in or regain the chondrocyte 
phenotype at the same time. However, further research is required for assessing this 
possibility. Furthermore, instead of these nuclear processes explaining the growth 
enhancing effect of HMGA on chondrocytes, also other, yet unknown extracellular 
functions might play a role. For example, HMGB1, which is a member of the HMGB 
family of proteins, was initially known to be a nuclear protein but was later shown to 
have additional extracellular functions. Although there is no evidence yet, similar 
functions of HMGA proteins cannot be ruled out completely. 
During the subsequent research conducted on HMGA2 peptide variants, focus was 
hence also set onto the cellular localisation of the administered peptides. These 
peptides were developed to allow for the production of a biologically active agent 
without the need for biological expression systems, ruling out possible side effects 
such as unwanted modifications or contaminations that might hamper its putative 
future therapeutic use, as well as to facilitate the necessary approval for use as a 
therapeutic agent in the long term. Precondition for a synthetic HMGA-based 
therapeutic agent is thus a similar or even better growth enhancing property 
compared to the recombinant protein. Due to constraints of peptide synthesis where 
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the length of a synthesised peptide is limited by the coupling efficiency of each 
elongation step, two shorter variants of the HMGA2 protein were synthesised, 
comprising the first 60 aa (HMGA2-A) or the first 80 aa (HMGA2-B) of HMGA2, 
respectively. Both peptides thus contained the first two AT-hook domains including 
the nuclear localisation signal (NLS) of the second AT-hook, but not the 
carboxyterminal domain, and in case of HMGA2-A, the third AT-hook domain of the 
complete protein. Truncated HMGA2 comprising the AT-hooks was demonstrated to 
retain its DNA binding capability (Geierstanger et al. 1994) and remained functional 
in mice, albeit leading to gigantism and lipomatosis (Battista et al. 1999). However, 
this unwanted effect in mice is caused by the constitutive presence of the truncated 
but functional Hmga2 protein due to loss of miRNA binding sites in the 3’-UTR for 
Hmga2 mRNA regulation, and not to the truncation itself, as both mice over-
expressing the wild type Hmga2 or a truncated variant thereof lacking the 
carboxyterminal part develop a similar phenotype and are susceptible to e.g. pituitary 
adenomas (Fedele et al. 2002). As the HMGA2 peptides are only administered for a 
short period of time for enhancing cell growth e.g. during amplification for autologous 
transplantation, and will be degraded and removed over the course of time if not 
reapplied, these side effects will most likely be of no importance in a future 
therapeutic use of the HMGA2 peptides. 
To evaluate the growth inducing potential of the peptides, they were administered in 
the same experimental setup utilising isolated porcine chondrocytes as before, with 
full length HMGA2 and untreated cells as control. For comparability, molarities were 
chosen instead of mass (10?M instead of 100?g/ml), and for the two peptides, an 
additional incubation with 50?M peptide was chosen to check for any higher dosage 
dependent effect. Supplementing the proliferation ELISA, the cellular localisation of 
the 80 aa peptide was determined by fluorescence microscopy of cells supplied with 
a carboxyfluorescein-labelled variant thereof. Concurrently, cell integrity and thus 
viability was determined. The cell proliferation ELISA revealed that application of the 
full length HMGA2 protein led to a statistically significant increase in cell proliferation 
compared to the untreated control as described in the previous paper (Richter et al. 
2009). The shorter 60 aa HMGA2-A fragment also indicated this statistically 
significant growth inducing effect at both concentrations of 10?M and 50?M 
compared to the untreated control, but there was no difference between 10?M and 
50?M HMGA2-A. As there was no statistically significant difference of induced cell 
growth between the HMGA2-A peptide and the recombinant HMGA2, one can 
conclude that the HMGA2-A fragment is an adequate alternative to the recombinantly 
produced full length protein. Conversely, the longer HMGA2-B fragment could not 
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evoke any statistically significant effects compared to the untreated control group at 
both concentrations of 10?M and 50?M, although it showed comparable effect to the 
full length protein at 10?M. At 50?M however, there even was a statistically 
significant decrease in cell proliferation compared to the full length protein at 10?M, 
indicating a possible detrimental effect on cell proliferation at higher levels. This and 
the fact that there is no increase in case of HMGA2-A at 50?M compared to 10?M 
might indicate that saturation of cells or their DNA occurs at higher concentrations of 
the peptides, negatively influencing cell proliferation. In human embryonic stem (hES) 
cells, Li et al. (2006) determined the number of HMGA2 molecules per hES cell to be 
in the range of 105 molecules, considering the interaction of one HMGA2 molecule 
with one nucleosome core particle (NCP) under normal physiological conditions. 
Nevertheless, saturation of reconstituted NCPs with HMGA2 was only achieved at a 
molar ratio of 12:1, indicating that a huge amount of HMGA2 might still bind to DNA 
respectively nucleosomes, but might lead to detrimental effects on cellular 
processes. Concerning cellular localisation, internalisation of the fluorescently 
labelled variant of HMGA2-B (HMGA2-CC) could be detected, with green 
fluorescence both in the cytoplasm and the nucleus. Concurrent propidium iodide 
staining indicated intact cell membranes, leading to the conclusion that the 
HMGA2-CC peptide was taken up by living cells. While the mechanism for cellular 
uptake is unknown, the nuclear internalisation is probably due to the NLS of the 
HMGA2 peptide. Cattaruzzi et al. (2007) narrowed down the NLS to amino acid 
residues 45-53 of HMGA2, which is located within the second AT-hook and present 
in both the 60 aa and 80 aa peptide variants, as well as the full length recombinant 
HMGA2 protein. While there were no labelled variants of the 60 aa peptide or the full 
length protein, nuclear transport can also be assumed for these molecules due to 
presence of the NLS in both molecules. Concerning peptide integrity, it can be 
deduced from the green stain in the nucleus that HMGA2-CC comprising at least the 
fluorescently labelled N-terminus up to the second AT-hook was located into the 
nucleus, if not the complete peptide. For HMGA2-A or HMGA2, no conclusion can be 
made concerning molecule integrity, however as both showed proliferation 
stimulating effects on the cells, a functional molecule entering the nucleus can be 
assumed. Fluorescence in the cytoplasm might thus be caused by either intact 
molecules that are not yet transported into the nucleus, or degraded peptides lacking 
the NLS. 
Concluding, the stimulation of cell proliferation caused by the HMGA2-A peptide 
allows for further research of this fragment’s potential use in tissue regeneration of 
articular cartilage, as it induces comparable proliferation enhancement as the full 
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length HMGA2. As the peptide can be synthesized up to industrial scales without any 
biological expression systems it might be a promising agent for enhancing cell 
proliferation not only in tissue engineering of cartilage, but also in further fields where 
improved cell growth is an issue. 
One potential future application of this peptide in tissue engineering might be the 
colonisation of scaffolds in treating cartilage defects. These defects are not limited to 
humans, but also occur in animals such as the dog. Cartilage damage in dogs may 
be age or injury related, but also happens as the consequence of disease such as 
Osteochondritis dissecans (Newton et al. 1985), which primarily develops in the 
larger breeds and is thought to have hereditary nature (Morgan et al. 2000). 
Development of a valuable replacement therapy in dogs might then be transferred to 
humans with the dog acting as model organism for human therapy. 
Beta-tricalcium phosphate (?-TCP) is an established biodegradable synthetic 
material for the treatment of bone defects especially in oral surgery, but is also used 
in other fields where bone rebuilding is an issue. This led to the approach of utilising 
?-TCP in the related field of cartilage regeneration in the construction of a bone-
cartilage replacement. While there was previous research on the suitability of this 
material for cartilage regeneration in sheep and pig experimental models (Guo et al. 
2004; Gotterbarm et al. 2006; Jiang et al. 2007), no data were yet available for dogs. 
Experiments concerning the colonisation capability of ?-TCP cylinders with canine 
chondrocytes were conducted using both cartilage chips and isolated cells grown in 
cell culture, albeit, due to the preliminary nature of these trials, no protein or peptide 
application was done yet. Following colonisation and the subsequent incubation 
period, the cylinders that were inoculated with a solution of isolated chondrocytes 
showed an evenly distributed cell growth on the cylinders and within the cylinders’ 
macropores. Viability staining revealed only sporadic cell death, indicating 
compatibility of the material and the cells vital processes. Further detail revealed by 
scanning electron microscopy showed the cells’ filopodia anchoring onto the matrix 
surface and entering the construct’s micropores. Moreover, cell to cell contact could 
be detected in visible light as well as scanning electron microscopy. Cells studded 
with cartilage chips, on the other hand, exhibited much lower colonisation which only 
occurred within the region of the drill holes with fastened chips. This is comparable to 
the only marginal growth rate of chondrocytes in damaged areas of the injured joint 
that is not sufficient to fill up the defective area (Buckwalter 1998). Nevertheless, 
vitality staining proved the viability of these cells. Concluding, seeding of ?-TCP 
constructs with chondrocytes might be a useful approach in dogs when using isolated 
chondrocytes that were amplified in cell culture. However, further research is needed 
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in terms of long term colonisation of these constructs in vitro and in vivo. Successful 
trials performed in pig and sheep (Guo et al. 2004; Gotterbarm et al. 2006; Jiang et 
al. 2007) indicate this being a useful strategy for cartilage regeneration in dogs or in 
the long term, in humans. 
As is evident from the previous experiments and discussion, the dog can serve as a 
model organism, in this case for the research and treatment of cartilage damage. 
However, research is not only limited to this field, and as was mentioned before in 
this thesis and in many research papers, the dog is also an important model for other 
human diseases, in particular due to comparable disease development because of 
similar anatomy, physiology and living conditions (Ostrander et al. 1997; Kuska 1999; 
Ostrander et al. 2000; Ostrander et al. 2000; Starkey et al. 2005; Shearin et al. 
2010). The canine was proven as a suitable model for human aging, as elderly dogs 
also develop similar aspects of neuropathology, show age-related cognitive 
dysfunction and are deficient in neuropsychological tests of cognitive function 
(Cummings et al. 1996). Beta-amyloid accumulation in the aged canine brain makes 
the dog a model of early plaque formation in Alzheimer’s disease, with the advantage 
of better tissue availability and faster disease development due to the shorter lifespan 
as opposed to some primates (Cummings et al. 1993). Equally in cancer, the dog is 
an appropriate model for the human counterparts, including lymphomas, mammary 
tumours, soft tissue sarcomas, and osteosarcomas. Canine lymphoma resembles 
human non-Hodgkin’s lymphoma in clinical presentation, pathology, and treatment 
response. Mammary tumours are the most common tumour in the female dog, and 
are also markedly hormonal-dependent. Likewise, soft tissue sarcomas and 
osteosarcomas closely resemble human tumours (Hahn et al. 1994). Additionally, the 
dog is the only known nonhuman species to spontaneously develop prostate cancer 
(Rivenson et al. 1979) sharing similarities in age-dependence of tumour onset, 
tumour morphology and metastasis (Waters et al. 1998; Cornell et al. 2000). The 
connection between human prostate cancer and HMG proteins was shown before, as 
HMGB1 (Amphoterin) was linked to metastatic prostate cancer (Kuniyasu et al. 2003; 
Ishiguro et al. 2005), and increased expression of HMGA1 was determined in high 
grade prostatic cancer (Tamimi et al. 1993; Tamimi et al. 1996). Furthermore, 
HMGA2 expression could be shown in the Dunning rat prostatic cancer model (Diana 
et al. 2005), as well as in a cell line derived from a canine prostatic cancer (Winkler et 
al. 2005), and in canine prostate tumours (Winkler et al. 2007). These facts make 
clear the importance of knowledge on structure and function of canine genes, which 
resulted in the complete sequencing of the canine genome (Lindblad-Toh et al. 
2005). However, during the course of this thesis, the sequencing of the canine 
- 115 - 
Discussion 
genome was not yet completed, or provided only partial information concerning some 
genes of interest including the canine orthologues of the HMG proteins. Therefore, 
work conducted in collaboration included the characterisation of the canine HMGA1 
and HMGB1 genes as well as the identification and development of tools (e.g. 
sequences, BAC clones and expression vectors) for investigating their localisation 
and function. While initially being mapped to CFA 23 (Becker et al. 2003), probably 
due to cross-hybridisation of the BAC clone chosen for FISH or caused by presence 
of a pseudo-gene, the true chromosomal localisation of the canine HMGA1 was later 
located on CFA 12 (Beuing et al. 2008). This is consistent with synteny of HSA 6p21 
and parts of CFA 12 (Yang et al. 1999), as well as with the canine genome assembly 
(Lindblad-Toh et al. 2005). HMGB1 was located on CFA 25, but no synteny of HSA 
13 and CFA 25 was indicated by Yang et al. (1999). Nevertheless, the later released 
canine genome assembly confirmed the results obtained from BAC-mapping. 
Sequencing of parts of the canine HMGA1 and HMGB1 genes revealed large identity 
in the coding sequences (95% for both HMGA1 and HMGB1, respectively), and the 
resulting proteins (100% for HMGA1a, HMGA1b, and HMGB1), compared to their 
human orthologues (Murua Escobar et al. 2003; Murua Escobar et al. 2005), 
facilitating knowledge transfer of the extensive research already conducted in the 
field of human HMGs to canine genetics and medicine for the benefit of the dog. The 
other way round, newly evaluated therapeutic approaches in the dog might be easily 
transferable to human medicine. In addition to the work conducted on canine HMG 
genes, minor focus in this thesis was also set on canine RAS genes, including 
mapping and SNP analyses thereof. The chromosomal location of the canine NRAS 
could be mapped to CFA 17 (Richter et al. 2004), which is consistent with the known 
synteny of canine chromosome 17 and the centromer-proximal regions 11.1–13.3 of 
the p-arm of human chromosome 1 (Yang et al. 1999). RAS gene hot spot mutations 
frequent found in human tumours, however, could not be detected for NRAS in the 
canine fibrosarcomas or KRAS in the canine melanomas investigated (Richter et al. 
2005). 
Summarising the main aspects of this thesis, proteins of the HMGA family or 
peptides derived thereof may prove beneficial for volitional and controlled cell growth 
e.g. in tissue regeneration. As opposed to uncontrolled re-expression of these 
embryonic proteins in adult cells that usually promotes tumour development and 
progression, temporary application of the proteins or peptides might stimulate cell 
proliferation without the unwanted side-effects of tumourigenesis. While there is a lot 
of further research necessary for reaching the goal of a clinical application of these 
proteins or derivated peptides, results gained during the course of this thesis indicate 
- 116 - 
Discussion 
- 117 - 
a possible future role of these proteins in overcoming some of the problems that are 
still hampering cartilage regeneration up till today. The combination of HMGA 
enhanced cell growth for the colonisation of scaffolds is a promising aspect in tissue 
engineering, which might be evaluated in model organisms for human disease such 
as the dog. Furthermore, as HMGA proteins are involved in the regulation of a large 
number of genes in the developing embryo not limited to cartilage but also including 
other tissues such as smooth muscle, liver, skin, etc. (Gattas et al. 1999) the 
knowledge gained on cartilage in this thesis might be transferrable to other fields as 
well, opening up further possibilities for improving tissue engineering approaches for 
regeneration. Thus, HMGA use in tissue engineering might reverse the usually 
unwanted properties of these proteins in tumours to a volitional, yet time-limited 
presence for the better of the affected patients. 
Summary 
5. Summary 
Hyaline cartilage damage is widespread amongst the population, with injuries usually 
not healing to a satisfactory degree due to the specific nature of this avascular and 
aneural tissue that hinders cell renewal and proliferation. Tissue engineering 
strategies have been developed to overcome these problems by e.g. in vitro 
amplification of chondrocytes from undamaged joint regions for autologous 
transplantation into the defective area. However, there is room for improvement by 
e.g. enhancing cell growth for minimising the waiting time between explantation and 
re-implantation. 
One new strategy that was evaluated during the course of this thesis was the 
suitability of employing proteins of the embryonic high mobility group AT-hook 
(HMGA) family for influencing cell growth. Usually being involved in processes 
regulating cell growth during embryonic development, they are also active in 
processes controlling stemness and aging of stem cells, indicating a possible role in 
steering cell growth by means of HMGA application. In a study employing 
recombinantly produced HMGA1a, HMGA1b, and HMGA2 proteins, it could be 
shown that there is indeed improved cell proliferation with a nearly two-fold increase 
of chondrocyte proliferation in cells exposed to HMGA1b or HMGA2, respectively, 
and a slightly lower proliferative effect of cells exposed to HMGA1a (1.7 fold).  
Regarding a future potential medical use, shorter peptide variants of the HMGA2 
protein comprising two or three of the DNA-binding AT-hooks including the nuclear 
localisation signal were evaluated, overcoming some of the obstacles of 
recombinantly produced biological agents including unwanted modifications or 
contaminations from the expression system. Nuclear transport could be proven and a 
comparable proliferation enhancing effect comparable to that of the complete 
recombinant HMGA2 protein was evoked by the shorter 60 amino acid variant. This 
opens up possibilities of employing this peptide in e.g. tissue engineering of hyaline 
cartilage, by enhancing cellular growth of chondrocytes. 
One future application of HMGA-induced cell growth is the improved seeding of 
scaffolds with chondrocytes for cartilage regeneration. In a preliminary study for 
canine cartilage regeneration, yet without the administration of HMGA, beta-
tricalcium phosphate cylinders were seeded with isolated cells amplified in vitro, or 
studded with cartilage chips, respectively, to check for acceptance of these 
constructs by the cells, as there were no data available for the dog. While the 
construct was not suitable for seeding based on complete cartilage chips, which is 
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probably due to the low proliferation potential of chondrocytes embedded in their 
usual extracellular matrix, it was well accepted and colonised by isolated 
chondrocytes grown in cell culture. In a future combination with the growth enhancing 
properties of HMGA proteins or the 60 aa HMGA2 peptide, seeding of these 
structures with amplified chondrocytes might thus be a promising aspect for new 
strategies of treating cartilage damage. 
As the dog is an established model organism for human disease including but not 
limited to cancer, additional work was done to elucidate structure and function of 
canine genes whose human orthologues are known to be involved in the onset and 
development of disease. This included the canine HMGA1 and HMGB1 genes, and, 
to a lesser degree, RAS genes. By contributing to ongoing research on these canine 
genes, structure and function of the canine HMGA1 and HMGB1 genes could be 
determined, while no involvement of RAS hot-spot mutations common in humans 
could be detected in a subset of canine fibrosarcomas and melanomas. The high 
structural and functional similarity of the HMG genes and the resulting proteins 
nevertheless promise transferability of data obtained between both humans and dogs 
for the benefit of both species. Focusing on cartilage regeneration, methods of 
HMGA-assisted cartilage regeneration initially developed in dogs might thus be 
readily transferable to humans. 
 
Zusammenfassung 
6. Zusammenfassung 
Schäden des hyalinen Gelenkknorpels sind in der Bevölkerung weit verbreitet, wobei 
die Verletzungen in der Regel nicht auf ein zufriedenstellendes Niveau verheilen. 
Dies liegt in der spezifischen Struktur des Knorpels begründet, der als avaskuläres 
und aneurales Gewebe die Zellerneuerung und -proliferation erschwert. Tissue-
engineering-Strategien wurden entwickelt, um einige dieser Probleme zu 
überwinden, z. B. durch autologe Chondrozytentransplantation von Zellen, die aus 
nicht betroffenen Gelenkarealen explantiert und zur Reimplantation in den Defekt 
in vitro vermehrt wurden. Dennoch gibt es Bedarf, diese Methoden weiter zu 
verbessern, z. B. in Hinblick auf verbessertes Zellwachstum zur Minimierung der 
Wartezeit zwischen der Explantation und Reimplantation. 
Eine neue Strategie, die im Rahmen dieser Arbeit evaluiert wurde, hatte die 
Anwendung der High-Mobility-Group-AT-Hook (HMGA) Proteine zur positiven 
Beeinflussung des Zellwachstums als Ziel. HMGA-Proteine sind üblicherweise in der 
Steuerung des Zellwachstums während der Embryonalentwicklung involviert. Sie 
beeinflussen ebenfalls Stammzelleigenschaften („stemness“) und Stammzellalterung, 
so dass davon ausgegangen werden kann, dass eine Steuerung des Zellwachstums 
mittels HMGA-Proteinen möglich ist. Eine im Rahmen dieser Dissertation 
durchgeführte Studie ergab, dass rekombinant hergestellte HMGA1a-, HMGA1b- und 
HMGA2-Proteine tatsächlich Einfluss auf das Zellwachstum nehmen konnten und im 
Falle von HMGA1b und HMGA2 zu einer fast verdoppelten Wachstumsrate der 
Chondrozyten führten, während es bei HMGA1a eine etwas geringere, 1,7-fach 
erhöhte Proliferationsrate im Vergleich zur unbehandelten Kontrollgruppe gab. 
Im Hinblick auf eine zukünftige medizinische Anwendung wurden zusätzlich kürzere 
Peptidvarianten des HMGA2-Proteins, die zwei oder drei der DNA-bindenden 
AT-hooks sowie das Kernlokalisierungssignal umfassten, hergestellt und ebenfalls im 
Hinblick auf die proliferationsfördernde Wirkung untersucht. Mit der Peptidsynthese 
sollten eventuelle Probleme bei der Herstellung und Zulassung rekombinanter 
biologisch aktiver Wirkstoffe umgangen werden, wie z. B. Modifizierung der Proteine 
oder Kontaminationen aus dem Expressionssystem. Kerntransport konnte für beide 
Peptide nachgewiesen werden und ein dem rekombinanten Wildtyp-HMGA2 
vergleichbarer proliferationsfördernder Effekt zeigte sich bei der kürzeren, 60 
Aminosäuren umfassenden HMGA2-Peptidvariante. 
Dies ermöglicht weitergehende Versuche in der Geweberegeneration durch Tissue 
Engineering, indem das Zellwachstum des hyalinen Knorpels verbessert wird. 
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Eine zukünftige Anwendung des HMGA-induzierten Zellwachstums könnte z.B. die 
verbesserte Besiedlung von Strukturen (scaffolds) für die Knorpelregeneration mit 
Chondrozyten darstellen. In einer Vorstudie zur Knorpelregeneration beim Hund 
wurde - noch ohne zusätzliche HMGA-Applikation - untersucht, inwieweit sich Beta-
Tricalciumphosphatzylinder zur Besiedlung mit caninen Chondrozyten eignen, da 
hier noch keine Daten für den Hund vorlagen. Dazu wurden vereinzelte und in 
Zellkultur vermehrte Zellen oder komplette Knorpelchips auf die Zylinder aufgebracht 
bzw. daran befestigt und die Konstrukte im Hinblick auf die Besiedlung mit Zellen 
untersucht. Während sich die Besiedlung mit Knorpelchips als Ausgangsbasis als 
nicht geeignet erwies, höchstwahrscheinlich weil Chondrozyten in hyalinem Knorpel 
ein geringes Wachstumspotential aufzeigen, wurden die Konstrukte sehr gut von den 
vereinzelten in Zellkultur vermehrten Chondrozyten angenommen und komplett 
besiedelt. In Kombination mit dem 60 Aminosäuren umfassenden HMGA2-Peptid zur 
Verbesserung des Zellwachstums könnte sich dieser Ansatz daher als 
vielversprechend für die Behandlung von Knorpelschäden des Hundes erweisen. 
Da der Hund ein etablierter Modellorganismus für Krebs und andere Krankheiten des 
Menschen ist, wurden zur Ergänzung dieser Arbeit Studien auf dem Gebiet der 
Hundegenetik durchgeführt, um Struktur und Funktion von Genen, die beim 
Menschen mit Krankheitsentstehung assoziiert sind, zu bestimmen. Dabei handelte 
es sich um Gene der High-Mobility-Group Proteine sowie als Nebenaspekt um RAS-
Gene. Durch Mitarbeit in laufenden Projekten konnten Struktur und Funktion der 
HMGA1- und HMGB1-Gene des Hundes entschlüsselt werden. Hingegen zeigte sich 
bei den RAS-Genen, dass beim Menschen häufig vorkommende Mutationen an 
bestimmten Hot-Spots zumindest in den untersuchten Hundetumoren, bestehend 
aus Fibrosarkomen und Melanomen, nicht auftraten. 
Jedoch verspricht die hohe strukturelle und funktionale Ähnlichkeit der HMG-Gene 
und der davon kodierten Proteine bei Mensch und Hund die Möglichkeit, 
gewonnenes Wissen zwischen den Spezies transferieren zu können. Im Hinblick auf 
die HMGA-unterstützte Knorpelregeneration besteht daher die Möglichkeit, eine 
anfänglich beim Hund entwickelte Therapie an den Menschen anzupassen. 
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8. Abbreviations 
aa Amino acid 
ACT Autologous chondrocyte transplantation 
ADSC Adipose tissue derived stem cell 
ANOVA Analysis of variance 
ATM Ataxia-telangiectasia mutated 
BAC Bacterial artificial chromosome 
?-TCP Beta-tricalcium phosphate 
BLAST Basic local alignment search tool 
BrdU Bromodeoxyuridine 
CFA Canis lupus familiaris / Canis familiaris 
COL1A2 Collagen, type I, alpha 2 
COL11A2 Collagen, type XI, alpha 2 
CPD Cyclobutane pyrimidine dimer 
DAPI 4?,6-Diamidin-2-phenylindol 
DNA Deoxyribonucleic acid 
DSB Double strand break 
E. coli Escherichia coli 
ELISA Enzyme-linked immunosorbent assay 
FBS Foetal bovine serum 
FGF1 Fibroblast growth factor 1 (acidic) 
Fim3 Friend-murine leukemia virus integration site 3 homolog 
FISH Fluorescence in situ hybridisation 
h Hour 
H2A Histone H2A 
H3BO3 Boric acid 
HEK 293 Human embryonic kidney 293 
hES Human embryonic stem 
HMG High mobility group (canonical) 
HMG1 High mobility group protein 1 (HMGB1) 
HMG2 High mobility group protein 2 (HMGB2) 
HMG3 High mobility group protein 3 (HMGB3) 
HMG14 High mobility group protein 14 (HMGN1) 
HMG17 High mobility group protein 17 (HMGN2) 
HMGA High mobility group AT-hook 
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HMGA1 High mobility group AT-hook 1 
Hmga1 Murine high mobility group AT-hook 1 
HMGA1a High mobility group AT-hook 1 isoform a 
HMGA1b High mobility group AT-hook 1 isoform b 
HMGA2 High mobility group AT-hook 2 
Hmga2 Murine high mobility group AT-hook 2 
HMGB High mobility group box 
HMGB1 High mobility group box 1 
HMGB2 High mobility group box 2 
HMGB3 High mobility group box 3 
HMGI High-mobility group protein isoform I (HMGA1a) 
HMGI(Y) High-mobility group protein isoforms I and Y (HMGA1) 
HMGIC High-mobility group protein isoform I-C (HMGA2) 
HMGN High mobility group nucleosome binding domain 
HMGN1 High mobility group nucleosome binding domain 1 
HMGN2 High mobility group nucleosome binding domain 2 
HMGY High-mobility group protein isoform Y (HMGA1b) 
HPLC High-performance liquid chromatography 
HSA Homo sapiens 
IFNB1 Interferon, beta 1, fibroblast 
IGF1 Insulin-like growth factor 1 (somatomedin C) 
IGF2BP1 Insulin-like growth factor 2 mRNA binding protein 1 
IL4 Interleukin 4 
kDa Kilodalton 
KRAS V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog 
LMO2 LIM domain only 2 (rhombotin-like 1) 
LIN28B  Lin-28 homolog B (C. elegans) 
LPP LIM domain containing preferred translocation partner 
in lipoma 
M Molar 
MCF-7 Michigan Cancer Foundation - 7 
MDM2 Mdm2 p53 binding protein homolog (mouse) 
Mecom Murine MDS1 and EVI1 complex locus gene 
MEF Mouse embryonic fibroblasts 
?M Micromolar 
min Minute 
miRNA Micro ribonucleic acid 
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ml Millilitre 
mm Millimetre 
mM Millimolar 
MPC Mesenchymal progenitor cell 
mRNA Messenger ribonucleic acid 
MWCO Molecular weight cut off 
MYC V-myc myelocytomatosis viral oncogene homolog 
(avian) 
NaCl Sodium chloride 
NCBI National Center for Biotech Information 
NCP Nucleosome core particle 
NF-kappaB Nuclear factor NF-kappa-B p50/p65 heterodimer 
NHEJ Nonhomologous end joining repair 
NLS nuclear localisation signal 
NRAS Neuroblastoma RAS viral (v-ras) oncogene homolog 
OA Osteoarthritis 
OD Osteochondritis dissecans 
PAGE Polyacrylamide gel electrophoresis 
PBS Phosphate buffered saline 
PCR Polymerase chain reaction 
PDGF Platelet-derived growth factor 
PI Propidium iodide 
PRDII Positive regulatory domain II 
SDS Sodium dodecyl sulphate 
SELE Selectin E 
SEM Scanning electron microscopy 
SPC Side population cell 
SPPS Solid phase protein synthesis 
TP53 Tumour protein 53 
tRNA Transfer ribonucleic acid 
UTR Untranslated region 
UV Ultraviolet 
Vol Volume 
v/v Volume per volume 
w/v Weight per volume 
X-SCID X-linked severe combined immunodeficiency 
XPA Xeroderma pigmentosum complimentation group A 
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